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Stem cell based tissue engineering may provide ideal bone grafts for critical-
size bone defect. Typical tissue engineering approaches involve three elements: 
cell source, scaffold and bioprocessing techniques, which jointly determine the 
therapeutic efficacy of a tissue engineered product. Unlike cell sources and 
scaffolds which have been actively studied and developed over the decades, 
the influence of bioprocess has been insufficiently investigated. For example, 
although osteogenic priming is known to induce cellular differentiation, its 
influences on cellular paracrine effects and the efficacy for bone healing was 
unclear. In my thesis, the role of osteogenic induction in tissue engineered 
bone graft (TEBG) for bone regeneration was investigated, particularly on the 
cellular paracrine effects.  
Well-characterized human fetal MSCs (hfMSCs) were used as cell sources, 
and macroporous PCL and PCL-TCP were used as scaffolds to generate 3D 
cellular constructs. Compared with PCL scaffolds, PCL-TCP enabled a 40% 
higher cellularity of the TEBGs achieved, although the degree of osteogenic 
differentiation did not differ between scaffold types. As cellularity of scaffolds 
is a key component for effective regeneration, PCL-TCP scaffolds were used 
for the rest of the thesis. 
To investigate how osteogenic culture influences cellular secretion, three-
dimensional cellular constructs were cultured in either osteogenic 
differentiation media or basal media for 2 weeks. Quantitative PCR array on 
the lysate showed that both osteogenic genes and angiogenic genes were up-
regulated by osteogenic culture; ELISA on conditioned media verified the 
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secretion of VEGF was increased for three times. Furthermore, endothelial cell 
tube formation supported by conditioned media demonstrated the functional 
differences of the cellular secretome. Subsequently, the effect of culture 
duration on cellular secretome was studied. A rotating bioreactor system was 
used and cellular secretion of constructs cultured for 1, 2 and 4 weeks were 
tested. Results showed that VEGF secretion and FGF secretion was increased 
during the osteogenic induction, but Ang-1 secretion was decreased. Vascular 
formation assay showed that TEBGs induced for longer duration (4 weeks) 
performed greater paracrine support for endothelial cell tube formation. 
In order to evaluate in vivo efficacies of hfMSC-TEBGs induced with different 
durations of time, a rat femoral defect was applied. Radiographic images 
showed that the rats implanted with long-term cultured TEBGs achieved the 
best bone repair with significantly improved neovascularization. Moreover, in 
all experimental groups, implanted hfMSCs vanished within 4 weeks after 
implantation, suggesting that the healing was enhanced primarily through 
paracrine effects, rather than by functional engraftment. The function of the 
repaired bones implanted with 4-week induced TEBGs, as shown by torsional 
test, was highest among all groups. 
Taken together, osteogenic induction promotes fetal MSCs’ secretion of 
proangiogenic factors and improves their in vivo therapeutic efficacies for 
bone repair. This is the first systematic study revealing the effect of osteogenic 
induction on MSC’s functional secretion in terms of angiogenesis. My thesis 
indicates the value of conducting dynamic osteogenic culture on MSC loaded 
scaffolds for healing bone defects, and sheds light on the optimal strategy to 
prepare clinically relevant tissue engineering bone grafts. 
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Chapter 1. Introduction  
1.1. Bone fracture and healing  
Bone fracture is one of the most common injuries in the world, frequently 
occurring in sports injuries, traffic collisions and other personal accidents. 
Although bone is capable of self-healing in most cases with minor injuries, 
severe bone fractures such as those resulting in large bone loss impede healing, 
lead to complications and necessitate clinical interventions. According to hip 
fracture database, nearly 9 million hospital admissions worldwide for bone 
fracture were recorded in 2000 and the number has increased to over 15 
million as estimated in 2013 (Boulton. 2014). On average, 50% women and 20% 
men in the world suffered fragility fractures at their ages over 50 (Akesson 
2013) . In the United States alone, there were 1.6 million admissions for 
traumatic fractures costing over 60 billion dollars, with the need for 1.6 
million bone grafts each year (O'Keefe and Mao 2011). Furthermore, fractures 
may cause complication and adverse outcomes in certain vulnerable patient 
populations which significantly increases the death rate among these patients 
(Tentori 2014).  
Consequently, clinical approaches with ideal solutions to severe fractures are 
being actively pursued. In the past decade, tissue engineering and regenerative 
medicine have emerged as promising treatment for tissue damages, including 
excessive bone loss. Today, these approaches are making increasing progress 
in provision of efficacious and reliable bone grafts for traumatic bone loss, 
facilitating drug development processes, and continuing to benefit the clinical 
and scientific fields. However, many significant questions have yet to be 
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answered. This doctoral thesis focuses on addressing some of the critical gaps 
in the field of bone tissue engineering and regeneration.  In this first chapter, 
the basic bone physiology and natural healing process will be illustrated, 
followed by the introduction of current and emerging clinical interventions 
available for the treatment of severe fractures. 
 1.1.1. Bone anatomy and physiology 
Similar to other organs and tissues, bone tissue is a composition of multiple 
cellular populations and extracellular matrix (ECM). In addition, bone tissue 
has unique histological structures and active metabolism. In this section, 
different cell types, properties of ECM and the histological structure of bone 
tissue will be illustrated, and the metabolism of the bone will be introduced. 
Bone is composed of different cell populations, including osteoprogenitor cells, 
osteoblasts, osteocytes and osteoclasts (Figure 1-1). Osteoprogenitor cells are 
the multipotent stem cells that can eventually differentiate into specialised 
bone cells. The osteoprogenitors reside mainly in the bone marrow, but can 
also be derived from umbilical cord blood, adipose tissue, dental pulp, 
periosteum and many other mesenchyme tissues (Bieback 2004; Branch 2012; 
Chamberlain 2007; Kern 2006; Prockop 1997). Because of their origin and 
multipotency, they are usually referred as mesenchymal stem cells or marrow 
stromal cells (MSC). Osteoblasts are specialised osteoprogenitor cells, which 
are responsible for the formation of new bones. In adults, osteoblasts persist in 
bone marrow, periosteum and damaged bones where bone formation occurs. 
By producing most of the proteins present in the bone extracellular matrix 
(ECM) and regulate ECM mineralization, osteoblasts induce bone formation, 
and can further differentiate into osteocytes when surrounded by fully 
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mineralised matrix (Caetano-Lopes 2007; Ducy 1997). Osteocytes are 
therefore terminal bone cells and trapped in the bone matrix. However, they 
develop long branches that can make contacts with each other and other bone 
cells. In addition, osteocytes can sense pressures or cracks and trigger 
reparative responses from other cells (Bonewald and Johnson 2008; Klein-
Nulend 1995). Osteoclasts, on the other hand, are another type of specialized 
cells whose function is to resorb bones, as opposed to the bone-forming 
osteoblasts. Osteoclasts are large, multinucleated cells derived from 
monocyte/macrophage hematopoietic lineages. They often form sealed 
compartment next to the bone surface and secrete acids/enzymes which 
degrade the bone matrix. The osteoclast plays a significant role in bone 
remodelling process and other physiological or pathological processes that 
involve bone resorption (Boyle 2003; Teitelbaum 2000).  
 
Figure 1-1 Bone histology.  
Bone cells and mineralized structure as stained by Hematoxylin and Eosin. Calcified 
bone matrix is stained in pink, with osteocytes can be found embedded within. 
Osteoclasts are multinucleated cells pit in the surface of the bone where undergoes 
resorption, followed by osteoblasts that attach aside with the surface and form new 
bones. (Image acquired from Histology Self-study Resources at SIU SOM. 
(http://www.siumed.edu/~dking2/ssb/remodel.htm)) 
 
 - 4 - 
 
In addition to cellular population, extracellular matrix (ECM) also acts a key 
role in bone tissues. Compared to other tissue, the ECM in bone is highly 
mineralised in order to confer mechanical strength. In fact, Bone is composed 
of 50 – 70% mineral, 20 to 40% organic matrix, 5 to 10% water, and <3% 
lipids (Clarke 2008). The mineral elements in bone are mostly calcium and 
phosphate, in the form of hydroxyapatite crystal (Ca10(PO4)6(OH)2); while 90% 
of the proteinous contents are collagenous proteins, mainly type I collagen 
(Gentili and Cancedda 2009). This unique composite of inorganic minerals 
(calcium phosphate) and proteins (collagen) provides bone with both 
loadbearing toughness and strong mechanical stiffness. Apart from the 
chemical elements, bones have unique histological structures that enable them 
to maximize their mechanical strength, and to remain spatial compartments for 
other tissues such as marrows and blood. 
The cellular populations and ECM in bones are arranged in certain manner, in 
order to maintain their mechanical strength and physiological activity. Based 
on the structure and density difference, bones are categorised into cancellous 
and cortical bones (Figure 1-2). Cancellous bone (also referred to as trabecular 
bone or spongy bone) is porous, which provides structural support and 
organization for bone marrow interspersed inside. In contrast, cortical bone is 
the compact bone surrounding the marrow space, and confers mechanical 
strength to the bone (Augat and Schorlemmer 2006). The outer layer that 
covers the surface of cortical bones is periosteum, containing mainly blood 
vessels and osteoblasts, which are activated during appositional growth and 
bone repair (Buck and Dumanian 2012). The basic functional unit of the 
cortical bone is the osteon (or Haversian system) which contains cells and 
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extracellular matrix organised in a lamellar pattern, surrounding the haversian 
canal, in which nerves and blood vessels reside (Ascenzi and Roe 2012). 
Osteoblasts and the mature osteocytes stay in osteon, contributing to the 
generation and maintenance of ECM that gives bone structural strength 
(Klein-Nulend 2003). These cells are derived from osteoprogenitor cells that 
reside in the bone marrow and periosteum.  
 
Figure 1-2 Overview of bone structure, depicting gross overview, and main 
elements.  
Osteoprogenitor cells and osteoblasts are found abundantly in the periosteum and 
bone marrow, where they perform critical roles in bone growth and repair. Bone is 
vascularised, with blood vessels in intramedullary canals, haversian canals and 
periosteal region. (Image acquired and modified from (Bao 2013))  
 
Aside from its unique composition and structures, bone is also a highly 
dynamic tissue. Bone remodelling is a constant metabolic process throughout 
one's lifetime, when mature bones are replaced by the new bone tissue. Bone 
homeostasis is achieved through the coordination of osteoprogenitors, 
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osteoblasts, osteocytes, and osteoclasts. In general, bone formation is 
associated with the differentiation of osteoprogenitor cells and proliferation of 
osteoblasts. The osteoblasts are responsible for collagen production and ECM 
mineralization through expression of functional proteins such as osteocalcin 
and alkaline phosphatase (Harada and Rodan 2003; Szulc 2005). Osteoblasts 
trapped in the mineral ECM eventually differentiate to osteocytes, and form 
syncytial networks that support bone structure and metabolism. On the other 
hand, osteoclasts are responsible for bone resorption, in response to calcium 
concentration, mechanical stimuli and physiological activities such as 
inflammation (Claes 2012; Frost 1990; Teitelbaum 2000). The bone 
remodeling process thus involves a balance between bone formation and 
resorption, and is crucial for maintaining bone renewal, mechanical strength 
and mineral homeostasis (Cao 2011). 
 1.1.2. Fracture healing 
The dynamic metabolism enables the bone with self-healing capability. In case 
of fractures, bones are able to initiate and undergo a complex repair cascade to 
generate new bones. However, completion of this self-healing requires optimal 
conditions such as sufficient stability and blood supply, and can be affected by 
various factors such as severity, type and location of the fracture, and the 
presence of other diseases. Nevertheless, the understanding of natural healing 
processes can lead to better interventions being developed, in terms of 
fulfilling optimal healing conditions and developing new treatment for more 
severe or complicated cases. This section will briefly introduce the fracture 
healing process, and discuss the conditions required for fracture healing and 
emphasize the importance of neo-vascularization. 
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Fracture healing is a complex process which can be divided into three partially 
overlapped phases: inflammation, repair and remodeling (Figure 1-3). 
Inflammation caused by a disruption of blood vessels at the fracture site can 
initiate healing cascade and is essential for effective healing (Cottrell and 
O’Connor 2010). Once fracture has occurred, the soft tissue surrounding the 
fracture exudes plasma and leukocytes, with fibrinogen in defect area would 
fill up the fracture gaps. As a result, a hematoma forms, and provides initial 
nidus for functional cells, cytokines and growth factors to start repair process 
as well as revascularization (Kolar 2010). Subsequently, the repair phase takes 
place. Bone repair follows the same patterns as bone growth during normal 
development, characterized as primary bone formation (similar to 
intramembranous ossification) and secondary bone healing (similar to 
endochondral ossification). Detailed repair procedures and patterns have been 
extensively reviewed in many publications (Claes 2012; Marsell and Einhorn 
2011), which will not be elaborated here. Once the fracture gap is filled by 
new bone, the remodeling process begins and fully load-bearing reconstructed 
bone forms. In particular, more mature lamellar bone replaces primary woven 
bone formed during repair phase, with level of inflammatory cytokines 
gradually resolving and vascularization reduced from hypervascular states 
found during the repair phase to the pre-fracture state (Dimitriou 2005). 
Complete healing process takes between 3-9 months in rats and years in 
human depending on the condition and location of the fractures. During the 
entire process, neo-vascularization is a crucial component to successful 
healing, which will be discussed in following contents.  
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Figure 1-3 Fracture healing cascade.  
Fracture healing can be divided into three overlapped phases: inflammation, repair 
and remodelling. The entire process takes 3 to 9 months in rats and probably years in 
human, following a well organised cascade: 1. Vessel rupture and marrow exposure 
initiate an inflammation reaction and healing cascade of cytokine release. 2. 
Hematoma is formed as a result of bleeding, serving as temporal scaffold for healing. 
3. Functional chemokines, cytokines, growth factors and cells are delivered to 
hematoma and fracture site and start repair process. 4. New-vascularization induced 
by angiogenic factors occur as a result of hypoxia. 5. Primary healing is achieved in a 
way that is similar to intramembranous ossification. 6. Secondary healing undergoes 
at distant site and is the major healing mechanism, characterized as callus formation 
and mineralization.  7. After bony bridge is achieved, remaining cartilage tissue is 
resorbed and new bone is remodeled into stronger structural patterns. 8. Vessels are 
reduced to normal level.  
 
Bone is highly vascularised tissue and neo-vascularization is essential for 
fracture healing. There is abundant evidence showing that the prevention of 
neo-vascularization causes a delay or failure of fracture healing (Hausman 
2001; Tomlinson 2013). Neo-vascularization starts few days after the primary 
injury, induced by the release of endogenous angiogenesis growth factors 
including VEGF (Carano and Filvaroff 2003), FGF-2 (W. J. Chen 2004) and 
Angiopoietins (Ai-Aql 2008). New blood vessels are formed in hematoma as a 
result of hypoxia, providing an excellent resource for osteogenic progenitor 
cells and other cells to initiate healing. The neovascularization process peaks 
at week 2 to week 4 after injury in rats, and gradually reduces thereafter (Claes 
2012). At the remodelling phase, the established vessel networks can further 
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recruit circulating osteoprogenitor cells and monocytes, which are actively 
involved in bone resorption and formation, ensuring successful remodelling 
and completion of healing.  Neo-vascularization is thus a critical step for the 
entire fracture healing process and effective neo-vascularisation improves the 
healing efficiency. 
The outcome of fracture healing can be assessed by radiographic imaging and 
load-bearing capacity of the repaired bone. Although many complex situations 
exist, successful healing is generally characterized by the achievement of bony 
bridging between fracture ends, and recovery of mechanical functions of the 
bones such as loadbearing. Accordingly, permanent failure of either of the two 
aspects in a fracture healing is termed as non-union. The non-union can be 
caused by many reasons, including patient dependent factors such as advanced 
age, medical comorbidities and genetic disorders, as well as patient 
independent factors such as fracture location, soft tissue injury and degree of 
bone loss (Hak 2014). Once established, non-unions are difficult and 
expensive to treat. However, proper clinical interventions can be applied to 
effectively prevent such outcomes, especially when no complications coexist 
such as comorbidities or genetic disorders. In next section, current clinical 
interventions as well as potential therapeutic strategies for the non-union 
defects without other complications, in particular, critical-size defects will be 
discussed.  
 1.1.3. Critical-size defects and clinical interventions  
In the clinic, permanent failure of healing from a bone fracture is considered 
as non-union, and the minimal size of the defect that will lead to non-union 
without interventions is defined as critical-size defect (Spicer 2012). Critical-
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size defects often lack the framework necessary for bone regeneration, aside 
from disruption of bone integrity and rupture of blood vessels. Hence, a 
supporting framework, in addition to the stimuli which can actively improve 
the healing is often required. As a result, bone graft implants are frequently 
applied to treating critical-size defects, together with other enhancement 
strategies such as bone morphogenetic protein treatment or biophysical 
treatment (Einhorn and Gerstenfeld 2015). Among the implants, autologous 
bone grafts serve as “gold standard”, while alternatives are being highly 
pursued and increasingly emerging. 
Autologous graft transplantation serves as the most common treatment for 
critical sized defect in clinic.  An autograft is derived from autologous bone 
chips from the patients themselves, which can provide large amount of bio-
active cells and proteins to the defects which aids in bone healing without the 
risk of immune rejection, as can be the case when using non-matched donor 
bone. Although this is one of the safest and most effective sources, patients 
may suffer from donor site morbidity, insufficient sources and poor efficacy 
among aged populations (Banwart 1995; Goulet 1997). Alternatively, 
allografts are processed (frozen, cleaned, dry) allogeneic bones from tissue 
bank, usually cadavers.  Allografts have low capacity of healing due to 
reduced amount of bioactive cells and proteins, and risk of immune rejection 
and pathogen transmission (Betz 2002). Therefore, the ideal bone graft should 
provide a reliable framework and bioactive functions, as well as minimal risks 
of pathogen transmission and immune rejection. 
Tissue engineering has become a major force in regenerative medicine, since 
the concept was raised by Robert Langer and Joseph P. Vacanti in early 1990s 
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(Langer and Vacanti 1993). The idea of tissue engineering is to combine 
biology and engineering principles to produce functional substitutes for 
damaged tissues. Over the last two decades, numerous bone graft substitutes 
have been developed using tissue engineering principles. In following sections, 
the state of bone tissue engineering and future trends in advanced fracture 
treatment will be discussed, focusing on the elements in tissue engineering, 
animal models and trials, and the potentials of bone tissue engineering 
approaches. 
 1.1.4. Summary 
Bone tissue is composed of different types of cells and mineralized 
extracellular matrix, and arranged in well-organized histological structures. In 
addition, bone is highly dynamic and constantly undergoes remodelling in 
response to homeostatic regulations, mechanical stress and wound healing. 
The dynamic status of the bone allows self-healing when slight fractures occur. 
The fracture healing process is rather complicated and successful outcomes 
depend on many strict conditions. The permanent failure of complete healing 
is termed as non-union, and the smallest size of the bone loss that could result 
in non-union without any interventions is defined as critical-size defect. In 
order to provide a framework that can provide mechanical support during the 
healing period in critical-size defects, a graft is usually implanted on the defect 
site. The most common source is autologous bones, which contains bioactive 
components such as cells and proteins from the patients of their own. However, 
the inevitable problems of autograft such as donor site morbidity and source 
limitation call for alternative solutions. The ideal solution would be a bioactive 
framework, which can be produced in large scale and actively participating in 
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healing process while transplanted, with minimal risks of side effects such as 
immune rejection, pathogen transmission and tumorigenesis. Tissue 
engineering, as the most promising sources for bone graft substitutes, may 
offer a breakthrough solution for critical-size defects. In next section, the three 
main elements in bone tissue engineering application will be discussed. 
1.2. Bone tissue engineering  
Tissue engineering approach combines the principles of life science and 
engineering to create biological substitutes in vitro for tissue repair.  Since its 
inception, attempts have been done for different tissue types, including bone 
(Sundelacruz and Kaplan 2009), cornea (de Araujo and Gomes 2015), heart 
(Hirt 2014), cartilage (Vinatier 2009), and liver (Ohashi 2007). Among the 
applications, bone tissue engineering has been gone through huge 
breakthroughs since early 1990 and pushed the boundaries of clinical 
interventions on bone defects (Maniatopoulos 1988; Ohgushi 1989). Three 
essential elements are involved in bone tissue engineering approaches: cell 
source, biomaterial scaffold and processing strategy. The combination of 
cellular components with structured materials can provide both biological 
elements and mechanical framework to the defect, while additional 
bioprocessing techniques can further enhance the efficacies of cellular 
scaffolds.  In this section, these elements will be introduced separately, with 
the particular focus on state of the arts in bone tissue engineering approaches. 
 1.2.1. Stem cell sources 
Cells are the essential element in tissue engineering approaches. In fact, the 
idea of engineering tissue in an experimental environment is achieved by 
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manipulating cell and tissue growth in vitro. Instead of mature cells such as 
osteocytes, osteoblasts and their precursor cells are capable of self-renewal 
and differentiation into functional bone cells, which empower them as better 
candidates for tissue engineering. When implanted in vivo, the mechanism of 
the cellular functioning could be complicated, which will be further discussed 
in Section 1.4.2.  In this section, the current available stem cell sources will be 
reviewed, with particular discussion on their advantages and limitations based 
on manipulation feasibility and potential efficacies.  
The main osteogenic progenitor cells – mesenchymal stem cells (MSCs) are 
considered consisting of a variety of cell populations, which can be derived 
from including bone marrow, adipose, muscle, and many other multiple 
mesenchymal tissues. As laid out in a consensus statement from the 
International Society of Cell Therapy, MSCs are characterized by: 1) the 
expression of mesenchymal cell-surface markers including CD73, CD105 and 
CD90 without expression of haemopoietic or endothelial markers; 2) the 
capacity for tri-lineage differentiation into osteocytes, chondrocytes and 
adipocytes (Dominici 2006). MSCs are most abundantly found in the bone 
marrow (BM), and BMSCs (bone marrow derived MSC) are actively explored 
for both autologous and allogeneic transplantations (Berner 2013; Mauney 
2005). BMSCs may offer favorable characteristics, including superior 
proliferation and differentiation abilities, and availability as an autologous cell 
source (Petite 2000). Moreover, it is suggested that BMSC are immune 
privileged and thus suitable for allogeneic transplantation (Krampera 2003).  
Apart from bone marrow, MSC can also be derived from multiple 
mesenchymal tissues including adipose tissue, muscles, dermal tissue, 
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amniotic fluid, umbilical cord, cord blood and even urine (Bueno 2009; Guan 
2015; Jager 2007; Levi 2010; Reddy 2013; Rodrigues 2012). Adipose derived 
stem cells (ASCs) are shown to be efficacious in bone repair, facilitating the 
repair of critical size defects in both calvarial and femoral segmental defects 
(Cowan 2004; Peterson 2005). MSCs derived from muscular tissues, umbilical 
cord and cord blood also possess the potency of osteogenic differentiation, 
capacitating their application in bone tissue engineering (Bieback 2004; Lee 
2004; Shaw 2011; Zuk 2001). Additionally, sources such as adipose tissues 
and umbilical cords can be acquired from medical waste, which are easily 
accessible and regarded as non-invasive for donors (Malgieri 2010). 
In addition to their mesenchyme origin, osteoblasts and their precursors can 
also be harvested from bone tissues. Osteoblasts can be isolated by explant or 
enzyme digestion on minced bone pieces, and can actively support bone 
formation after implanted in vivo (Keskin 2008). However, the technical 
difficulties in cell isolation and poor expansion efficiency limit their potential 
for large-scale applications (Declercq 2004). Similar challenges also remain in 
other stem cell sources derived from bones, such as dental pulp and 
periosteum. Although studies have been conducted to demonstrate their 
healing capacities (Petridis 2015; Sakata 2006), their efficacies are yet to be 
optimized before they can meet the clinical needs. 
Besides multipotent stem cells, embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs) are also the potential cell sources for bone tissue 
engineering (Gepstein 2002; K. Takahashi 2007). Although these primitive 
stem cells can be induced into osteogenic cell lines, the risk of nonspecific 
differentiation and tumorigenesis, as well as the immune rejection for ESCs 
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are the major challenge for their clinical application (Kim 2008; Tashiro 2009). 
To sum up, each type of cell source has their advantages and major limitations; 
and the bone marrow derived MSCs have the widest application in clinical 
trials. The table below reviewed the cell sources based on several comparative 
studies (D. Y. Chen 2011; Kern 2006; Lv 2012; Sakaguchi 2005; Shimko 
2004; P. Wang 2015; Zhang 2009a), and the attempts used different cell 
sources on representative animal models will be reviewed in Section 1.3.3. 
Tissue origin Proliferation Differentiation Limitations Advantages 










Cord blood Medium Medium  Limited sources 
High potential, 
good efficiency 













Table 1-1 Comparison of different stem cell sources. 
 
As introduced above, mesenchymal stem cells from different organ origin 
perform differently in bone tissue engineering application. In addition, the 
developmental stages of the donor also vary the cellular characteristics 
(Guillot 2008; Jo 2013; Zhang 2009a). In last decade, a new source of MSC 
has been isolated from fetal tissues, including the blood, bone marrow, liver, 
pancreas, kidney thymus and bone (O'Donoghue and Chan 2006). Compared 
with MSCs from adult bone marrow, the fetal source expressed higher level of 
osteogenic genes, and demonstrated higher potential for osteogenic 
differentiation (Guillot 2008). The advantageous property of fetal MSCs has 
also been utilized in bone tissue engineering and achieved remarkable 
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outcomes (Zhang 2012). The application of this type of stem cells will be 
particularly elaborated in Section 1.4.1. 
 1.2.2. Biomaterial scaffolds  
Along with cellular content, scaffolds are also important for engineering bone 
tissue, as they provide a structural framework that is similar to extracellular 
matrix in natural bones. Therefore, the development of scaffolds is a major 
aspect in bone tissue engineering research. On one hand, these scaffolds 
should be rigid and resilient since they function as the main supporting frame 
work of bone graft. On the other hand, they should also be porous, 
biocompatible, osteoinductive and osteoconductive so that bone tissue can 
regenerate within the scaffolds (Burg 2000). The composition of materials 
determines not only the chemical properties, but also surface roughness, 
mechanical properties and degradation rate. Therefore, choosing the proper 
materials is the priority in scaffold design.  
Natural materials have been utilized to engineering bone tissue, categorized as 
either biological polymers (such as collagen and hyaluronic acid) or ceramic 
materials (such as hydroxyapatite and tri-calcium phosphate). Natural 
polymers in native bone, such as collagen, are advantageous in possessing the 
innate biological cues that favour cell attachment and promote chemotactic 
response when being implanted in vivo (Stevens 2008). However, the 
telopeptide within these polymers may be immunogenic, and some of the 
polymer’s nature (poor inherent rigidity and high degradation rate) limit their 
application in bone repair. The main minerals in bone matrix – hydroxyapatite 
(HA) and tri-calcium phosphate (TCP), are other candidates for bone scaffolds, 
characterized as ceramic materials. Their mechanical properties are stiff 
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enough to provide the mechanical support at the defect area. However, the 
brittle character may dispose the ceramics to an unfavorable response to 
impact (C. Gao 2014).  
As natural polymers may incur physiological issues such as immune rejection, 
synthetic materials can be designed and customized for highly specified 
chemical and physical properties. These properties contribute to controllable 
mechanical properties of the scaffolds, including tensile strength, resiliency 
and degradation rate and to tailor desirable biological outcomes, such as 
reducing risks of toxicity, immunogenicity and infection (Rezwan 2006). The 
most often used synthetic materials for three dimensional scaffolds are 
saturated poly-α-hydroxy esters, including poly (lactic acid) (PLA), Poly 
(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), and Poly(ε-
caprolactone) (PCL) (Rezwan 2006). Such materials, however, lack bioactive 
properties such as biocompatibility, osteoinductivity and osteoconductivity, 
necessitating further modification prior to use. Therefore, most attempts used 
combined materials with different attributes, and compensated each other to 
achieve optimized performance (Ramay and Zhang 2004; Smith and Grande 
2015). 
Recently, a macroporous scaffold using polycaprolactone (PCL) incorporated 
with 20% TCP was developed and widely used in bone applications (Nga 
2015; Rai 2004; Rai 2005; Zhang 2009a). This scaffold combines the natural 
advantages of TCP in load-bearing ability, and the flexibility of using PCL 
material. Consequently, the scaffold showed good support for cell attachment, 
osteoinduction and osteoconduction in different cell lines, including adult and 
fetal BMSC, adipo-derived MSC and MSC from umbilical cord (Zhang 
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2009a). In a followed pre-clinical study, human fetal mesenchymal stem cells 
(hfMSC) loaded PCL-TCP scaffolds showed great efficacy in healing bone 
defect with both improvement in bone formation and neo-vascularization 
compared with scaffold alone. However, the scaffold provides essential frame 
work for the bone ingrowth and initial space for fracture repair, leading bone 
formation compared with the non-treated critical-size defect model (Zhang 
2010a). 
 1.2.3. Bioprocessing (tissue culture) 
Apart from stem cell sources and biomaterials, bioprocessing is the other main 
element of tissue engineering approach. Bioprocessing can be broadly referred 
to all the processes that involve handling of cells and cellular scaffolds. In 
order to create tissue engineering products, general bioprocessing steps are 
complementary including cell isolation, expansion and seeding onto scaffolds. 
Specifically, tissue culture processes are not only the essential steps to create 
tissue engineered bone products, but also capable of modifying the cellular 
phenotype by inducing cellular differentiation. For instance, priming stem 
cells in basal media supplemented with specific cues can induce them to 
differentiate into more favourable lineages before transplantation, which may 
enhance the in vivo efficacies of the engineered bone grafts. In this section, I 
will introduce the tissue culture strategies in bone tissue engineering which 
can significantly enhance the healing efficacy of the engineered bone grafts. 
In bone tissue engineering, a general bioprocessing step is to induce the stem-
cell differentiation into osteoblasts,  in order to acquire more mature 
osteogenic cell populations capable of immediate bone formation (Mauney 
2005).  The classical strategy to induce the stem cells into osteoblasts is to 
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manipulate the culture conditions, particularly by providing supplements in 
media, which composed of dexamethasone, ascorbic acid and 
glycerophosphates (Vater 2011). Dexamethasone (Dex) is a synthetic 
glucocorticoid that is essential for MSC differentiation, by triggering 
transcriptional effects such as activation of Runx-2 (Langenbach and 
Handschel 2013). Addition of Dex in growth media increases alkaline 
phosphatase activity, osteopontin expression and mineralization (Cheng 1994). 
Ascorbic acid leads the secretion of collagen 1 type I, the most abundant 
proteins in extracellular matrix (ECM). Beta-glycerophosphate (β-GP), on the 
other hand, provides phosphate sources for hydroxylapatite and also influences 
intracellular signaling molecules. Alternative supplements such as BMP-2 
have also been used in some studies to enhance the differentiation efficiency 
(Hildebrandt 2009; Jorgensen 2004). In addition to utilizing differentiation 
media, attempts have been made to induce osteogenic differentiation of the 
stem cells by using osteoinductive materials, surface modification, electrical 
stimulation and other physical interventions, but these special approaches are 
inefficient and costly to be considered as general protocol (Faia-Torres 2015; 
Jansen 2010; Thibault 2010). 
Inducing cellular differentiation can be achieved either before seeding the cells 
into scaffolds or after. Cultivating monolayer mesenchymal stem cells in 
osteogenic medium can provide “osteoblast-like” cell lines with high level of 
osteogenic proteins such as osteonectin, alkaline phosphatase and collagen 
type I (Zhang 2009a), which may subsequently improve bone formation after 
seeding into scaffolds and implanting in animals. However, inducing cellular 
differentiation before seeding might incur changes of cell niche and loss of 
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mineral accumulation. Therefore, it is common to induce the seeded cellular 
scaffolds in a three dimensional environment (3D) (Ratcliffe and Niklason 
2002). This post-seeding induction will allow the cells to proliferate and 
differentiate in a stable 3D environment before transplantation, thus avoid cell 
niche changes. Furthermore, the accumulate deposited minerals and secretory 
proteins in TEBGs during post-seeding induction can be subsequently 
delivered to in vivo environment, which enriches the active factors at defect 
site after transplantation (Rodrigues 2012). 
Challenges remained in 3D culture, however, include distribution of medium, 
nutrient transition, oxygen tension and waste transfer (Martin and Vermette 
2005). To address these issues, sophisticated bioreactors are designed with 
features such as media perfusion, stirring devices and rotation of the container 
(Plunkett and O'Brien 2011). Compared with traditional static culture, these 
devices can provide a dynamic cultivating system which leads to 
homogeneous cell distribution, constant mass transfer, and moderate shear 
stress that stimulates cell growth and differentiation (Rauh 2011). A recently 
developed biaxial rotating bioreactor (BXR) integrated a rotating chamber and 
a perfusion system, which can provide the inside 3D scaffolds a gentle fluidic 
environment with abundant gas exchange and mass transfer. The bioreactor 
system has displayed a superior efficiency in supporting osteogenic induction 
over static culture and other bioreactors (Zhang 2009b; Zhang 2010b). 
Detailed previous findings in tissue engineered bone grafts generated in this 
BXR system will be elaborated in Section 1.4.1. 
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 1.2.4. Summary  
Bone tissue engineering approaches involve three critical elements: cell 
sources, scaffolds and processing strategies. The active cellular components 
provide the functional units of the tissue engineered bone grafts  (TEBGs), 
which can be obtained from multiple tissues and perform various 
physiological roles to the fracture healing. Because bones are rigid tissues and 
responsible for load-bearing support, scaffolds are required in addition to 
cellular contents to serve as special frame works. The composed materials 
determine both the chemical and physical properties of the scaffolds, which 
are crucial for the efficacies of the scaffolds. In addition to cell sources and 
scaffolds, bioprocessing steps are the other main element involved in bone 
tissue engineering. Besides complementary expansion culture which supports 
cellular growth, supplementing essential ingredients in culture media can 
change the phenotype of the cells. By applying medium-primed induction, the 
seeded stem cells can undergo differentiation and transfer to osteoblast 
phenotypes and contribute to mineralization accordingly when implanted in 
vivo. Therefore, the healing mechanism and efficacies of a TEBG are jointly 
determined by the cell source, biomaterial scaffold and bioprocessing applied 
during the preparing process. In order to investigate the in vivo performances 
of a TEBG, representative animal models are required. In next section, studies 
that used pre-clinical animal model – critical-size defect model and tested the 
efficacies of TEBGs will be reviewed. 
 - 22 - 
 
1.3. Review of literatures: bone tissue engineering applications 
for critical-size defect  
In last section, the state of the art in bone tissue engineering has been 
introduced, and future trends and challenges were briefly discussed. In this 
section, a systematic review of literatures on the application of bone tissue 
engineering approaches for critical-size bone defect will be presented. The 
critical-size defect models were developed to represent the clinical settings of 
bony defects, in order to evaluate clinical efficacies of the TEBGs. Based on 
the criteria of bone tissue engineering approaches and critical-size defect 
animal models, 175 studies were selected and analyzed in the review. This 
section will summarize the main findings from these 175 articles, with 
particular discussion on animal models, cell sources and bioprocessing that 
enhances the efficacies of bone grafts.  
 1.3.1. Searching strategy and inclusion criteria 
A systematic literature review has been conducted to review the recently 
published studies using tissue engineering approaches to treat critical-size 
bone defect. A keyword search was conducted through online database and 
relevant articles that are published within 15 years were collected for the 
review. For each selected article, basic experimental settings such as cell 
source, scaffold material, processing strategy and animal model were recorded. 
Moreover, the major findings were concluded based on the objective of each 
study. Statistical analysis has been performed based on experimental settings 
to outline the states of bone engineering approaches and animal model designs. 
Finally, the main findings were reviewed and summarized according to study 
design and research objectives. Literature search strategy and inclusion criteria 
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will be introduced in this section, followed by review of findings based on 
study design and results. 
To initiate the article collection, a keyword searching was carried out on 
PubMed online database (http://www.ncbi.nlm.nih.gov/pubmed/). After trials 
and adjustment on different combination of keywords, the following keyword 
criteria were used to get the most relevant search results: (cell OR cells) AND 
(graft OR scaffold) AND critical AND bone AND defect”. To keep the 
information up to date, only the articles published from January 2000 to 
November 2015 (by the time of thesis completion) are included. Accordingly, 
340 preliminary results were found using the above criteria.  As the review is 
focused on tissue engineering approaches for critical-size bone defects, 
treatments without cells (for example, using growth factors alone or 
incomplete cell populations such as platelet-rich plasma) were excluded; 
animal models that are not bone defect (such as osteochondral defect, cartilage 
defect) or not critical defect were excluded. Accordingly, by examining the 
contents (abstracts or full text) of all the articles in search results, irrelevant 
studies were excluded and 159 articles were finally selected for the review. 16 
more articles were found in the reference list of reviewed articles, which met 
the criteria but were missed in the systematic search result. After 
supplemented with these 16 articles, 175 articles were found and included in 
this review. All the selected studies involved using cell sources in 3D matrix 
as scaffold for the treatment of critical-size bone defects in animals, which are 
consistent with my definitions and descriptions for bone tissue engineering 
and critical-size defect in Section 1.2 and Section 1.1.3. 
 - 24 - 
 
According to the main findings of the studies, the selected articles can be 
categorized as follows: 1) Development of novel TEBGs (52% of the studies); 
2) Evaluation on the efficacy of elements or strategies used for engineering 
bone tissue (40% of the studies); 3) Investigation of mechanism or medical 
treatment in tissue engineering mediated bone repair (8% of the studies). In 
order to achieve the goals, appropriate animal model was selected and TEBGs 
were developed in various ways. A summary of results will be presented in 
following sections based on animal models and study design. In Section 1.3.2, 
the design of animal models is introduced and models used in the studies are 
reviewed. Cell sources and tissue culture strategies used are reviewed in 
Section 1.3.3 and 1.3.4. Due to the complexity and diversity in scaffold design, 
the use of scaffolds will not be specifically reviewed, but will be given in 
context of other reviews. 
 1.3.2. Animal models of critical-size defect 
As introduced in Section 1.1.3, bone tissue engineering approaches were 
brought to solve one of the major challenges in orthopedics – non-union 
defects which are caused by excessive bone loss. Therefore, several animal 
models were developed to mimic the clinical cases of critical-size bone defect 
in order to evaluate the feasibility, clinical efficacy and safety of the tissue 
engineering products. In this section, animal models used in the reviewed 175 
studies will be introduced with a discussion on their characteristics. In addition, 
the assessment for bone healing outcomes will also be discussed. 
A wide range of mammalians have been used and developed for bone defect 
including both rodents such as mice, rats, rabbits and large animals such as 
dogs, goats, sheep and pigs (Figure 1-4).  Rodents have been extensively used 
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for fracture studies, occupying more than 70% of studies in the field. Small 
rodents such as mice and rats are advantageous in providing large sample size 
and faster healing process, compared to large animals. Additionally, genetic 
manipulations are feasible, which allows possibilities of varied complex 
experimental designs. However, rodent models are limited in reflection of 
some clinical applications, such as fracture site, defect size and external 
fixation that subjected to certain bone size to implement. On the contrary, 
large animals such as sheep and dogs are easier to match these clinical settings 
(Ronca 2014; J. Wu 2015), and it is claimed that the bone biology and 
composition of large animals are more similar to human’s (Pearce 2007). The 
selection of animal species also depends on the purposes of the study, methods 
of assessment, and unique requests for anatomic location or surgical procedure.  
In addition to the options among animal species, the bone defect type and 
location are other main factors to be considered in designing a ciritical-size 
defect model (Figure 1-4). Segmental defect on long bones is widely used, 
because it can be readily created using standard surgical procedures. The 
defined dimensions and anatomic location facilitate the tracking of new bone 
formation and neo-vascularization. Furthermore, mechanical outcomes can be 
easily assessed by measuring torsional torque and bending strength. The 
femoral and tibial diaphysis tends to be used most often, but require internal or 
external fixation (Foo 2013; Z. Zhao 2009). Radius, ulna, and metatarsal 
models can be used without complimentary fixations in many settings, but 
only limited to rabbits or larger animals due to the bone size (Niemeyer 
2010c). Facial/cranial defects, on the other hand, usually do not require 
internal fixation, thus eliminate the effects of stress shielding and any 
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compromise of radiographic imaging or histological assessment associated 
with metal fixation tools. Therefore, these models were commonly used as the 
primary screening tools or entry point for the biomaterials (N. Liu 2014). To 
sum up, the combination of animal species and defect types jointly determines 
the characteristics of each animal model. Figure 1-4 summarized the use of 
different animal models used in selected articles. 
 
Figure 1-4 Pie chart and table summarizing animal models used in selected 175 
studies.  
In pie chart, studies are grouped based on animal species used; numbers and 
percentages of the studies were labeled. The table below further separates the studies 
based on locations of the bone defect, and elaborates the distribution of animal 
models used in selected studies. 
 
In addition to the creation of models, evaluation of healing outcomes is 
another major challenge in designing and conducting an animal study. The 
assessment of bone bridging is primarily determined by the mineral ECM 
formed, which can be observed through radiographic imaging on bones and 
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histopathology staining on sample sections. Radiography is the most effective 
non-invasive measurement to track bone repair status, and computed 
tomography (CT) further allows analysis on quantitative assessment of 
regenerative bones, such as volume and area (Kallai 2011). Histological 
analysis is another major way to evaluate bone repair, which can only be 
conducted on sections of extracted samples.   Haematoxylin and eosin (H&E) 
stain is mostly used, which allows direct observation of ECM formation and 
the cellular ingrowth. Von Kossa staining and Mason’s Trichrome staining are 
other commonly used methods for bone ECM staining (Rentsch 2014). While 
histopathology staining can display the morphology of the repaired bone, 
immunohistochemistry techniques allow specific detection of genes or cell 
types, providing evidence for mechanistic explanations and findings. In order 
to evaluate the functionality of the repaired bones, mechanical tests such as 
torsional test and bending test are often conducted on bone extracts at the ends 
of the studies (Nau 2015). Besides evaluations on bone formation or repair, 
assessments on indirect indicators for healing outcomes such as neo-
vascularization, chimerism, inflammation, tumorigenesis and other safety tests 
are actively  performed in each study (Choi 2011; Eldesoqi 2014; G. Liu 2013; 
J. Wu 2015; Zou 2012).  
Along with the progress in tissue engineering technologies, animal models for 
bone defects also enjoyed a major improvement in variety and new models are 
being actively pursued. More sophisticated models can be expected for not 
only testing the efficacies of bone grafts, but also for investigating the 
mechanisms behind the therapies. Nevertheless, according to George 
Muschler’s review, the design of animal models for critical-size defect should 
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follow general guidelines (Muschler 2010), namely: (1) to use animal species 
that provide metabolic background and physiological responsiveness 
comparable to humans; (2) to apply surgical techniques that match or are most 
analogous to clinical methods; (3) to apply therapy in the manner that to be 
delivered in a clinical setting; (4) to assess outcomes that be done as closely 
matched as clinical settings; (5) to apply potential medical treatments that will 
be used clinically. To obtain the most clinical-relevant results, the animal 
models used in pre-clinical studies should follow these guidelines, in addition 
to apply the novel therapeutic strategies. 
 1.3.3. Cell sources used for treating critical-size defect 
In order to engineer bone tissue as grafts, various cell types were used. The 
advantages and limitations of cell sources are mostly covered in Section 1.2.1.  
In this section, the preference of cell sources, summary of cell sources used for 
critical-size defect and comparison of the efficacy of different cells will be 
reviewed.  
The cell sources can be divided in two major subgroups: human origin and 
animal origin (Figure 1-5). For both subgroups, bone marrow derived 
mesenchymal stem cells (BMSC) and adipose tissue derived stem cells (ASC) 
were most common sources, occupying 70% of the trials. The use of 
autologous or allogeneic BMSC and ASC can avoid the problems with 
immune rejection or cell niche changes after implantation, thus provides an 
entry point for testing new scaffolds or trying out processing strategies and 
medical treatment. As presented in Figure 1-5, BMSC plays a dominant role in 
autologous/allogeneic cell transplantation studies (68 out of 121), mainly due 
to its simplicity in harvesting and expansion, recognized efficacy and immune 
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privilege for allogeneic cell lines. By contrast, studies using human cell lines 
provided translational insights on tissue engineering for clinical applications, 
thus more attempts were tried on diverse source. In addition, the use of ASC 
(14 studies) was comparable with BMSC (16 studies) in human cell lines, 
probably because adipose tissue is more approachable than bone marrow from 
the donor. Figure 1-5 showed the distribution of using cell sources from 
different origin (outer doughnut chart) and cell types (inner pie chart) 
respectively. 
 
Among the reviewed 175 articles, most of the tissue engineering approaches 
healed the critical-size defect or improved the healing efficacy, compared to 
the control groups such as an empty scaffold (Yuan 2007), or positive controls 
such as autograft and BMP-2 treatment (Peterson 2005; Viateau 2007). 
Although BMSC and ASC have been mostly used as cell sources, attempts 
also have been done on other mesenchymal cells derived from tissues 
including muscle, dental pulp, periosteum, umbilical cord, cord blood, 
amniotic fluid and even urine. Additionally, pilot studies in primitive stem 
Figure 1-5 Cell types used in animal 
studies for tissue engineering treatment 
of bone repair.  
Numbers of studies using particular cell 
type were labeled. The outer doughnut 
chart displays the origins of cells (human 
versus animal), while the inner pie chart 
displays the cell types – namely BMSC 
and ASC and the others – that are used 
under each subgroup of the studies. 
Abbreviations: Auto/Allo – autologous or 
allogeneic cell lines (animal origin); 
human – human cell lines; BMSC – bone 
marrow derived mesenchymal stem cells; 
ASC – adipose tissue derived stem cells. 
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cells such as induced pluripotent stem cells (iPSC) and embryonic stem cells 
(ESC) were also attempted by a few groups and achieved promising outcomes. 
Table 1-2 reviewed the studies using different cell lines for the treatment of 
critical-size defect, in which one representative study was included for each 
type of cells. Genetically modified cell lines were not included in the table, 
while the culture media used for either expansion or differentiation were listed, 
as the culture history might modify the cellular phenotypes. 
Although most of the bone engineering approaches healed the critical defect or 
significantly improved the outcomes, about 7% (13 out of 175) of the studies 
showed little healing after the treatment with cellular scaffolds. The 
compromised healing efficacy could be ascribed to inappropriate choice of 
cells or scaffolds, poor conditions or insufficient amount of cells. Notably, in 8 
studies using osteoblast cell sources, 4 of them showed no improvement to the 
healing, while two studies of the rest that showing positive results used BMP-
2 transduced cell lines (Bagher 2012; Gallego 2010; Haberstroh 2010; Keskin 
2008; Sommar 2013; Tayton 2015; Wehrhan 2012, 2013). The inferior 
efficacy of osteoblasts suggests that they are not the best choice for bone 
tissue engineering, probably due to the cell conditions were compromised 
during the harvesting process. On the other hand, other types of cells, mostly 
mesenchymal cells, demonstrated more or less improvement in healing 
outcomes. Because of the variety in experimental settings, it is not possible to 
compare the potency of each TEBG developed in these studies. However, 
several comparative studies have been done to apply the same conditions to 
different cell lines and compare their efficacies to treat the same animal model. 
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Table 1-3 reviewed these comparative studies, with information of scaffold, 
animal models and briefing of findings given. 
  
 
Table 1-2 Review of studies using different cell sources for healing critical-size bone defect.   
Abbreviations: MSC, mesenchymal stem cell; EPC, endothelial progenitor cell; iPSC, induced pluripotent stem cell; ESC, embryonic stem cell; 
BMSC,  bone marrow derived mesenchymal stem cell. 
Study design Reference Cell type Cell origin Culture media Animal Model Main conclusions 
Studies using 
autologous or 
allogenic cell sources 
(Petite 2000) MSC Bone marrow Growth media Sheep Metatarsus  
The addition of cells significantly 
improved the healing efficacy in 
bone defect compared with empty 
scaffold 
(Cui 2007) MSC Adipose Bone media Dog Crannium 
(Jang 2008) MSC Cord blood Growth media Dog  Radius  
(Caballero 2015) MSC Umbilical cord Bone media Pig  Mandible  
(Atesok 2010) EPC Bone marrow Endothelial media Rat  Femur  
(Eldesoqi 2013) EPC Spleen Endothelial media Rat  Cranium  
(Haberstroh 2010) Osteoblast Periosteum Growth media Sheep Cranium 
Studies using human 
cell lines 
(Zhang 2010a) MSC Fetal bone marrow Bone media Rat  Femur  
The addition of cells significantly 
improved the healing efficacy in 
bone defect compared with empty 
scaffold. 
 
The implanted cells vanished 
eventually although the animals 
were immuno-deficient. 
(Levi 2010) MSC Adipose  Growth media Mouse  Cranium  
(Petridis 2015) MSC Dental pulp Growth media Rat  Cranium  
(Bueno 2009) MSC Muscle Growth media Rat  Cranium  
(Sakata 2006) MSC Periosteum Growth media Rat  Cranium  
(Reddy 2013) MSC Placenta Growth media Rat  Femur  
(Jager 2007) MSC Cord blood Growth media Rat  Femur  
(Guan 2015) MSC Urine  Growth media Rat  Femur  
(Rodrigues 2012) MSC Amniotic fluid Bone media Rat  Femur  
(Gallego 2010) Osteoblast  Cancellous bone Bone media Rat  Mandible  
(P. Wang 2015) iPSC Bone marrow Bone media Rat  Cranium  
(Kuhn 2014) ESC Embryo Growth media (MSC) Mouse  Cranium  
Studies that obtained 
negative results 
(Annibali 2013) Human dental MSC Growth media Mouse  Cranium  
TEBG did not significantly improve 
the healing compared with using 
scaffolds alone. Both TEBG and 
empty scaffold obtained minimum 
healing. 
 
(Pennington 2015) Allogenic amniotic MSC Bone media Rabbit  Tibia  
(Bagher 2012) Autologous osteoblast Bone media Rabbit  Tibia  
(Kunkel 2015) Allogenic tendon MSC Growth media Rat  Femur  
(Tayton 2015) Autologous osteoblast Bone media Sheep  Femur  






Table 1-3 Review of comparative studies comparing the efficacy of different cell sources for critical-size bone defect.  
Abbreviations: MSC, mesenchymal stem cells; BMSC, bone marrow derived MSC; ASC, adipose derived stem cells; UC-MSC, umbilical cord derived MSC; 
BM-EPC, bone marrow derived endothelial progenitor cells; iPSC, induced pluripotent stem cells; TEBG, tissue engineered bone graft; PRP, platelet-rich 
plasm.






with allogenic cells 
(G. Liu 2013) ASC Coral Growth media Dog Cranium 
No difference between autologous cell lines 
and allogeneic cell lines for bone repair, 
although allogenic cells may induce higher 
inflammation. Both autologous and allogenic 
cells can integrate into host bone. 
(Berner 2013) BMSC PCL-TCP Bone media Sheep Tibia 
(Tsuchida 
2003) 
BMSC Collagen Growth media Rat Femur 
(J. Wu 2015) BMSC Coral Bone media Dog Mandible 
Compare different 




BMSC / ASC Collagen Growth media Sheep Tibia BMSC performed better than ASC with PRP. 
(Walmsley 
2015) 
ASC / BMSC / 
osteoblast 
PLGA Growth media Mouse Cranium 






PCL-HA Bone media Rat Femur 
Addition of EPC significantly enhance both 
neo-vascularization and bone healing 
mediated by BMSC, BMP-2 transduction in 











autologous sources  
(Niemeyer 
2010c) 
BMSC HA Growth media Rabbit Radius Autologous BMSC significantly enhances 
defect healing, while the efficacy of human 
BMSC is comparable to empty scaffold. 
(Niemeyer 
2010b) 
BMSC HA Growth media Sheep Tibia 
Compare different 




UC-MSC / BMSC HA-TCP Bone media Rat Cranium BMSC performed better than UC-MSC and 
dental pulp MSC. All TEBGs improved 
healing compared with empty scaffold. 
(Moshaverini
a 2014) 




Growth media Mouse Cranium 
(Maraldi 
2013) 
Dental pulp MSC / 
Amniotic fluid 
MSC 
Collagen Bone media Rat Cranium 
Both TEBG improved healing. Amniotic fluid 




iPSC / BMSC / UC-
MSC 
CaP Bone media Rat Cranium 
iPSC performed betther than BMSC and UC-





BMSC and EPC 
from buffy coat 
β-TCP Growth media Rat Femur Co-culture significantly improved vessel 
formation and bone formation compared with 
using MSC alone. 
(Seebach 
2010a) 
BMSC and EPC 
from buffy coat 
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In studies comparing different cell lines, varied results were obtained. For 
mesenchymal cell source, the efficacy mostly relied on the processing 
techniques and experimental settings other than the tissue origin, and their 
therapeutic potential could be further improved by use of co-culture system 
such as with endothelial cell lines (Table 1-3). Wang et. al. showed a good 
potential of iPSC, while plenty of barriers are yet to be conquered in a clinical 
setting (P. Wang 2015). Intriguingly, in studies comparing mesenchymal cell 
source form autologous donor with allogenic donor, no significant difference 
was found in their efficacies and response of host animals. These observations 
further confirmed the immune privilege of allogenic MSC in the critical-size 
defect models, and provided insights on using allogenic cell lines as potential 
therapies for clinical cases. However, the implantation of human BMSC in 
animals resulted in inferior healing efficacy compared to autologous cell lines, 
despite of no inflammation response was caused by xenogeneic implantation 
(Niemeyer 2010b; Niemeyer 2010c). Moreover, many other studies using 
human cell sources claimed the disappearance of implanted human cells after 
weeks of transplantation, even when immunosuppressive treatment was given 
(Chuang 2010; Jager 2007; Zhang 2010a). The rejection of human cells may 
be caused by the inevitable primary immune reaction, or the xenogeneic cell 
niche. Although the underneath mechanism is unclear yet, precautions for 
xenogeneic rejection should be considered when designing such pre-clinical 
study. 
As the key functional element, cell sources used in tissue engineering 
mediated bone repair play dominant role in the healing mechanism and 
efficacies. The review of cell sources in these attempts showed the current 
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states of different sources, and might provide implications on the selection of 
suitable cell sources according to clinical needs. Furthermore, the biological 
properties of the cells may also be affected by the bioprocessing methods and 
scaffold used, which alter the healing mechanism and efficacies of the TEBGs. 
In next section, bioprocessing methods used in engineering bone grafts for 
critical-size bone defect and their efficacies will be reviewed.  
 1.3.4. Tissue culture in bone tissue engineering for critical-size defect  
In addition to the selection of cell sources, tissue culture methods – both pre-
seeding and post-seeding – are also crucial in bone tissue engineering 
processes. By cultivating stem cell sources or stem cell-seeded scaffolds in 
media supplemented with a combination of ingredient, the in vivo efficacy and 
healing mechanisms of cellular scaffolds may be altered. In reviewed 175 
articles using tissue engineering approaches to treat critical-size defect, around 
one third of the studies induced the stem cells or cellular scaffolds before 
transplantation. Notably, several studies compared the efficacies of utilizing 
different tissue culture methods to prepare TEBGs. This section will review 
these comparative studies and discuss the efficacies of using differentiation 
induction culture media based on the findings in these studies. 
Efficacies of pre-seeding osteogenic induction are varied in comparative 
studies. In a treatment of a rabbit radial defect model, no difference was found 
between using BMSC cultured in growth media and osteogenic media (L. 
Zhao 2008). Another study, however, showed that early differentiate stage of 
BMSCs achieved the best healing outcome over undifferentiated BMSCs and 
mature osteoblasts in a rat model (Castano-Izquierdo 2007). The compromised 
healing efficacy of long-term induced cells could be caused by the change of 
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cell niche when transferring monolayer cells into 3D scaffolds, and fully 
induced cells lacked proliferation and adhesion activity compared with less 
differentiated cells. Moreover, in a comparison of pre-seeding induction 
among different cell sources, MSCs derived from umbilical cord (UC-MSC) 
and adipose tissues (ASC) showed an improved healing capacity when pre-
differentiated in osteogenic media, while induced differentiation seemed to 
reduce the healing capacities of MSCs derived from bone marrow (BMSC) 
and cord blood (UCB-MSC) (Jo 2013). The results indicated that the 
responses of different cell lines to osteogenic induction are varied, and 
suggested that UC-MSC and ASC might be the “less osteogenic” cells that 
required additional osteogenic commitment before transplantation.  
On the other hand, studies have been done to evaluate post-seeding osteogenic 
induction efficacies, especially comparing the effects of media, the duration of 
induction and the usage of bioreactors (Table 1-4). In studies comparing 
efficacies of osteogenic media with growth media, it showed that the efficacies 
of short-period osteogenic induction (less than 2 weeks) were controversial in 
supporting defect healing (Di Bella 2008; Dumas 2009; X. Li 2010; Zong 
2010) (Sikavitsas 2003). However, studies applying long duration of time in 
osteogenic induction on TEBGs (more than 4 weeks) showed improved 
healing outcomes over untreated ones or TEBGs cultured in growth media 
(Kirker-Head 2007; Meinel 2006; Sommar 2013). In a study comparing the 
efficacies of TEBGs induced for different duration of time, long-term induced 
TEBGs (3 weeks) showed superior healing capacities over those induced for 
shorter period (Rodrigues 2012). These studies suggested that although 
controversial might be caused by the different cell source and experimental 
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settings used, long-term osteogenic induction tends to improve the healing 
efficacies of MSC derived TEBGs. In studies comparing the efficacies of 
static culture and perfusion system, the results also suggested that the 
advantages in use of bioreactors were distinct only when applying long-term 
induction (Gardel 2014; Sikavitsas 2003).  
Osteogenic induction is a common tissue culture strategy for preparing TEBGs. 
The review of comparative studies investigating the efficacies of osteogenic 
induction showed controversial results and a trend that long duration of 
osteogenic induction promoted the healing capacities of TEBGs. Table 1-4 
listed the detailed experimental settings and main findings of these reviewed 
articles. In addition to osteogenic induction, attempts inducing MSCs into 
other cell lines such as endothelial cells and chondrocytes also showed 
promising results (Cornejo 2012; Sahar 2012; van der Stok 2014). 
Nevertheless, osteogenic induction is still the most common and effective 
induced differentiation bioprocessing to prepare TEBGs (Sahar 2012).   
However, the mechanistic role and efficacies of osteogenic induction are 
varied among different cell sources and remain to be determined. A novel 
TEBG was developed recently which may provide valuable insights on the 
remaining gaps. In next section, previous progress and findings on this TEBG 
will be introduced, and the unresolved key questions regarding its healing 









culture (3D)  




Allogenic BMSC BM or GM 1 week BM or GM 1 week Rabbit  Radius BM=GM (L. Zhao 2008) 
Allogenic BMSC 
BM 4, 10, 16 days 
or GM 6 days 





GM expansion or  
BM 4 days 
0 day Rat  Femur  
UC-MSC/ASC: BM>GM;  





Allogenic ASC GM expansion BM or GM 14 days Rat  Cranium  BM=GM (X. Li 2010) 
Allogenic BMSC GM expansion BM or GM 14 days  Mouse Cranium  BM=GM (Dumas 2009) 
Autologous ASC GM expansion BM or GM 2.5 days Rabbit  Cranium  BM>GM (Di Bella 2008)  
Human dermal fibroblast GM expansion 
BM or GM 8 weeks 
Spinner flask  
Rat  Femur  BM>GM (Sommar 2013) 
Human BMSC GM expansion 
BM or GM 14 days 
Perfusion bioreactor 
Rat  Cranium  GM>BM  (Zong 2010) 
Human amniotic fluid 
stem cells 
GM expansion BM 0/1/2/3 weeks Rat  Femur  
BM 3 weeks > others  
(bone repair and neo-vascularization) 
(Rodrigues 2012) 
Human BMSC GM expansion 
BM 5 weeks or 0 
day Spinner flask   
Rat  Femur  BM 5 weeks > 0 day (Meinel 2006) 
Human BMSC GM expansion 
BM 4 weeks or 0 
day Spinner flask 





Autologous BMSC GM expansion 
BM 14 days 
Perfusion or static 
Goat  Tibia  Perfusion > static (Gardel 2014) 
Allogenic BMSC BM 6 days 
BM 1, 4, 8 days 
Perfusion or static  
Rat  Cranium  Perfusion=static, 1 day > 4/8 days, (Sikavitsas 2003) 




EM 8 days or  
BM 21 days 
EM or BM 2 days Rat  Cranium  
EM > BM  
(bone repair and neo-vascularization) 
(Cornejo 2012) 
Human ASC GM expansion 
EM 8 days or BM 
21 days 
Rat  Cranium  
Bone repair: BM>EM;  
Neovascularization: EM>BM 
(Sahar 2012) 
Human BMSC GM expansion 
Chondral media  
0/3/21 days 
Rat Femur  21 days >3 days > 0 day 
(van der Stok 
2014) 
Table 1-4 Comparative studies on pre-transplant tissue culture methods.  
Studies were categorized based on their objectives and experimental settings. Culture history was further divided into pre-seeding culture (monolayer culture) 
and post-seeding culture (static culture on 3D cellular scaffolds or using bioreactor as stated). The results were concluded based on overall outcomes of the 
healing and the efficacies of TEBGs generated from different culture methods were given. “>”,”=” and “<” stand for better efficacy, similar efficacy and 
poorer efficacy respectively. All efficacies were referred to bone repair outcomes unless otherwise stated. Abbreviations: GM, growth media; BM, bone 
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 1.3.5. Summary 
In this section, practical application of bone tissue engineering in healing 
critical-size defect was reviewed, particularly on animal models, cell sources 
and tissue culture methods used in these studies. Designing an animal model 
with critical-size bone defect requires considerations of animal species, defect 
type and necessary medical or surgical treatments. In addition, proper 
assessment for bone repair is also required to evaluate the healing outcomes 
and thus to present the healing efficacy of tissue engineering approaches. In 
studies using tissue engineering approaches to treat critical-size bone defect 
models, mesenchymal stem cell derived from bone marrow (BMSC) was the 
most common cell sources, due to its easiness of harvesting, demonstrated 
stable efficacies and immune privilege in allogeneic sources. Moreover, 
diverse stem cell sources from human origin were being actively explored and 
applied in the critical-size defect models, and their therapeutic efficacies were 
evaluated in the clinically relevant environment. Tissue culture period can 
change the cellular differentiation stage and phenotypes, and thus may alter 
the healing efficacy of a TEBG. However, studies comparing the efficacies of 
TEBGs cultivated in different methods showed controversial results, 
especially in those applying short-term osteogenic induction. Although 
inducing cellular differentiation is believed to provide more osteogenic cell 
sources to the host for immediate bone formation, the mechanistic role and 
efficacies of osteogenic induction are varied among different cell sources and 
remain to be determined. In next section, the potential role of osteogenic 
induction on a novel TEBG will be discussed, which was developed using 
hfMSCs and composite PCL-TCP scaffolds. 
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1.4. HFMSC engineered bone graft for defect healing 
In previous sections, tissue engineering approaches have been introduced, and 
studies using TEBGs for healing critical-size bone defects have been reviewed. 
In addition to cell sources and biomaterial scaffolds, tissue culture process – a 
critical bioprocessing step to prepare TEBGs – may also significantly change 
the properties and thus determine healing efficacies of a TEBG. However, 
previous studies investigating the efficacy of osteogenic induction showed 
conflicting results, suggesting that the role of osteogenic induction could be 
dependent on the cell source utiliszed. Previously, a novel highly osteogenic 
TEBG was generated using hfMSC and PCL-TCP composite scaffolds, which 
demonstrated great efficacies in mediating critical-size segmental defects. In 
this section, previous progress and findings in this TEBG will be elaborated, 
and the potential role of osteogenic induction on healing efficacy of this 
TEBG will be discussed. 
 1.4.1. hfMSC engineered bone graft 
Previously, hfMSC was identified and isolated from fetal bone marrow 
(Campagnoli 2001). This marrow derived MSC lineage expressed multiple 
mesenchymal markers including CD105, CD73, CD90, CD44, CD29, Laminin 
and Vimentin, and was negative for haemopoietic markers CD45, CD14, 
CD34, and endothelial marker CD31 (O'Donoghue and Chan 2006). The cells 
can be readily harvested, and promptly expanded in serum supplanted basal 
media. Notably, hfMSC displayed a 40% higher proliferation rate compared 
with MSCs derived from umbilical cord, adipose tissue and adult bone marrow. 
Furthermore, when primed in osteogenic media, hfMSC demonstrated 
significantly higher osteogenic differentiation capacity and mineralization 
 - 41 - 
 
activities compared with these MSCs (Zhang 2009a). These studies indicated 
that hfMSC is a promising cell source for bone tissue engineering. 
In addition, it has been shown that these highly osteogenic hfMSCs can be 
developed to TEBGs by loading on macroporous polycaprolactone tricalcium 
phosphate (PCL-TCP) composite scaffold and induced in osteogenic media 
(Zhang 2009a; Zhang 2009b). PCL-TCP is a macroporous scaffold developed 
by incorporating 20% tricalcium phosphate (TCP) in polycaprolactone (PCL) 
basal scaffold. The addition of TCP was intended to improve load-bearing 
strength lacked in polymeric PCL scaffolds, and was believed to improve the 
osteoconductivity and osteoinductivity of the basal scaffolds (Nga 2015; Rai 
2004; Rai 2005). However, whether the inclusion of TCP can enhance hfMSC 
cellular responses such as attachment, proliferation and differentiation has not 
been examined. As the addition of materials in scaffolds can take strong 
effects on cell behaviors, it is crucial to understand how TCP inclusion affects 
hfMSC differentiation on PCL based scaffolds. 
Although the superiority of using composite material instead of PCL basal 
scaffold was not justified, PCL-TCP scaffold has presented favorable 
compatibility and osteoconductivity when loaded with hfMSCs. Again, 
hfMSCs with PCL-TCP showed superior differentiation efficiency and 
mineralization activity among cellular scaffolds assembled by PCL-TCP 
scaffold and MSCs from other origins (Zhang 2009a). To further enhance the 
cellular viability and efficiency of osteogenic induction, a biaxial rotating 
bioreactor (BXR) system was used, which featured two-axis rotation, a gas 
exchange system and a perfusion pump. Dynamic culture of hfMSC loaded 
PCL-TCP scaffolds in BXR system resulted in improved cellular viability and 
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proliferation, as well as more mineral deposition (Zhang 2009b).  Furthermore, 
in a comparative study of among different bioreactors, the BXR system 
showed better efficiency in induced differentiation than other bioreactors, 
including perfusion bioreactor, spinner flask and rotating wall vessel (Zhang 
2010b). Previous findings justified that BXR bioreactor is an effective 
bioprocessing system for osteogenic induction of hfMSC-TEBGs. 
The hfMSC-TEBG generated by hfMSC, PCL-TCP scaffold and BXR 
bioreactor has been used for treatment of critical-size defect, and evaluated its 
pre-clinical efficacy in a rat femoral defect model (Zhang 2010a). When 
compared with the animals treated with empty scaffolds, animals implanted 
with hfMSC-TEBG achieved significant improvement in both bone formation 
and vascular formation. These findings suggested that implant of the TEBG 
promoted neo-vascularization in the host body, in addition to the support for 
bone repair. Intriguingly, the implanted hfMSCs can no longer be located in 
the scaffolds within 4 weeks after the implantation, while the efficacy of the 
implants continued to improve bone repair until the end of the study (3 
months), as indicated by the bone volume between TEBG group and the 
control group. According to the previous findings, it is suggested that the 
implanted hfMSC-TEBG not only involved in bone regeneration as functional 
engraftment, but also regulated the host bone repair cascade such as neo-
vascularization through paracrine effects. In next section, I will discuss the 
hypothetic role of hfMSC-TEBG in healing of bone defects, and particularly 
introduce the paracrine effects of the TEBG. 
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 1.4.2. Potential mechanism of hfMSC-TEBG mediated bone healing 
In last section, a recently developed TEBG using hfMSC, composite PCL-
TCP scaffold and a biaxial rotating bioreactor system was introduced, with 
discussion of its superiority and pre-clinical efficacies. Although the exact 
mechanism of hfMSC derived TEBG was not systematically investigated, 
previous findings suggested that the TEBG not only involved in bone 
formation processes, but also contributed to neo-vascularization. This section 
will introduce the potential healing mechanism of the hfMSC-TEBG based on 
previous observations on this TEBG and published studies on other MSC-
derived TEBGs, and focused on the importance of paracrine effects. 
Defining the exact role of the MSC derived TEBGs during TEBG mediated 
bone healing remains a challenge, partially because MSCs are heterogeneous 
and behave variedly depending on its origin (Bielby 2007; Maumus 2013). It 
has been showed that when implanted in vivo, differentiated MSCs can 
actively synthesize bone ECM through releasing proteins such as alkaline 
phosphatase (ALP), collagen type I α 1 (Col1A1) and osteonectin (Chai 2012). 
Moreover, TEBGs generated by allogenic ASCs (adipose derived MSCs) can 
functionally engraft in host body and integrate within the repaired bones (X. 
Gao 2014a; G. Liu 2013). These evident observations demonstrated the direct 
contribution of implanted TEBGs in new bone formation. In terms of hfMSCs, 
although they are of human origin and did not persist in the xenogenic hosts 
(rats) after one month, they were shown to be highly activated in ALP, 
Col1A1 and ostenectin expression during osteogenic induction in vitro, and 
the differentiated cells might continue to participate in early osteogenesis 
processes immediately after  implantation (Guillot 2008; Zhang 2009a).  
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In addition to the direct contribution, TEBGs were also able to secrete 
functional growth factors and cytokines, and regulate the host bone repair 
process, that is, the paracrine effect. As introduced in Section 1.1.2, several 
growth factors and cytokines that are critical to bone repair were released and 
activated during the fracture healing cascade, including TGF beta family, 
BMP family, FGF family, inflammatory cytokines IL-1, IL-6 and angiogeneic 
stimulates VEGF, IGF and angiopoietins (Ai-Aql 2008; Doorn 2012; Z. J. Liu 
2009; Maumus 2013). As the main functional cells, osteoblasts and their 
precursors can express and secrete most of these proteins, and thus regulate 
the host bone repair process when implanted as TEBG components. The major 
functional proteins reported to be released by MSCs were listed and 
characterized based on their major functions (Table 1-5). It has been shown 
that when implanted in vivo, MSC derived TEBGs were able to release these 
functional proteins and thus improve the host bone healing (X. Gao 2014a). 






Promote MSC differentiation and proliferation, 
stimulate angiogenesis, induce intramembranous and 







ANG,  IGF 
Promote mobilization of progenitor cells, induce 
angiogenesis, stimulate proliferation of tubular cells 








Induce inflammation, initiate fracture healing 




Table 1-5 Bone repair related proteins secreted by MSCs.  
The major functional proteins involved in bone repair process were listed with 
examples of typical proteins. Depending on the main functions, proteins can be 
categorized as osteogenic stimulates, angiogenic growth factors and inflammation 
cytokines. Abbreviations: TGFβ, transforming growth factor beta; BMP, bone 
morphogenetic protein; IGF, insulin-like growth factor; VEGF, vascular endothelial 
growth factor; ANG, angiopoietins; FGF, fibroblast growth factor; IL-1/IL-6, 
Interleukin 1/6. 
 
In a previous study using hfMSC-TEBG to heal the rat femoral segmental 
defect, it has been shown that the TEBG-implanted group obtained 
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mineralized bridging of the defect and more neo-bone volume than scaffold-
only implanted group after 3 months. However, the bone volumes were similar 
between two groups after 1 month of implantation, around the time that the 
implanted hfMSC were no longer present in the implants (Zhang 2010a). This 
may suggest that hfMSC-TEBG made minimal direct contributions in bone 
formation and repair, even in the early stage of fracture healing. Notably, neo-
vascularisation was far more vigorous in TEBG-implanted group than the 
empty scaffold-implanted group at 1 month post-implantation. As hfMSC had 
vanished at the time point, the neo-vascularization should be driven by 
paracrine effects, and might subsequently impact favorably on fracture repair. 
As a result, TEBG implanted animals achieved union and more bone volume 3 
month after implantation. These findings suggested that hfMSC-TEBG 
improved the defect healing mainly through paracrine effects, especially the 
induction of neo-vascularization. 
As MSCs are heterogeneous cells, the secretome of different batches or 
isolates might be varying, and the paracrine effects of hfMSC-TEBG in 
supporting neo-vascularization remained to be defined. Furthermore, the 
culture history, especially induced differentiation, can significantly change the 
cellular phenotypes and might also alter the secretome. The osteogenic 
induction processing on hfMSC-TEBG might not only trigger cellular 
differentiation, offering more mature cell lines for direct contributions; but 
also alter cellular secretome and modify its paracrine effects. In the next 
section, I will further discuss the potential role of osteogenic induction on 
MSC-derived TEBGs based on literature reviews, and introduce the remaining 
gaps in the field. 
 - 46 - 
 
 1.4.3. Potential role of osteogenic induction in hfMSC-TEBG mediated 
bone regeneration 
In the previous section, previous findings in TEBGs generated using human 
fetal MSC (hfMSC) were reviewed and the potential role of the TEBG in bone 
defect healing was discussed. Results in healing of critical-size defect model 
suggested that hfMSC-TEBG might play a major role in supporting neo-
vascularization through paracrine effects, while the direct contributions such 
as functional engraftment and improvement in ossification were less effective. 
Since osteogenic induction on MSC loaded scaffolds induces cellular 
differentiation and possibly changes the cellular secretome, the efficacy of 
osteogenic induction on MSC-derived TEBGs could be more than just induced 
differentiation. In this section, I will review the studies that investigated the 
effects of osteogenic induction on MSC cell lines, focusing on paracrine 
effects, and discuss the potential role of osteogenic induction in hfMSC-
TEBG’s bone healing efficacy. 
Since osteogenic induction can induce MSC differentiation into osteoblast 
lineages which play a major part in bone formation, it can be assumed that 
osteogenic induction improves the direct contributions of the TEBG to bone 
healing. Studies showed that after transplantation, MSCs can participate in 
early fracture healing processes such as callus formation and mineralization 
(Granero-Moltó 2009). Furthermore, studies on hfMSC showed that 
osteogenic induction significantly enhances the expression of functional 
proteins including osteonectin, collagen 1A1 and ALP, which directly 
participate in bone formation (Guillot 2008; Zhang 2009b). These results 
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suggested that osteogenic induction might promote the direct contributions of 
hfMSC-TEBG after the transplantation for fracture healing. 
In addition to the direct contribution, hfMSC were also believed to improve 
the fracture healing through paracrine effects (Zhang 2012). Several studies 
have showed that enhanced functional protein expression can improve the 
healing capacities of the cellular TEBGs. Overexpression of osteogenic 
stimulates such as BMP-2 in TEBGs achieved significant improvement for 
bone repair efficacies (X. Gao 2014b; Hsu 2007; H. W. Li 2007; Peterson 
2005). In addition, transfection of angiogenic growth factors such as VEGF or 
FGF in MSC-based TEBGs also resulted in higher neo-vascularization and 
better bone repair outcomes, compared to untreated cells (Geiger 2012; Geiger 
2007; R. Li 2009; Qu 2011). According to these facts, the culture history may 
not only change cellular amount and phenotype, but also alter the paracrine 
effects of the TEBGs, and influence their therapeutic efficacies.  
Several studies have investigated the changes of gene expression and secretion 
caused by osteogenic induction, focusing on functional proteins during 
fracture repair. Although the osteogenic stimulates were mostly up-regulated 
by osteogenic induction, the effects on angiogeneic growth factors or 
proinflammatory cytokines were varied among different cell lines and 
processing time. Schubert et. al. showed that the osteogenic induction 
promoted VEGF secretion in MSCs derived from bone marrow (BMSC), but 
reduced that in MSCs from adipose tissue (ASC) (Schubert 2011).  Studies on 
BMSC lines showed that short-term osteogenic induction (7 days) might lower 
the VEGF expression, but the expression continued to increase until the sixth 
week, and long-term osteogenic induction (more than 4 weeks) resulted in 
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much higher VEGF expression than non-induced cells (Hoch 2012; Mayer 
2005). In addition, studies also showed that osteogenic induction exerted 
diverse influences on the secretion of proinflammatory cytokines (Bischoff 
2008; Haynesworth 1996). As the cellular secretion of TEBGs will create 
major impact on their in vivo efficacies, it is crucial to understand the effects 
of osteogenic induction on TEBG’s paracrine effects.  
Since the paracrine effects might play a dominant role in hfMSC-TEBG 
mediated defect healing instead of direct contribution, the osteogenic 
induction on hfMSC-TEBG may alter its paracrine effects and thus determine 
the clinical-relevant efficacies of the TEBG. However, no systematic study has 
been performed on hfMSC-TEBG, and results from studies using other cell 
sources varied among different cell lines and received conflicting outcomes. 
Moreover, the spatial structure and the cell-material interaction within the 
scaffold may further complicate the cells’ behaviors, addressing the need for 
answering the question in a 3D setting. This thesis aims to fill these gaps 
through a systematic research, and to provide insights on the strategies to 
improve clinical-relevant efficacies of the TEBG.   
 1.4.4. Summary 
It is believed that after implantation, TEBG improves fracture healing through 
both direct contributions to osteogenesis and paracrine effects on the host 
healing process. There is compelling evidence showing that MSCs are able to 
participate directly in formation of ECM and mineralization after transplanted 
in vivo, and even integrate into the host bones. In addition the direct 
contribution, MSCs can secrete a wide spectrum of trophic factors and 
proinflammatory cytokines involved in fracture healing, and regulate the host 
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fracture healing process. Recently, a novel TEBG was developed using 
hfMSC, PCL-TCP scaffold and bioreactor enhanced osteogenic induction. 
This hfMSC-TEBG has been used to heal the critical-size bone defect in a rat 
femoral segmental defect model, and demonstrated great efficacies in 
supporting both bone regeneration and neo-vascularization. It has been 
showed that after implantation, MSCs can improve the fracture repair by both 
direct participation in bone formation process and indirect regulation of host 
healing cascade. However, the implanted hfMSC vanished within 4 weeks, 
suggesting the major efficacy of the TEBG was from paracrine effects instead 
of direct contribution. Therefore, the role of osteogenic induction in 
therapeutic efficacy of hfMSC-TEBG had been questioned, as the effects of 
the induction on TEBG’s cellular secretion and paracrine effects remained 
unclear. TEBGs derived from other types of MSCs showed inconsistent 
responses to osteogenic induction, and no study has been done on hfMSC cell 
lines. In this thesis, the role of osteogenic induction on hfMSC derived TEBGs 
will be investigated, focusing on both the efficacies for bone defect repair and 
the function of paracrine effects.  
1.5. Summary  
Bone is capable of self-healing, but excessive bone loss leads to non-union 
and requires clinical interventions – bone grafting. Compared with traditional 
grafts, TEBGs may conquer the problems in source limitation, inadequate 
healing capacities and potential risks. Typical tissue engineering approach 
involved three main elements: cell source, scaffold and bioprocess. Cells act 
as functional unit of tissue engineered bones, providing biological activities to 
the TEBGs. The scaffolds provide structural support and mechanical strength 
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to the bone graft, and interact with cells. Bioprocessing is the necessary steps 
to expand the cellular populations and allow cellular attachment on the 
scaffolds. In addition, the bioprocessing can significantly modify the 
performance of the cells and thus affect the healing efficacies of the TEBGs.  
In order to evaluate the pre-clinical efficacies of TEBGs, several animal 
models have been developed with critical-size bone defects that lead to non-
union without interventions. In a review of studies using tissue engineering 
approaches to treat critical-size bone defect models, osteogenic induction has 
been used as the most common pre-transplantation bioprocess to prepare the 
TEBGs with more mature cellular populations. However, osteogenic induction 
showed varied efficacies to TEBGs generated with different cell sources and 
culturing methods. The mechanistic role and efficacies of osteogenic induction 
remain to be determined in context of cell sources. 
A novel TEBG was developed previously using hfMSCs and composite 
materials (hfMSC-TEBG). In a study using hfMSC-TEBG to treat rat femoral 
critical-size defect, the rats implanted with the TEBG that osteogenically 
induced for 2 weeks showed great improvement in both new bone formation 
and neo-vascularization, compared to those implanted with scaffolds alone. 
The results suggested that the osteogenically induced cellular TEBG 
contributed to both bone repair and vascular repair after implantation. 
Moreover, as the human cells vanished within 4 weeks and completely lost at 
Week 4, the improvement of neo-vascularization and bone formation would 
most likely be attributed to the paracrine effects, instead of functional 
engraftment. Since the effects of osteogenic induction on MSCs’ paracrine 
effects were varied among cell lines and unknown in hfMSCs, the therapeutic 
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efficacy of osteogenic induction on hfMSC-TEBG remained unclear and to be 
investigated. Accordingly, the research gaps remained in the application of 
hfMSC-TEBG for bone defect healing were elaborated below. 
Research gaps 
1. The significance of TCP inclusion in PCL based scaffolds on 
supporting osteogenic induction efficiency of hfMSC-TEBG; 
2. The effects of osteogenic induction on hfMSC-TEBG’s paracrine 
effects, especially on proangiogenic effects; 
3. The clinical-relevant efficacy of osteogenic induction on hfMSC-
TEBG’s healing capacity. 
This thesis aimed to fill this research gap in a systematic approach, based on 
related findings and evidence in studies using hfMSCs and other MSC cell 
lines, I propose my main hypothesis as described below. 
Hypothesis  
Osteogenic induction promotes human fetal mesenchymal stem cells’ 
proangiogenic paracrine effects and improves their efficacy for bone 
defect repair 
Specifically, my thesis is proposed to test the above hypothesis by 
accomplishing the objective with following specific aims: 
Specific aims 
Specific aim #1: Generate the TEBG by seeding hfMSC into PCL and PCL-
TCP scaffolds, and compare the their responses to osteogenic induction; 
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Specific aim #2: Compare the properties of hfMSC-TEBG induced 
osteogenically with the non-induced TEBGs, including gene expression 
related to angiogenesis and osteogenesis, functional protein secretion and 
paracrine effects; in order to investigate the effects of osteogenic induction; 
Specific aim #3: Evaluate the healing efficacy of hfMSC-TEBGs that were 
osteogenically induced with different duration in a rat critical-sized femoral 
defect model. 
Thesis overview 
In order to fulfil these aims and fill the remained research gaps, studies are 
designed and conducted accordingly. The experimental approaches and results 
will be elaborated in the following chapters of this thesis. Chapter 2 introduces 
the materials and methods used in this project, categorized based on the 
objective of each study, namely generation of TEBG, evaluation of paracrine 
effects of the TEBG and the healing efficacy of the TEBG. Chapter 3 
presented the results obtained from the comparative study for Specific aim #1, 
in which the effects of TCP inclusion in PCL based scaffolds were tested. 
Chapter 4 demonstrated the gene expression, protein secretion and paracrine 
effects of hfMSC-TEBGs that were induced into different differentiation level, 
in order to test the effects of osteogenic induction hfMSC-TEBG’s paracrine 
effects in supporting bone healing (Specific aim #2). Following in vitro assays, 
Chapter 5 demonstrated the pre-clinical efficacy of TEBGs induced with 
different duration in a rat femoral defect model, and the results were 
elaborated and discussed as the research findings for Specific aim #3. In the 
following chapter, the materials and methods used in this thesis will be 
introduced based on the objectives of the studies. 
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Chapter 2. Materials and Methods 
2.1. Generation of tissue engineered bone graft 
The TEBG used in this study was generated by loading hfMSCs onto 
macroporous scaffold, followed by proper osteogenic induction processes. 
This section introduced the methods used to isolate and characterize hfMSC, 
and to generate TEBGs using hfMSCs. Additionally, the effects of different 
materials on supporting osteogenic induction were evaluated and compared to 
determine the suitable material as the scaffold. 
 2.1.1. Characterization of hfMSCs 
To generate TEBG, hfMSC were isolated and used as cell source. 
Characterization assays had been done on the harvested cells to confirm the 
cell type. This section introduces the method of stem cell isolation, and the 
characterization of the cell lines. 
 2.1.1.1. Cell isolation and expansion 
Human tissue collection for research purposes was approved by the Domain 
Specific Review Board of National University Hospital Systems (DSRB 
D/10/727). The isolation and use of fetal tissue was in compliance with 
international guidelines and ethics concerns as previously published (Y. Liu 
2012a; Zhang 2009a). In this thesis, all human mesenchymal MSC were 
derived from a 21 weeks gestation fetal donor (Sample # S135). Briefly, bone 
marrow were aspirated from fetal long bones by DMEM (Dulbecco’s modified 
Eagle’s medium – Glutamax, Gibco, Grand Island, NY, 
http://www.invitrogen.com ) using a 22-gauge needle. After passing through a 
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70 µm cell strainer (BD Biosciences, San Diego, 
http://www.bdbiosciences.com ), mononuclear cells were obtained by 
centrifuging at 400g for 8 minutes and resuspended with D10 medium – 
DMEM supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 
streptomycin (Gibco). The cell suspension was plating on flasks (Nunc, 
Rochester, NY, http://www.nuncbrand.com ) together with media. Adherent 
spindle-shaped cells were recovered from the primary culture within 24 hours. 
Non-adherent cells were removed with initial medium changes every 2–3 days. 
Confluent cells (occupied 70% of the area) were to be passaged, used for 
experiments or frozen in liquid nitrogen.  
 
 2.1.1.2. Immunophenotyping 
The harvested MSC samples were screened by immunocytochemistry (ICC) 
and flow cytometry was performed as previously described (Campagnoli 
2001). Cells were collected and screened for CD34–fluorescein isothiocyanate 
(FITC), CD45-FITC, CD14-FITC, (DAKO, Glostrup, Denmark, 
http://www.dako.com) CD105 (SH2)-PE, CD73 (SH3, SH4)-APC (Abcam, 
Cambridge, MA, http://www.abcam.com) and CD90- FITC (Chemicon, 
Temecula, CA, http://www.chemicon.com). The samples were analyzed by 
FACS - calibur flow cytometry (Becton Dickinson) and mouse 
immunoglobulin G was used as isotype control. 
 2.1.1.3.  Tri-lineage differentiation assay 
hfMSC was induced into osteoblast lineage, adipose lineage and chondral 
lineage to test its differentiation ability. All the induced differentiation 
processes were achieved by media culture, and the ingredients of each media 
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were given in Table 2-1. For osteogenic induction, MSCs were plated at 
20,000 cells/cm
2
 and cultured in osteogenic medium for up to 20 days, with 
medium changed three times per week. Extracellular accumulation of calcium 
was assayed by von Kossa staining (2% silver nitrate solution) and alizarin red 
staining (2g/ml alizarin red). For adipogenic induction, MSCs were plated at 
20,000 cells/cm
2
 and cultured in adipogenic medium for up to 25 days, the 
lipid vacuoles were stained by oil red staining (2mg/ml oil red in 60% 
isopropanol). For chondrogenic differentiation, one million cell pellet was 
cultured in chondrogenic medium for 28 days with medium changed three 
times per week. The micromass pellets were formalin fixed, paraffin 
embedded, and sectioned in 10 µm slices. Thereafter, they were dewaxed and 
rehydrated before Alcian blue staining (2% alcian blue in 0.5M acetic acid).  
Media types Ingredients 
Growth 
medium 
Dulbecco’s modified Eagle’s medium (DMEM) + 10% fetal 
bovine serum + 50 U/ml penicillin and streptomycin (Pen-strep) 
Osteogenic 
medium 
Growth medium + 10
-8
 M Dexamethasone + 0.2 mM ascorbic 
acid + 10 mM β-glycerophosphate 
Adipogenic 
medium 
Growth medium + 5ug/mL insulin + 10
-6






DMEM + 50 U/ml Pen-strep + 10
-7
 M Dexamethasone + 0.2 mM 
ascorbic acid + 0.1mg/ml sodium pyruvate + 40 µg/ml L-proline 
+ 10 ng/ml transforming growth factor β (TGF-β) + 1% insulin-
transferrin sodium-selenite (ITS+) 
Table 2-1 Ingredients for four types of media. 
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 2.1.2. Generation of tissue engineered bone graft 
The harvested and well-characterized hfMSCs were used for generating 
TEBGs. The cells were loaded on macroporous scaffolds, and the cellular 
scaffolds were osteogenically induced into bone tissue in vitro. This section 
describes the bioprocessing steps to prepare the cellular scaffolds, and induce 
them in vitro to form TEBGs. 
 2.1.2.1. Preparation of cellular scaffold  
The scaffolds used in the thesis, namely PCL scaffold and PCL-TCP scaffold 
were commercially available (Osteopore International Pte Ltd, Singapore 
http://www.osteopore.com.sg/) and fabricated as published (Rai 2005). Both 
scaffolds in honeycomb-like structure with triangular pores and a porosity of 
70% (free volume). PCL scaffolds were fabricated with pure polycaprolactone 
(PCL) while PCL-TCP was PCL incorporated with 20% tri-calcium phosphate 
(TCP). Scaffolds were cut into cubes or cylinders for each experiment and the 
sizes were different (to be indicated). Before usage, the scaffolds were treated 
in 5 M NaOH for 3 hours to enhance their surface hydrophilicity. After rinsing 
3 times with PBS, they were sterilized in 70% ethanol for 24 hours, rinsed 
again and dried before cell seeding. 
Depending on the size of the scaffold, cellular scaffolds were completed by 
loading certain amount of hfMSCs on the scaffolds with diluted fibrin glue 
solution (Tisseel kit, Immuno AG,Vienna, Austria, http://www.baxter.com). 
Each free volume of the scaffold was seeded with 3,000 hfMSCs and same 
volume of fibrin glue mixtures (50% PBS, 25% Tisseel® fibrin and 25% 
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thrombin). For example, for cubic scaffold in the size of 100 mm
3 
(5mm*5mm*4mm), 210,000 cells were to be seeded with 70mm
3 
fibrin glue 
mixture based on the free
 
volume. Fresh loaded cellular scaffolds were dried in 
incubator at 37 ℃ for 30 minutes before transferred into culture media or 
experimental use. 
 2.1.2.2. Osteogenic induction 
In order to induce the cellular scaffolds into TEBG, osteogenic induction was 
conducted with or without a bioreactor system. For static induction (inducing 
without bioreactor), dried cellular scaffolds as prepared following the steps 
described in last section were placed in 24-well culture plates, added with 2ml 
osteogenic media (Table 2-1) and cultured in incubators. Thereafter, hfMSC 
cellular scaffolds were incubated in a humidified atmosphere at 37 ℃ and 5% 
CO2 for a period with medium changed 3 times a week to allow cell attachment, 
growth and differentiation. As control groups, growth media was used instead 
of osteogenic media in exactly the same way, to maintain the cell attachment 
and growth without differentiation. Before each experiment, the TEBG (i.e. 
induced cellular scaffold) or the non-induced cellular scaffolds were collected 
and rinsed in PBS three times to remove the media. 
 2.1.2.3. Bioreactor processing 
In some experiments, a biaxial rotating bioreactor system was used instead of 
static induction, in order to enhance the inducing efficiency. The efficacies of 
the bioreactor system was previously reported (Zhang 2009b). Specifically, 
the bioreactor system used in this thesis consists of a spherical vessel (volume 
500 ml), where the cellular scaffolds can be anchored to the lip of bioreactor 
by pins. A medium reservoir (500 ml) was connected to the system which 
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allows the continuously replenishing medium and the real time monitor and 
control of oxygen, pH, and temperature. The vessel and reservoir were 
connected by tubings and formed a perfusion system driven by a pump 
(perfusion flow rate: 3.8 ml/minute). The entire bioreactor was placed in an 
incubator with humidified atmosphere at 37℃ and 5% CO2. The spherical 
vessel was programmed to rotate in two perpendicular axes with both axial 
rotation set to 5 rpm.  
Similar to static osteogenic induction, cellular scaffold prepared following 
steps in Section 2.1.2.1 were induced in osteogenic media, except in a 
bioreactor system. For dynamic osteogenic induction, up to 24 scaffolds were 
transferred to the biaxial rotating bioreactor loaded with 500 ml osteogenic 
media (Table 2-1) which filled the entire vessel. Additional 300 ml osteogenic 
media was added in the reservoir in order for media exchange. The medium 
was changed once a week. By the end of the induction, TEBGs were harvested 
and rinsed in PBS for three times before usage. 
 2.1.2.4. FDA/PI staining and confocal microscopy 
In order to examine the cell attachment and viability of TEBGs or cellular 
scaffolds, fluorescein diacetate/ propidium iodide (FDA/PI) staining was 
performed and results were observed under confocal microscope (Olympus, 
FV300 Fluoview, Japan). The collected cellular scaffolds were cut into half or 
three sections in order to stain and image the centre of the scaffold. Sections 
were immersed in 4 μg/ml FDA for 15 min at 37˚C, rinsed 3 times in PBS, and 
placed for 5-10 min in a 10 μg/ml PI solution at room temperature. The 
stained scaffolds were rinsed again with PBS before confocal laser microscope 
imaging. 
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 2.1.3. Osteogenic profiling 
In order to measure the efficiency of osteogenic induction on cellular scaffolds, 
several assays were used jointly to profile the osteogenic stages of the TEBGs. 
Namely, dsDNA amount were measured to indicate the cellular amount, 
alkaline phosphatase activity were assayed to demonstrate the differentiation 
stages of the cells, and mineralization and calcium content were observed and 
measured by Von Kossa staining, calcium assay, and micro computed 
tomography (µCT). 
 2.1.3.1. Sample processing 
TEBGs were required to be processed before assays. Harvested TEBGs were 
cut into sections and digested in 2 ml collagenase-trypsin mixture (50mg Type 
I Collogenase + 30ml Trypsin + 20ml PBS) for 3 hours in 37℃. The digested 
TEBGs were then stored in -30℃, underwent freeze-thaw cycle for 3 times so 
that the inner cell mass will be distracted. After the freeze-thaw cycles, 
samples were centrifuged at 10000G for 10 minutes. The supernatant was 
carefully collected for pico-green assay and alkaline phosphatase assay, while 
the sediment including scaffold and deposited minerals were used for calcium 
measurement. 
 2.1.3.2. Pico-green assay 
Total cell amount in 3D cellular scaffolds was estimated by quantifying the 
double strand DNA content (dsDNA) of each scaffold using the Quant-iT™ 
PicoGreen® ds DNA Quantification Kit (Molecular Probes Inc., Eugene, OR, 
http://probes.invitrogen.com) following manufacturer’s instructions. The 
method utilizes an ultrasensitive fluorescent nucleic acid stain for quantitating 
double-stranded DNA (dsDNA) in the supernatant prepared as stated in last 
section. After reacted with the reagent, supernatant samples were excited at 
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480 nm and the fluorescence emission spectra were collected using a 
spectrofluorometer. By coordinating with standard curve, the concentration of 
dsDNA in the samples was detected. 
 
 2.1.3.3. Alkaline phosphatase activity assay 
The intracellular alkaline phosphatase (ALP) activities of the cellular scaffolds 
were measured using SensoLyte pNPP Alkaline Phosphatase Assay Kit 
(AnaSpec, San Jose, CA, http://www.anaspec.com) following the 
manufacturer’s instructions. Data were normalized to total protein content 
obtained through the Bradford assay (Bio-Rad, Hercules, CA, http:// 
www.bio-rad.com). The colorimetric assay for detecting ALP in collected 
samples used pNPP (p-Nitrophenyl phosphate) as a phosphatase substrate and 
ALP conjugated secondary antibody-based ELISA. Upon dephosphorylation 
by phosphatases, pNPP turns yellow and samples were measured at 
absorbance of 405 nm. By coordinating with standard curve, the concentration 
of ALP in supernatant was detected. In order to eliminate the effect of cellular 
amount, total protein in the supernatant was also quantified and used for 
normalization. The total protein was measured by staining samples with 
Coomassie blue reagent (Thermo Scientific, Singapore 
http://www.thermoscientific.com) and tested at absorbance of 595nm. 
 2.1.3.4. Calcium assay 
As another major indicator of osteogenic differentiation, mineral deposition 
was measured by quantifying the calcium content in one cellular scaffold. 
Followed by sample preparation as described in Section 2.1.3.1, the sediment 
including scaffold was collected and treated in 0.4 ml 0.5 N acetic acid. After 
three days when calcium was dissolved in acetic acid, the supernatant was 
collected after centrifuge and assayed by Calcium Assay kit (BioAssay 
Systems, USA). The kit used a phenolsulphonephthalein dye which forms 
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stable blue colored complex specifically with free calcium in sample solution. 
The intensity of the color was measured at 612 nm which was directly 
proportional to the calcium concentration in the sample. Calcium dissolved in 
acetic acid was then quantified. The Cell-free empty scaffolds cultured in 
same conditions as TEBGs were used as a negative control to offset the 
elution of calcium, because PCL-TCP scaffold contains the tri-calcium 
phosphate which can also be dissolved in acetic acid and be quantified.  
 2.1.3.5. Von Kossa staining 
In order to observe the level of differentiation, minerals in TEBGs were 
stained with Von Kossa staining. Briefly, harvested TEBGs were fixed in 10% 
formalin for overnight and washed in dH2O three times to remove formalin 
completely. Finally, they were stained with freshly made 2% silver nitrate in 
dH2O for 10 min in the dark and exposed to an incandescent lamp (100 W) for 
40 min. The calcium phosphate minerals could then be visualized according to 
the colour change (calcium phosphate would be stained in black). 
 2.1.3.6. Micro CT imaging 
Micro computed tomography (µCT), which is usually used for bone imaging 
and analysis, was applied to visualize and quantify the mineralization within 
the TEBGs. At the end of osteogenic induction, TEBGs were harvested and 
fixed in 10% neutral buffered formalin, placed in the sample holder and 
scanned through 180 degree in a µCT machine (Skyscan, Belgium). The scan 
files were reconstructed at a step size of 1 using a modified Feldkamp 
algorithm as provided by Skyscan (Belgium). The reconstructed data were 
loaded onto the 3D modeling software, VGstudio (Volume Graphics GmbH, 
Germany) to stack the 2D image into a 3D model for quantitative 
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histomorphometric analysis. The threshold was set until the signals from 
empty PCL scaffold vanished, which presented only the mineral contents in 
scaffolds or TEBGs. Empty scaffolds cultured in the same conditions as 
TEBGs were utilized as negative controls. 
2.2. Evaluation of paracrine effect 
In comparison with PCL scaffolds, PCL-TCP scaffold showed advantages in 
cell attachment, proliferation and higher total mineral contents. Therefore, 
PCL-TCP was selected as scaffold material to generate TEBGs to be used in 
the rest of the study. In order to investigate the osteogenic induction on 
TEBGs’ healing efficacy, gene expression, secretion and paracrine effects of 
TEBGs conducted with different level of osteogenic induction were evaluated. 
This section introduced the methods used for testing the relative gene 
expression and functional secretion of the cellular scaffolds that had been 
cultured with different media and for various durations. 
 2.2.1. Gene expression 
In order to investigate the effects of osteogenic induction on cellular 
performance, healing related genes were profiled using quantitative PCR array. 
TEBGs were generated by cultivating in either osteogenic media or growth 
media, and assayed for gene expression that is related to bone healing 
capacities, namely angiogenesis and osteogenesis.  
 2.2.1.1. cDNA synthesis 
Total RNA was extracted from TEBGs using the RNeasy kit (Qiagen, 
Valencia, CA) as per the manufacturer’s protocol. Briefly, TEBGs were 
homogenized with buffer solution and beta-mercaptoethanol, and total RNA 
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was extracted using silica-membrane spin columns with a binding capacity of 
RNA. The extracted RNA was then used to synthesize cDNA for qPCR arrays. 
Extracted total RNA of cultured TEBGs was converted to cDNA reverse-
transcribed using the Superscript II First Strand cDNA synthesis kit (Life 
Technologies, Austin, Texas, http://www.invitrogen.com) in a total volume of 
111µl. The ratio of absorption A260/A280 of synthetic cDNA was 1.70. 
 2.2.1.2. Quantitative RT-PCR array 
Quantitative PCR were assayed with two PCR profiler array kits (Qiagen, 
Valencia, CA) – angiogenesis and osteogenesis. Each of them included 84 
genes related to the respective pathway. Synthetic cDNA transcribed from 
TEBG’s mRNA was mixed with SYBR Green PCR Master Mix (Applied 
Biosystems, Carlsbad, California, http://www.appliedbiosystems.com) and 
added equally to wells of the PCR array plate. The plate was then placed in 
ABI Prism 7000 (Applied Biosystems, Carlsbad, California. 
http://www.appliedbiosystems.com) and underwent RT-PCR reaction. Results 
were normalized against the housekeeping gene β-actin, and relative gene 
expression was analyzed using the online analysis platform (Qiagen, Valencia, 
CA  https://www.qiagen.com/sg/). Scatter chart and genes with more than 2 
fold difference were exported. 
 2.2.2. Protein secretion 
To further confirm the secretion of TEBGs, conditioned media which 
contained TEBGs’ secretory proteins was analysed with ELISA assay, 
focusing on angiogenic growth factors including VEGF, Angiopointin-1, basic 
FGF, IGF-1 and osteogenic growth factor BMP-2. 
 - 64 - 
 
 2.2.2.1. Conditioned media 
TEBGs were prepared according to methods described in Section 2.1.2.1. The 
harvested TEBGs were transferred to 24 well plates and cultured with 2ml 
serum free medium – DMEM with 50 U/ml penicillin, and streptomycin 
(Gibco) for 48 hours at 37℃ incubators. After 48 hours, the entire conditioned 
medium in each well was collected and stored in -80℃ before protein analysis 
and tube formation assays. Each sample was thawed only once for the 
experiments and stored no more than two weeks in -80℃. 
 2.2.2.2. ELISA assay 
The prepared conditioned media which contained secretory proteins of the 
TEBGs was tested for enzyme-linked immunosorbent assay (ELISA), as per 
manufacture’s protocol (R&D Systems Inc, MN, USA. 
https://www.rndsystems.com). Conditioned media of empty scaffold treated 
with the same procedures was used as baseline control. The concentration of 
each protein was normalized with the total protein amount of the sample, 
which was tested using Bradford assay as described in Section 2.1.3.3.  
 2.2.3. Endothelial cell vascular network formation assay  
In order to evaluate the functions of proteins secreted by TEBGs, the 
conditioned media prepared as in Section 2.2.2.1 was used to incubate human 
umbilical vein endothelial cells (HUVEC) and the vascular formation was 
measured. This section introduces the source of the cells and the experiments 
done for vascular network formation assay. 
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 2.2.3.1. Isolation and expansion of HUVEC  
Umbilical cords were obtained following term deliveries. Cords were 
superficially rinsed with saline to remove excess blood. An 18G needle was 
inserted into one end of the vein, and held in place using vascular clamps. 50 
ml of PBS was used to flash the residual blood in the vein, followed by 15 ml 
of 1 mg/ml Collagenase I (Sigma-Aldrich, USA. www.sigmaaldrich.com). 
Then, the opposing end was clamped, and added 5 ml collagenase into the 
vein again. The whole cords were incubated at 37°C for 30 min. Cords were 
retrieved, and 30 ml of PBS was flushed through to retrieved dislodged cells. 
The cells in PBS were spun down and resuspended for seeding in endothelial 
growth medium EGM-10 – EGM™-2 BulletKit™ (Lonza, Swizerland. 
http://www.lonza.com) supplemented with 10% FBS (Gibco). Media was 
changed three times per week until the cells grew to confluency and were 
passaged to next generation. 
 2.2.3.2. Vascular network formation 
Conditioned media was used to support HUVEC vascular formation in order 
to test the functional efficacy of TEBG’s secretions. To provide cells with 
sufficient nutrition, conditioned medium of each sample was mixed with 
endothelial basal media (Lonza, Swizerland) supplemented with 10% FBS 
(EBM-10) in 1 - 1 ratio, which would be termed as conditioned media mix in 
the following context. The 3D matrix for vascular networks was prepared as 
published (Montanez 2002). Briefly, type I rat tail collagen (BD Biosciences, 
Bedford, MA) was diluted with the conditioned media mix to final 
concentration of 1.2mg/ml. After neutralized with 1M NaOH (Ph=7.2), the 
collagen mixture was coated on wells of a 10µl matrix on µ-Slide 
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Angiogenesis (ibidi, Germany. http://ibidi.com/) slides. The slides were 
subsequently incubated in incubator at 37°C for 2 hours until the collagen 
matrix solidified. 
Confluent  HUVECs at Passage 4 were washed with PBS and starved in EBM-
10 for 3 hours. Subsequently, starved HUVEC were trypsinized and spun 
down, resuspended in EBM-10 for cell counting. 50,000 cells were then mixed 
with 100µl conditioned media mix and seeded on the matrix of each well. 
After 3~6 hours when the cells were attached to the surface of the matrix, 
medium was taken out and another 10 µl of the collagen mix (1.2mg/ml 
collagen in condition media mix neutralized by NaOH) was placed on top of 
the cells to cover the whole area. 100µl new conditioned media mix was then 
added to the wells. The plate was incubated at 37°C , 5% CO2 for up to 48 
hours before the vascular network formed.  
After up to 48 hours of incubation, vascular networks were visualized and 
pictured under 4X light microscope. Tube nodules in each entire well were 
identified manually and labelled with numbers using imageJ 
(http://imagej.nih.gov/ij/). The number of nodules in each well was counted. 
2.3. Critical-size defect model 
 2.3.1. Creation of femoral segmental defect 
 2.3.1.1. Animal care  
Fifty seven adult Sprague Dawley (SD) Rats (4 months old, weighing 300–350 
g) were used in this study (InVivos Pte Ltd, Singapore. www.invivos.com.sg). 
All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at National University of Singapore (NUS). Anesthesia/ 
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Analgesia/ Antibiotics medical reagents were purchased from comparative 
medicine of NUS. Immunosuppressive medicine – Ciclosporine A was 
purchased from National University Hospital (Novartis, Switzerland. 
www.novartis.com). Animals were housed in ABSL2 vivarium in 
Comparative  Medicine, NUS and monitored daily throughout the housing 
period following IACUC protocol. 
 2.3.1.2. Creation of rat segmental femoral defect model 
The segmental defect model was created and transplantation procedure was 
performed as previously published (Zhang 2010a). Briefly, a longitudinal 
incision over the proximal hind limb was performed to expose the femur after 
anethesia, and the left femur of each animal was stabilized with a custom-
made radiolucent fixation plate and titanium screws (Figure 2-1 A). A 7 mm 
segmental defect was then created with a miniature oscillating saw (Aesculap, 
USA. www.aesculapusa.com) (Figure 2-1 B). TEBGs prepared as described in 
Section 2.1.2.3 or acellular scaffolds were pressed fitted into the defects 
(Figure 2-1 C), and the wound was closed on muscles and skins respectively. 
Cyclosporin A (30 mg/kg body weight per day, Novartis, Switzerland) was 
given orally one week before the transplantation until the end of the study to 
prevent / reduce the risk of immune rejection of xenogenic hfMSC. 
 
Figure 2-1 Rat femoral segmental defect model.  
(A): After anesthesia, an incision will be made on the anterior side of the hind leg and 
femur will be exposed carefully without damaging the muscle and soft tissue. A bone 
plate will be then fixated on the femur by screws. (B): A 7 mm segmental defect will 
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be created on the middle of the bone by oscillating saw. (C): A TEBG will be placed 
in the defect by press-fit method, and the soft tissue and skin will be closed carefully. 
Abbreviations: TEBG, tissue engineered bone graft. 
 2.3.2. Evaluation of bone repair 
 2.3.2.1. Microfil® infusion 
In order to evaluate neo-vascularization in vivo, Microfil® contrast reagent 
(MV-122, Flow Tech, USA) was infused in the rats’ vascular system and 
imaged by µCT at Week 4 after the implantation. During limited thoracotomy 
after conduction of non-recovery anesthesia, the left ventricle of the rat was 
cannulated and perfused with heparinized normal saline initially. Afterwards 
100 ml of Microfil® reagent was injected and allowed polymerization for over 
two hours. When the reagents fully solidified, the femur was extracted with 
minimal surrounding soft tissues and fixed in 10% formalin. Thereafter, 
femurs were decalcified in 30% buffered formic acid at room temperature. 
After two weeks, decalcified femurs were rinsed thoroughly and scanned 
under µCT (Perkin Elmer, USA, www.perkinelmer.com) to detect the pure 
vasculature network. Detailed steps for operating µCT imaging will be 
introduced in the following paragraph. A threshold of 2000 was used to 
visualize the neo-vascularization and vessels surrounding repaired bone were 
calculated for volume and branches. A volume of 550 mm3 (a cylinder 
volume with diameter of 10 mm and height of 7 mm) encompassing the 
surgical defect was selected as the region of interest for calculation of vascular 
volume. 
 2.3.2.2. Micro CT imaging 
Real time live imaging of the rat femoral defects through micro CT (Perkin 
Elmer, USA) was performed at Day 4, Week 1, 2, 4, 8 and 12 after the surgery. 
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Animals were scanned through 180 degree with a rotation step of 1 
degree/second at a spatial resolution of 59 µm per voxel. Scan files were 
reconstructed and previewed by Quantum FX viewer (Perkin Elmer), and 2D 
longitudinal sections of the femur with smallest gap distance were captured. 
To further quantify the bone repair in 3D perspective, the files were further 
processed to stack the 2D image tiles into a 3D model and the bone volume 
was calculated. (VGstudio, Volume Graphics GmbH, Germany). Global 
thresholding was applied to distinguish bone from scaffold and soft tissue 
(Threshold 2000). 
 2.3.2.3. Histology analysis 
At Week 4 and Week 12, femurs were harvested and fixed in 10% formalin 
for 4 weeks. Specimens were infiltrated by a graded series of methyl 
methacrylate solutions (ACROS Organics, USA) and embedded in either resin 
solution or paraffin. After polymerization, specimens were trimmed of excess 
plastic and longitudinally sectioned with 5 µm thickness. Sections from 
paraffin embedded specimens were then stained with Hematoxylin and Eosin 
(H&E) to detect general tissue morphology and microvessels. Sections from 
resin embedded specimens were stained with Masson’s Trichrome, and von 
Kossa, in order to detect woven and mature bone structure respectively. 
 2.3.2.4. Mechanical testing 
At week 12, femurs were removed from euthanized rats, wrapped in PBS 
soaked gauze, and frozen at -20℃  for torsional strength test in order to 
evaluate the biomechanical properties of the new bone. Femurs were thawed 1 
day prior to the torsional testing, and the femoral ends were potted in dental 
cement (Meliodent, Heraeus Kulzer, USA), which was contained within 
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plastic molds and prepared according to manufacturer’s instruction. After 
carefully removing the bone plates, bones were wrapped in PBS-soaked gauze 
to maintain moisture during the whole preparation process until testing. 
Femurs were mounted into a torsional testing machine equipped with 2Nm 
load cell (Mini-Bionix 858, MTS, USA) with the defects coaxially aligned 
with the system axis of rotation.  
Femurs were tested to failure in torsion at the temperature of 27℃ and at a 
rotation rate of 3 degrees per second until 90 degrees of angular displacement 
(totally 30 s) and data were collected at 100 Hz. The angular displacement and 
torque were recorded. Torsional stiffness was calculated as the slope of the 
linear portion of the torque-angular displacement curve and failure torque 
strength was recorded as the maximal torsional torque before an over 40% 
drop in strength. 
 2.3.2.5. Immunohistochemistry 
Human-specific Lamin A/C immunostaining was used to investigate 
chimerism of human cells in rat tissue as previously described (Y. Liu 2012a; 
Zhang 2010a). Femurs implanted with TEBG constructs at Week 2 and Week 
4 were retrieved, embedded in OCT medium (Tissue-Tek, USA) and frozen in 
-80 degree. The frozen bulks were sectioned at 20 µm thickness with a 
Cryostat (CM 3050S, Leica, Germany) with the aid of CryoJane Tape-
Transfer system (Instrumedics, USA) onto poly-lysine slides. The processed 
sections were blocked with 2% bovine serum albumin (Sigma-aldrich) for 2 
hours, and left to react with monoclonal mouse anti-human Lamin A/C 
antibody (1:100, Vectorlabs, UK) overnight at 4 ℃ ; sections were then 
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incubated with goat anti-mouse secondary antibodies (1:100 Alexaflour 488, 
Life Technologies, UK) for 1 hour, and counterstained with DAPI. Stained 
sections were imaged through confocal microscopy as described above.  
2.4. Data Analysis 
Parametric data has been represented as mean and standard deviation. 
Unpaired T-test was used to compare any two independent samples. One-way 
ANOVA with post-hoc Turkey’s multiple comparison tests were used to 
compare any independent multiple samples that more than two. Two-way 
ANOVA was used to compare any two groups of samples with each group 
contains multiple samples (e.g. time points). 
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Chapter 3. Development of tissue engineered 
bone graft using human fetal mesenchymal stem 
cells  
3.1. Experimental design 
In order to develop highly osteogenic TEBGs, hfMSC were loaded on 
macroporous scaffolds, and induced in osteogenic media. Previously a 
composite scaffold was designed based on PCL materials and incorporated 
with TCP, and hfMSC showed superior proliferation and differentiation 
abilities when combined with PCL-TCP scaffolds (Zhang 2009a). However, 
although the addition of TCP enhanced the load-bearing strength and surface 
area of the PCL scaffold, the efficacy of TCP inclusion in PCL scaffolds for 
generating TEBG has yet to be justified. In this chapter, I generate the TEBGs 
by loading the hfMSC in PCL and PCL-TCP scaffolds, and compared the 
osteogenic profilers after conducting osteogenic induction. By doing so, the 
efficacy of using composite materials as the scaffold would be determined. 
Before generation of TEBGs, hfMSC isolated from fetal bone marrow was 
characterized by testing growth kinetics, immunophenotype and differentiation 
capacities. The well-characterized cells were than loaded in scaffolds and 
cultured in osteogenic media for up to 32 days. TEBGs were grouped based on 
materials of the scaffold, namely PCL and PCL-TCP, and one empty accelular 
scaffold treated in same condition (including osteogenic induction) was used 
as control for each group at each time point. To compare the performance of 
the two scaffolds, cellular amount, differentiation marker and mineralization 
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was evaluated at Day 2, 4, 8, 16 and 32. The cellular viability and 
mineralization was further observed using fluorescent imaging and 
radiographic imaging at Day 8, 16, 32 and Day 32 respectively (Figure 3-1).  
 
Figure 3-1 Experimental design.  
TEBG Samples were prepared by loading hfMSC in PCL or PCL-TCP scaffolds and 
inducing the cellular scaffolds in osteogenic media for up to 32 days. At particular 
time points, TEBGs were collected for FDA/PI staining or µCT imaging, or lysed for 
dsDNA, ALP and calcium assays. Abbreviations: PCL, polycaprolactone scaffold; 
PCL-TCP, polycaprolactone-tricalcium phosphate scaffold; hfMSC, human fetal 
mesenchymal stem cells; BM, osteogenic media; TEBG, tissue engineered bone 
grafts (induced cellular scaffolds); dsDNA, double strand DNA assay; ALP, alkaline 
phosphatase activity test; Ca, Calcium assay; FDA/PI, fluorescein diacetate/ 
propidium iodide staining; µCT, micro computed tomography. 
 
3.2. Characterization of hfMSC 
First of all, the isolated hfMSC as described in Section 2.1.1.1 was 
characterized for surface marker and differentiation ability, in order to validate 
the cell type used in my project. All TEBGs used in this thesis utilized the 
same cell line which was isolated, characterized and stored as described in 
Section 2.1.1. Monolayer hfMSC displayed a spindle-shaped morphology 
under wild-field microscopy (Figure 3-2 A). Confluent cell populations 
occupied approximately 70% of the area as shown in Figure 3-2 A. The 
growth kinetics of hfMSCs was presented by cell number per area at each day, 
which suggests the proliferation rate of these cells (Figure 3-2 B). When 
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seeded in a density of 5000 cells per cm
2
, nearly half of the cells attached and 
proliferated in a doubling time of 24 hours. The cell reached confluency at day 
4 and the growth curve entered plateau afterwards. 
As introduced in Section 1.2.1, the current consensus on MSCs requires the 
cells to express specific markers and be able to differentiate. Both the criteria 
have been characterized in this study. First, the phenotyping markers had been 
stained with particular antibodies and detected through Fluorescence-activated 
cell sorting using the method described in Section 2.1.1.2. Six phenotyping 
markers were used in this study, including three positive markers and three 
negative markers (Figure 3-2 C). Results showed that most of the cells 
expressed mesencymal makers (86.02% for CD105, 99.8% for CD73) and 
adhesion marker CD 90 (99.45%) over the isotype control. On the contrary, 
few cells expressed hematopoietic markers as compared to isotype control 
(0.35% for CD45, 2.28% for CD34, 0.30% for CD14). The FACS shows that 
the hfMSC isolated from bone marrows are positive for MSC markers and 
negative for hematopoietic markers, identifying them as mesenchymal stem 
cell lines. 
Second, tri-lineage differentiation assay was conducted following the protocol 
described in Section 2.1.1.3 to test the differentiation ability of hfMSCs. 
Results of differentiation was demonstrated by staining the histological 
markers (Figure 3-2 D). Cells cultured in growth media without differentiation 
supplements served as negative control. As presented in Figure 3-2 D, 
hfMSCs successfully differentiated into osteoblast lineage, adipose lineage 
and cartilage like cells. After 18 days of osteogenic differentiation, large 
amounts of calcium phosphate were detected by Alizarin red and Von Kossa 
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staining. After 25 days of adipogenic differentiation, lipid vacuoles were 
detected by Oil red staining. In addition, hfMSCs were able to differentiate 
into cartilage as confirmed by Alcian red staining on pellet sections. 
Altogether, these results indicated that the cells isolated and used this study 
are able to differentiate, and further confirmed that they are mesenchymal 
stem cell lines. 
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Figure 3-2 Characteristics of hfMSCs.  
(A): Morphology of monolayer cultured hfMSC. Confluent cell showed spindle shape 
when adhered on flasks, occupied approximately 70% of the area. (B): hfMSC 
growth kinetics over 10 days. Confluency was reached by day 4, when the cells were 
ready for passage and experiments. (C): Immunophenotype of the hfMSCs at the third 
passage by FACS. The MSCs were stained with monoclonal antibodies conjugated to 
FITC, PE, or APC. The open histogram shows the background signal (isotype control) 
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and the black histogram shows cellular reactivity with the indicated antibodies. The 
FACS results showed positive expression for CD105, CD73, CD90 and negative 
expression for CD45, CD34, CD14. (D): Tri-lineage differentiation of hfMSCs. The 
differentiation of the cells was demonstrated with histological staining together with 
non-differentiated cells (control). Osteogenic differentiation was confirmed through 
the staining of extracellular calcium phosphate in black with von Kossa staining and 
in red with Alizarin red staining. Adipogenic differentiation was confirmed through 
oil red by staining the intracytoplasmic lipids into red. Chondrogenic differentiation 
was confirmed with Alcian blue which stained cartilage tissue in blue. All control 
cells didn’t respond to staining reagents. 
 
3.3. Characteristics of tissue engineered bone grafts  
After the cell type was confirmed, hfMSCs were used to generate TEBG 
following the steps introduced in Section 2.1.2.1. Additionally, the overall 
performance of different materials as scaffolds for generating TEBGs were 
evaluated and compared, namely PCL and TCL-PCP. The particulars of the 
scaffolds given in Section 2.1.2.1, and the cellular scaffolds were induced 
osteogenically according to the static induction method (Section 2.1.2.2). 
After induced in osteogenic media for 8, 16 and 32 days respectively, both 
PCL and TCL-PCP groups were collected for microscopy or FDA/PI staining, 
in order to visualize the cellular morphology and viability. Under light 
microscopy, cellular networks can be observed at the angles of the triangle 
structures in scaffolds (Figure 3-3 A). The results show that both PCL and 
TCL-PCL allowed for good attachment of the cells, while after 32 days, 
deposited minerals are obvious in both groups (dark contents within the 
porosity). Moreover, PCL-TCP group showed slightly more mineral contents 
compared to PCL group at Day 32.  
Next, in order to compare the viability of the cells between PCL and PCL-TCP 
groups, I stained the TEBG with FDA and PI to track live and dead cells. 
Following the method given in Section 2.1.2.4, TEBG induced for 8, 16 and 
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32 days were collected stained with FDA/PI. Confocal microscopy showed the 
increasing cellular densities were achieved with increasing culturing period 
(Figure 3-3 B). At day 8, cells were mainly attached to the surface of the 
scaffolds in both group, while cells in PCL-TCP scaffold showed denser 
population than those in PCL scaffold. From Day 16, cells began to occupy 
the free space in the porous scaffolds, and eventually reached confluency at 
Day 32. These results suggest that hfMSCs undergo active cell proliferation 
when cultured on both scaffolds. On the other hand, PI staining for dead cells 
presented that both PCL and PCL-TCP groups maintained good viability. 
 - 79 - 
 
 
Figure 3-3 Cellular morphology and viability for hfMSC cultured in PCL and 
PCL-TCP scaffolds.  
(A): Cells formed networks at the corner of the triangle structures, deposited minerals 
were obvious in both scaffolds, with slightly more in PCL-TCP at scaffold Day 32 
compared with PCL scaffold. (B): Cell viability was detected through live cell stained 
with FDA and dead cell stained with PI under confocal microscopy. For both PCL 
and PCL-TCP group, hfMSC expanded and filled the small internal porosities in the 
scaffold by Day 16 and reached a maximal density by Day 32. Both groups 
maintained good cellular viabilities with little evidence of cell death throughout the 
induction period.  
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3.4. Cellular proliferation and differentiation  
Based on previous observations, I next quantified the proliferation and 
differentiation of hfMSCs cultured in the two material scaffolds. Three 
TEBGs were collected at 5 time points throughout 32 days’ of osteogenic 
induction. In order to represent the cellular amount, Picogreen assay (Section 
2.1.3.2) was used to calculate the dsDNA of hfMSCs cultured with PCL and 
PCL-TCP scaffolds. Within 32 days of incubation, both cellular scaffolds 
showed continued increase in cell numbers (Figure 3-4 A). However, the cell 
amount in PCL-TCP scaffolds appeared significantly more than that of PCL 
group (p<0.05) after 8-day cultivation. After 32 days, cells in PCL-TCP group 
proliferated to 5-fold numbers whereas the fold number was only 4 for PCL 
group.  
Next, as ALP activity is considered as an early marker for osteoblast 
differentiation, I measured alkaline phosphatase (ALP) activity (Section 
2.1.3.3) in TEBGs at each time point (n=3).  In this way the effect of the 
scaffold material on cellular differentiation can be evaluated. Figure 3-4 B 
showed the level of intracellular ALP within 32 days. The ALP amount was 
normalized with total protein to reduce the influence of cell numbers. Both 
groups were observed a peak at similar level of ALP at Day 8, and the 
amounts dropped from then. Despite of a trend towards higher ALP peak was 
observed in PCL-TCP groups, no significant difference was found, which 
suggests that these two materials have similar influence on cellular 
differentiation regarding hfMSCs. 
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Figure 3-4 Cellular proliferation and differentiation of TEBGs.  
(A): Total cell amount changes within 32-day osteogenic induction as indicated by 
dsDNA amount. PCL-TCP group showed an overall significant more cell amount 
(p<0.05) when cultured in osteogenic media than that of PCL groups. (B): 
Intracellular ALP activity. Cell differentiation was assayed by testing ALP protein 
activity, and no significant difference in differentiation stages between two cellular 
scaffolds was observed. The ALP amount was normalized with total protein content 
in TEBGs in order to eliminate the effect of cell amount. Statistics: both results were 
obtained from One-way ANOVA analysis. Abbreviations: ALP-- Alkaline 
Phosphatase. PCL (PCL-TCP): TEBG that generated by inducing hfMSC loaded PCL 
(PCL-TCP) scaffolds. 
 
3.5. Calcium deposition and mineralization 
In addition to biological markers (ALP) of cellular differentiation, 
mineralization was also evaluated in order to determine the osteogenic stages 
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of different TEBGs. Previous results showed a similar level of cellular 
differentiation in PCL and PCL-TCP scaffolds when induced in osteogenic 
media, here, I further looked at calcium deposition and mineralization and 
quantified in different manners. 
The calcium contents in TEBGs were measured by Calcium Assay (Section 
2.1.3.4). Because PCL-TCP contains tricalcium phosphate that was also 
dissolved in the solution and thus to be quantified together with the minerals, 
empty scaffolds cultured in the same manner as TEBGs were used as baseline 
controls. Accordingly, the accumulated calcium contests at 5 time points 
throughout 32 days were calculated (Figure 3-5). As can be seen, both cellular 
scaffold started with a gradual increase in calcium deposition before Day 4, 
and had a rapid increase from Day 8 until the end of the induction. Although 
total calcium in PCL-TCP groups were much higher (Figure 3-5), the 
deposited calcium was similar between two groups without significant 
difference at each time point (p=0.5). The results suggest that PCL and PCL-
TCP have similar influence on hfMSC for mineralization, which is in 
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Figure 3-5 Quantity of calcium content over time in PCL and PCL-TCP scaffold 
loaded with hfMSCs.  
The deposited calcium was calculated by measuring dissolved minerals in TEBGs 
after the osteogenic induction. The PCL-TCP empty scaffolds contained a large 
amount of calcium and thus were subtracted from the total amount of calcium 
contained in PCL-TCP composite TEBGs (PCL-TCP w. scf). After subtracted the 
calcium amount in empty scaffold controls (PCL and PCL-TCP wo. Scf.), the result 
showed no significant difference between the two groups at any time point from day 
2 to day 32 (p=0.5). Statistics: One-way ANOVA, N=3. Abbreviations: w/wo. Scf, 
with / without scaffold. 
 
To further confirm the observations on mineralization, µCT was performed on 
TEBGs induced for 32 days (Section 2.1.3.6). The mineral structures of 
TEBGs can be visualized under radiographic scanning, and this µCT scanning 
was reconstituted into 3 dimensional images (Figure 3-6 A). Furthermore, the 
volume of the mineral structures were quantified using image processing 
software and the results were presented ((Figure 3-6 B). Again, in order to 
reduce the influence of mineral contents in PCL-TCP scaffolds, empty 
scaffolds cultured for 32 days in osteogenic media were used as baseline 
controls. Comparison between two groups showed no significant difference in 
mineralization, although the total minerals in PCL-TCP groups were higher. 
The results further confirmed that the influence of two materials on cellular 
mineralization was similar, despite of the difference in total amount caused by 
the mineral components in PCL-TCP scaffolds. 
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Figure 3-6 Micro-CT imaging and analysis of Mineralization on cellular 
scaffolds at Day 32.  
(A): 3D reconstructed images of TEBGs through Micro-CT scanning. Empty scaffold 
cultured in osteogenic media for 32 days were used as control, and three TEBGs were 
used as triplicate. Aggregation of calcium around porous scaffolds after 4 weeks can 
be seen in each sample. (B): Quantification of the volume of accumulated calcium in 
cellular scaffolds. The volume of accumulated minerals were measured based on 3D 
images and calculated by subtracting the empty scaffold control. Although total 
minerals were more in PCL-TCP groups, the accumulated minerals in PCL-TCP 
groups showed a similar level as PCL groups (p=0.4). Statistics: unpaired T test. 
 
3.6. Discussion 
PCL-TCP composite scaffolds have been developed in order to address the 
need for biocompatible and osteoconductive scaffold for bone tissue 
engineering, which showed an improved capacity to deliver osteogenic 
inductive proteins against its basal material – PCL scaffolds (Rai 2005). In this 
study, I evaluated the osteogenic differentiation of well-characterized hfMSCs 
which were seeded on PCL and PCL-TCP scaffolds, and demonstrated the 
efficacy of the scaffolds for conduction osteogenic induction. Although the 
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inclusion of TCP in PCL scaffolds improved cellular numbers, markers of 
osteogenic differentiation such as ALP secretion and mineralization showed 
only a non-significant trend towards a higher degree of differentiation with the 
addition of TCP.  
Polycaprolactone (PCL) is a widely used polymer material for bone 
application, due to its bioresorbable and biocompatible properties (Hutmacher 
2001). Moreover, by fuse deposition modeling, PCL can be fabricated into 
reproducible 3D scaffolds with interconnected porous networks, which allows 
cell attachment and potential vascular invasion when implanted in vivo (Zein 
2002). However, because of its weak stiffness and polymeric nature, it is 
usually incorporated or coated with ceramic materials in order to meet the 
requirement in bone tissue engineering applications (Rai 2004). The tricacluim 
phosphate (TCP) component can enhance the mechanical properties of the 
porous PCL construct and spontaneously bond to bone minerals (Hutmacher 
2000). Moreover, it is reported that TCP contents can integrate with bones, 
provide a high binding affinity for proteins such as BMPs and a calcium 
enriched microenvironment when implanted in vivo (Chai 2012; Rai 2005). 
Consequently, the PCL-TCP used here has been designed to address the 
deficiencies in PCL based scaffolds. 
Throughout the 32 days of static culture, both PCL and PCL-TCP scaffolds 
maintained good viability as presented by FDA/PI staining. Moreover, 
beginning from the corner and surface of the scaffold, the cells started to grow 
on the porous area and cross-link each other from Day 14. The accumulated 
minerals by mineralization during osteogenic induction might provide 
additional surfaces for the cells to attach and supported the cross-link structure. 
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Our findings in cellular viability are similar with previous observations and 
further confirmed the biocompatibility of both PCL and PCL-TCP scaffolds 
(Zhang 2009b). 
Culturing cellular scaffolds in osteogenic media resulted in a slightly higher 
cellularity in groups using PCL-TCP as scaffold, which can be observed under 
FDA/PI stained confocal microscopy and dsDNA content measurements. This 
finding is consistent with studies using other basal materials as scaffolds 
including PLA, gelatin and collagen (Arahira and Todo 2014; Haimi 2009; 
McCullen 2009; Y. Takahashi 2005). The improvement of cellular amount by 
TCP inclusion indicated that PCL-TCP favored cellular attachment and 
proliferation, probably because the additional mineral contents in PCL-TCP 
scaffolds provided more porosity and surface area for cell growth, allowing to 
grow a denser cell population within the same time (Y. Takahashi 2005).  
Alkaline phosphatase (ALP) is produced by active osteoblasts and involved in 
the early induction of mineralization, which serves as early marker of MSC 
differentiation. Despite the difference in cellular proliferation, the cell 
differentiation as indicated by normalized intracellular ALP concentration 
displayed similar level between the two groups. Some studies claimed that the 
existence of TCP can promote cellular differentiation (Arahira and Todo 2014; 
Haimi 2009; Jensen 2015). However, others showed that this effect was 
subjected to the percentage of TCP incorporated, material degradation rate and 
culture method (McCullen 2009; Y. Takahashi 2005). Particularly, studies 
using gelatin(80%)-TCP(20%), PLA(80%)-TCP(20%) and PCL-TCP showed 
no difference in ALP content after cultivating the cellular scaffolds in 
osteogenic media for 2 weeks, compared with those without TCP contents 
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(Jensen 2015; McCullen 2009; Y. Takahashi 2005). These findings are in 
agreement with the results in my study. 
As ALP can induce mineralization, the calcium contents in cellular scaffolds 
throughout 32 days of osteogenic induction were measured. Similarly, the 
accumulated calcium during osteogenic induction showed similar amount and 
growth between PCL and PCL-TCP groups. Notably, the calcium amount in 
empty PCL-TCP scaffolds was also increased when cultivating them in 
osteogenic media, probably because the initial calcium contents formed 
nucleation in the media solution with high concentration of calcium (Y. 
Takahashi 2005). Therefore, although the total calcium in PCL-TCP groups 
were higher, the deposited calcium calculated by subtracting the calcium in 
cellular scaffolds from that in empty scaffolds was the same. Mineralization 
has been further confirmed by radiographic imaging, which drew the same 
conclusion as calcium measurement assay. 
My results showed that PCL-TCP resulted in higher cellularity than PCL 
scaffold when seeded with hfMSC and osteogenically induced in media, 
which might lead to better distribution of donor cells and more robust bone 
repair capacities in vivo (Villa 2014). Moreover, although the inclusion of 
TCP didn’t promote hfMSC differentiation and mineralization, the total 
mineral contents in PCL-TCP composed TEBG are beyond the PCL composed 
TEBG. Those extra mineral contents may enrich the calcium concentration at 
the defect site, which support the formation of bone ECM after implanted in 
vivo (Tan 2013; Vaquette 2013). Based on these comparison results between 
PCL and PCL-TCP scaffolds, I next used PCL-TCP composite material as the 
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scaffold for the rests of my studies, and focused on the performance of TEBG 
generated by hfMSC and PCL-TCP scaffold.  
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Chapter 4. Effects of osteogenic induction on 
hfMSC-TEBG paracrine effects 
4.1. Experimental design 
After confirming the characterization of hfMSC and the hfMSC derived 
TEBG, I next studied the role of osteogenic induction on the healing efficacy 
of hfMSC-TEBG. Osteogenic induction is known to induce hfMSC 
differentiation, initiate mineralization, and provide more osteogenic specific 
cell populations for defect healing (Vater 2011). However, previous studies on 
the efficacy of osteogenic induction drew controversial conclusions and results 
were varied among cell sources (Section 1.3.4). As introduced in Section 1.4.2, 
the implanted TEBGs may promote the defect healing through both direct 
contribution and paracrine effects. Furthermore, previous study using critical-
size defect model indicated that both bone repair and neo-vascularization were 
improved by hfMSC-TEBGs, suggesting a role of paracrine effects produced 
by implanted TEBGs on angiogenesis (Zhang 2010a). Therefore, in this 
chapter, the role of osteogenic induction on hfMSC-TEBG’s paracrine effects 
that are related to osteogenesis and angiogenesis was specifically investigated. 
Depending on the influential factors, the study was carried out as two separate 
parts: the effect of culture media and the effect of culture duration. 
Firstly, the effects of osteogenic induction on hfMSC-TEBG’s gene 
expression and secretion were examined and compared with non-induced 
TEBGs. Cellular viability, quantity and differentiation stages of osteogenically 
induced TEBGs were assessed to validate the quality of osteogenic induction. 
TEBGs were prepared as described in Section 2.1.2.1 and osteogenically 
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induced for two weeks as described in Section 2.1.2.2. Cellular scaffolds 
cultured in growth media without the supplement of differentiation ingredients 
(Table 2-1) were used as control (Figure 4-1 A). After the quality of 
osteogenic induction was confirmed, the gene expression and functional 
secretion were assayed and compared between the induced and non-induced 
TEBGs. Quantitative PCR arrays were used to examine the gene expression 
that is related to angiogenesis and osteogenesis on both TEBG groups. 
Thereafter, the secretion of functional proteins that are critical to bone healing 
and neo-vascularization were measured by testing the protein concentration in 
conditioned media of the TEBGs. Finally, to confirm the angiogenic potential 
in paracrine secretions of the TEBGs, the ability of the conditioned media to 
support endothelial cell tube formation was done.   
Next, the effects of duration of osteogenic induction on hfMSC-TEBG’s 
paracrine effects were evaluated. As previous work showed that prolonged 
static osteogenic induction led to poor cellular viability, a biaxial rotating 
bioreactor (BXR) system was applied to promote the cellular viability and 
homogeneous distribution for long-term osteogenic induction (Zhang 2009b). 
TEBGs were prepared by inducing hfMSC/PCL-TCP cellular scaffolds for 1, 
2 and 4 weeks in osteogenic media, and assayed for secretion and paracrine 
effects after profiling the differentiation (Figure 4-1 B). For each assay, 
samples from an empty scaffold treated in the same ways as cellular scaffolds 
(including tissue culture period, conditioned media preparation and TEBG 
lysate) were used as baseline controls. 
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Figure 4-1 Experimental design.  
(A) Experimental design for testing the effects of osteogenic induction. TEBG 
samples were prepared by cultivating hfMSC/PCL-TCP cellular scaffold in either 
osteogenic media or growth media for 14 days. After induction TEBGs were used for 
either osteogenic profiling or paracrine effects tests. For osteogenic profiling, FDA/PI 
staining and von Kossa staining was done on intact TEBGs, while dsDNA, ALP and 
calcium assay were done on lysed TEBGs. For paracrine effect tests, TEBGs were 
cultured in serum free media for additional 2 days. cDNA of these TEBGs were 
screened for quantitative PCR array, and conditioned media was used for ELISA 
analysis and tube formation assays. (B) Experimental design for testing the effects of 
duration of dynamic induction. TEBG samples were prepared by cultivating 
hfMSC/PCL-TCP cellular scaffolds in a biaxial rotating bioreactor system filled with 
osteogenic media for 1, 2 or 4 weeks. Osteogenic profiling and paracrine effect tests 
were done similarly as stated above. For all the assays, empty scaffold treated the 
same as cellular TEBGs were used as baseline control. Abbreviations: GM, tissue 
culture with growth media; BM, tissue culture with osteogenic media; SFM, tissue 
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culture with serum free media; BM BXR, tissue culture in osteogenic media with a 
biaxial bioreactor system. 
 
4.2. Effects of osteogenic induction 
The effects of osteogenic induction were investigated by evaluating the gene 
expression and functional secretion of the TEBGs with and without osteogenic 
induction, and comparing the difference. hfMSCs were seeded on PCL-TCP 
scaffolds, and cultured either in bone differentiation media (induced TEBGs as 
experimental group) or in growth media (non-induced TEBGs as control group) 
for two weeks. Osteogenic profiling assays were conducted to validate the 
outcomes of the induction, followed by investigations on gene expression, 
functional secretion and paracrine effects. 
 4.2.1. Osteogenic profiling 
To prepare the TEBGs, hfMSC loaded PCL-TCP scaffolds were cultured in 
either osteogenic media (BM) or growth media (GM) (Ingredients listed in 
Table 2-1) using static culture method (Section 2.1.2.2). In order to confirm 
the efficiency of the osteogenic induction, four TEBGs of each group were 
characterized for osteogenic profilers as quality control. Cell viability 
observed from FDA/PI-stained confocal microscopy (Section 2.1.2.4) showed 
that both media maintained good cellular proliferation and viability, as live 
cells stained in green grew across the scaffold and few dead cells in red were 
detected (Figure 4-2 A). Compared with cells cultured in growth media, 
hfMSCs reached higher density and formed smaller morphology when 
cultured in bone media. Picogreen assay (Section 2.1.3.2) further confirmed 
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that the cellular amount in BM group was almost twice more DNA amount 
compared to GM group (Figure 4-2 B).  
After the cellular amount and viability was determined, I next conducted three 
assays to examine the cellular differentiation stage. First, alkaline phosphatase 
(ALP) activity was assayed (Section 2.1.3.3) as early osteoblast differentiation 
marker. The results showed that a significant amount of ALP was released in 
TEBGs cultured with osteogenic media, while very little was detected in GM 
group (Figure 4-2 C). Mineralization, another major sign for osteogenic 
differentiation, was also examined by von Kossa staining (Section 2.1.3.5) and 
calcium quantification assay (Section 2.1.3.4). Mineral contents of TEBGs 
cultured in osteogenic media were stained in black by Von Kossa staining, 
while the TEBG cultured in GM showed no response to the reagents (Figure 
4-2 D). The deposited calcium was further quantified by calcium assay (Figure 
4-2 E). Accumulated calcium was calculated by subtracting the calcium 
contents in empty scaffold from those in cellular scaffolds, and BM group 
showed twice calcium amount of that in GM group. From ALP activity and 
mineralization assays, the cellular differentiation of TEBGs cultured in two 
different media was confirmed. 
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Figure 4-2 Osteogenic profiling of cellular scaffolds cultured by osteogenic 
media and growth media for two weeks.  
(A): Cell viability in TEBGs cultured with osteogenic media and growth media after 
two weeks. Live cells were stained with FDA in green and dead cells were stained 
with PI in red. The dark background labeled with “scf.” indicated the region 
occupying by scaffolds. Differentiated hfMSC showed a distinct smaller cell shape 
with higher density as compared to undifferentiated spindle-shape cells. (B): Cell 
amount as indicated by dsDNA. TEBG cultured in bone media contained nearly twice 
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more cells than those in growth media after two weeks (p<0.05). (C): Intracellular 
ALP activity in TEBGs. Cellular scaffolds cultured in bone media released 
significantly more ALP than those cultured in growth media (p<0.05), as a result of 
induced differentiation. (D): Von Kossa staining of TEBGs. TEBG cultured in bone 
media responded to von Kossa staining and turn into black, while TEBG cultured in 
growth media showed nearly no change of color, indicating the accumulation of 
extracellular calcium during osteogenic induction. (E): Calcium deposition 
quantification. TEBGs cultured in bone media showed around two fold of deposited 
calcium than TEBGs cultured in growth media. Abbreviations: ALP, alkaline 
phosphatase; TEBG, tissue engineered bone graft. Statistics: unpaired T test with N=4 
for each test. Bar chart with mean value and SD was shown. 
 
 4.2.2. Gene expression  
In order to have a general outlook for the cellular responses to osteogenic 
induction, the expression of functional genes – namely osteogenesis and 
angiogenesis related genes – was evaluated and compared between TEBGs 
cultured in osteogenic media and growth media. To do so, cDNA of TEBGs 
cultured statically either in growth media or osteogenic media for 14 days was 
collected, and examined for healing related genes through quantitative PCR 
(Section 2.2.1). Two types of gene array kits were used for this assay, and 
each contained 84 genes involving in physiological processes of osteogenesis 
or angiogenesis. Results were analyzed on the online platform and displayed 
in scatter charts (Figure 4-3). 
The scatter charts plotted the logarithm to base 10 of the normalized gene 
expression values on the axis. Each dot represents the values of one gene, and 
the gene expression that significantly influenced by the osteogenic induction 
were labeled either in yellow (up-regulated) or in blue (down-regulated) 
according the given guides (dash lines) based on calculation (Figure 4-3 A and 
B). It can be seen that most of the genes related to osteogenesis (Figure 4-3 A) 
and angiogenesis (Figure 4-3 B) were upregulated by osteogenic induction, 
and many of them (22 of 84 for osteogenesis and 32 of 84 for angiogenesis) 
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were upregulated by at least two folds. By contrast, only some of the genes 
were downregulated (4 for osteogenesis and 7 for angiogenesis). This finding 
indicates that osteogenic induction on cellular scaffolds promoted the overall 
expression of the genes that are critical in osteogenesis and angiogenesis 
pathways. 
In addition to the overall observations, genes with significant changes in 
expression were given ranked by the fold change (Figure 4-3 C). As can be 
seen, most of the functional genes and secretory proteins during osteogenesis 
were up-regulated, including BMP2, TGFβ, SMAD2, SOX9 and RUNX2. The 
upregulation of these osteogenic genes in turn confirmed the activation of 
osteogenic programing. On the other hand, the overall angiogenic genes also 
displayed an overall up-regulation after osteogenic induction, although some 
angiogenic inhibitors were up-regulated as well, such as Interferon α 1 
(IFNA1). In addition, proinflammatory cytokines displayed varied responses 
to the osteogenic induction (CXCL1, IL-8 were up-regulated while IL-6 was 
down-regulated). Therefore, although genes related to angiogenesis were 
overall up-regulated by osteogenic induction, the main effects of osteogenic 
induction on angiogenesis were unpredictable and required further validation. 
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Figure 4-3 Comparison of osteogenic (A) and angiogenic (B) gene expression 
between induced and non-induced TEBGs.  
The scatter charts plotted the logarithm to base 10 of the normalized gene expression 
values on the axis. Each dot represents the values of one gene, and the value of 
induced TEBGs (osteogenic media cultured) corresponded to Y axis and that of non-
induced TEBGs (growth media cultured) corresponded to X axis. To compare the 
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results, unary linear regression between the two values was given, where the solid 
line (Y=X) represented the gene expression in induced TEBGs was equal to that of 
non-induced TEBGs, and two dash lines (Y~X±0.3) represented the gene expression 
in induced TEBGs was twice of half of that of non-induced TEBGs. Accordingly, the 
dots above the upper dash line represented the genes up-regulated (more than two-
fold) by osteogenic induction and were labeled with yellow color, while those below 
the lower dash line represented the genes down-regulated (more than two-fold) by 
osteogenic induction and were labeled with blue color. The black dots in between 
referred to the genes with no significant change (within 2-fold change) after 
osteogenic induction. (C): Combined list of the genes (both angiogenic and 
osteogenic) changed significantly (more than two-fold change) by the osteogenic 
induction. Genes listed in yellow shading represented those upregulated for at least 
two fold by osteogenic induction, and genes listed in blue shading showed those 
downregulated for more than two fold. 
 
 4.2.3. Secretion of healing related growth factors 
After understanding the relative gene expression altered by osteogenic 
induction, I next verified the protein secretion that has been shown critical to 
fracture healing process, as introduced in Section 1.4.2. To assess the cellular 
secretion, TEBGs cultured with either osteogenic media or growth media for 2 
weeks were then incubated in serum free media for 48 hours to allow the 
accumulation of secretomes (Section 2.2.2.2). Afterwards, conditioned media 
were collected and the concentration of five functional proteins – VEGF, 
Angiopoietin-1, FGF-2, IGF-1 and BMP-2 were measured using ELISA assay 
(Section 2.2.2.1). Conditioned media of empty scaffold treated similarly were 
used as baseline control for each sample, and none of these five proteins were 
detected in baseline control. Therefore, all the detected proteins were secreted 
and the concentration has been normalized with total protein amount of each 
sample (Figure 4-4). A large amount of angiogenic growth factors – VEGF 
(>500 pg/mg total protein) and ANG-1(>450 pg/mg total protein) were 
secreted by both groups. Of note, osteogenic induction resulted in a three-fold 
higher VEGF secretion than that in non-induced group. In comparison, no 
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significant differences were found in ANG-1 and FGF-2 between the two 
groups. Surprisingly, no BMP-2 or IGF-1 was detected in both groups, which 
was at odds with the high level of gene expression as presented before. This 
ELISA analysis indicates that osteogenic induction promotes VEGF secretion, 
which is the major functional growth factor involved in angiogenesis.  
 
Figure 4-4 Cellular secretion of VEGF, ANG-1, FGF-2, BMP-2 and IGF-1 by 
induced and non-induced TEBGs.  
The black bar showed the protein level in conditioned media of TEBGs cultured with 
osteogenic media, and patterned bar showed that of TEBGs cultured with growth 
media. None of these proteins were detected in control media (conditioned media of 
empty scaffold), meaning all detected proteins were secreted. The protein 
concentration was normalized with total protein in each conditioned media. A 
significant amount of angiogenic growth factors – VEGF and ANG-1 were detected, 
and induced TEBGs showed significant higher VEGF secretion than that in non-
induced group. No significant differences were found in ANG-1 and FGF-2 between 
two groups. No BMP-2 and IGF proteins were detectable in either group. 
Abbreviations: VEGF, vascular endothelial growth factor A; ANG-1, angiopoietin-1; 
FGF, fibroblast growth factor-basic; BMP-2, Bone morphogenetic protein 2; IGF, 
Insulin-like growth factor 1. Statistics: unpaired t-test for each protein; N=4 for per 
protein per group; ns, no significance, p > 0.05; *** p< 0.001. Mean±SD showed on 
bar chart. 
 
 - 100 - 
 
 4.2.4. Vascular network formation supported by conditioned media 
Next, I utilized an endothelial cell tube formation assay to evaluate the ability 
of the conditioned media to induce vasculogenesis. The conditioned media 
were collected as described in last section and vascular network formation 
assay was conducted following the description in Section 2.2.3. Conditioned 
media (CM) from three TEBGs per group were used as biological triplicates, 
and two wells of endothelial cells (HUVEC) were used as experimental 
duplicates. The CM of empty scaffold treated similarly to TEBGs were used 
as negative control. As no additional growth factors were added in collagen 
matrix and basal media (Section 2.2.3.2), the vascular network formation 
would be dominantly effected by the angiogenic growth factors in TEBGs’ 
CM. 
After 24 hours of incubation, HUVEC cultured with the TEBG's CM  formed 
tube-like network morphology (Figure 4-5 A). As can be seen, HUVEC 
cultured in the CM from induced TEBGs showed the most branches, while the 
CM of empty scaffolds barely induced any complete vascular networks. To 
quantify these results, nodules at the joint of at least three branches were 
counted (Figure 4-5 B), as an indicator for vascular formation efficiency. By 
comparing the number of nodules formed, it is possible to qualitatively 
compare the potency of paracrine effects of differently cultured TEBGs. 
Statistical analysis on nodule numbers suggests that the osteogenic induction 
significantly improved the angiogenic paracrine effects of the TEBGs (about 
80% higher than non-induced TEBGs), and both induced and non-induced 
groups showed a significant improvement in angiogenesis compared to the 
CM from empty scaffolds (Figure 4-5 C).  
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From the endothelial cell tube formation assay, the results demonstrate that 
hfMSCs/PCL-TCP cellular scaffold have a critical paracrine effect on 
angiogenesis, and osteogenic induction can further enhance this effect. These 
results in vascular network formation are in line with those in gene expression 
and protein secretion analysis, and further demonstrate the functionality of the 
angiogenic growth factors such as VEGF that are secreted by TEBGs. 
 
Figure 4-5 Vascular network formation assay to compare paracrine effects of 
induced and non-induced TEBGs.  
(A): 4X microscopic images showed that tubes were formed after incubating 
HUVECs in conditioned media mix for 24 hours. Cells cultured in the conditional 
media from induced TEBGs showed the most condense branches, while the negative 
control barely formed any complete connections. (B): Illustration of nodule counting. 
Nodules of vascular networks were identified and counted manually; each nodule was 
identified as a joint of at least three branches. Numbers were labeled with ImageJ 
software and the total number of nodules in entire well was collected. (C): Number of 
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nodules in each well. HUVECs cultured in induced TEBGs’ conditioned media 
obtained the highest nodule numbers, compared with non-induced group. The 
conditioned media of both TEBGs significantly improved the vascular formation 
compared with that of empty scaffolds. Abbreviations: HUVEC, human umbilical 
vein endothelial cell. Statistics: Tukey's multiple comparison test (mean ±SD), N =6 
(biological triplicate * experimental duplicate), ** p < 0.01; *** p < 0.001. 
 
4.3. Effects of the duration of the induction 
Having known the effects of osteogenic induction on angiogenic paracrine 
effects of the TEBGs, I next investigated whether the duration of osteogenic 
induction could influence the paracrine secretion parameters. In order to 
support the culture of these large scaffolds beyond the limits of mass transfer, 
a dynamic culture system was used as described in Section 2.1.2.3. TEBGs 
were prepared by culturing hfMSC loaded PCL-TCP scaffolds in osteogenic 
media with a biaxial rotating bioreactor (BXR) system for 1, 2 and 4 weeks. 
After each time point, TEBGs were collected, processed and assayed for 
osteogenic profiling, secretion and paracrine effects (Figure 4-1 B). To 
simplify the terms, TEBGs and samples prepared for the assays will be termed 
based on their osteogenic induction time, respectively Group I for 1-week 
induction, Group II for 2-week induction and Group III for 4-week induction 
in the context of the rest of contents in this section (Section 4.3). 
 4.3.1. Osteogenic profiling 
Osteogenic profiling assays were conducted on the TEBGs in the same way as 
described in Section 4.2.1. TEBGs maintained good cellular viability 
throughout the 4 weeks’ culture period (Figure 4-6 A), and showed confluency 
from the first week, as indicated by plateauing of total dsDNA amount in all 
groups (Figure 4-6 B).  ALP activity showed an increasing trend until Week 4, 
indicating the maintenance of osteogenic induction efficiency (Figure 4-6 C). 
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Furthermore, mineralization was demonstrated by von Kossa staining and 
quantified using calcium assay, which further confirmed the efficiency of 
osteogenic induction mediated in the bioreactor (Figure 4-6 D and E). A large 
amount of calcium was accumulated in Group III TEBGs, in comparison of 
little accumulation in Group I and II at the end of the culture periods. 
Altogether, these results demonstrate that the cellular viability was good in all 
TEBG groups, and explicitly higher degree of osteogenic differentiation was 
achieved for the groups treated with longer duration. 
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Figure 4-6 Osteogenic profiling of TEBGs cultured in BXR for different 
durations.  
(A): Cell viability test with live cell stained by FDA in green, dead cell stained by PI 
in red. (B): Total cell amount indicated by dsDNA content. (C): Cellular 
differentiation indicated by intracellular ALP activity of TEBGs. Higher amount of 
ALP was detected in TEBGs induced for longer period (2 and 4 weeks). (D): Von 
Kossa staining on TEBGs. Extracellular matrix calcium phosphate stained by silver 
nitrate in black demonstrated the differentiation level of TEBGs induced for different 
time. Empty scaffold was incubated in the same condition for 4 weeks, which served 
as negative control. (E): Quantification of deposited calcium form TEBGs. The 
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results further displayed a significant increase of calcium deposition in TEBGs during 
the processing. Abbreviations: BXR, biaxial rotating bioreactor enhanced osteogenic 
induction; TEBG, tissue engineered bone grafts prepared by osteogenically induced 
hfMSC/PCL-TCP cellular scaffold.  Statistics: One-way ANOVA and Tukey's 
multiple comparison test (mean ±SD), N=4. NS, p>0.05; *, p<0.05; **, p < 0.01; ***, 
p < 0.001. 
 
 4.3.2. Secretion of healing related growth factors 
After the successful generation of the TEBGs (Groups I, II and III) were 
confirmed, their secretion of functional proteins was measured by ELISA 
assay. In agreement with results obtained from the first part of this study 
(induced TEBG versus non-induced TEBG), a large amount of VEGF and 
angiopoietin-1 (>100 pg/mg total protein) were secreted by TEBGs, while 
only a small amount of FGF (less than 10 pg/mg total protein) was detected 
and no BMP-2 or IGF-1 was detected (Figure 4-7). Additionally, VEGF 
secretion tended to increase during the osteogenic induction, presenting a 
significantly higher amount (3000 pg/mg total protein) in Group II and III than 
Group I (1500 pg/mg total protein). FGF also showed a significantly higher 
amount in Group III samples (CM of TEBGs induced for 4 weeks in 
bioreactor), compared with the other two groups (p<0.01), although the 
absolute amount was very low. On the other hand, angiopoietin-1 secretion 
showed a significant decrease along with the osteogenic induction period. 
 
Figure 4-7 Cellular secretion of VEGF, ANG-1 and FGF-2 by TEBGs.  
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The black, blue and red bars showed the protein level in conditioned media of TEBGs 
cultured for 1 week, 2 weeks and 4 weeks respectively. None of these proteins were 
detected in control media (conditioned media of empty scaffold induced for 4 weeks), 
meaning all detected proteins were secreted. The protein concentration was 
normalized with total protein in each conditioned media. No BMP-2 and IGF proteins 
were detectable in any groups. Longer time osteogenic induction seemed to promote 
VEGF and FGF-2 secretion, but reduce ANG-1 secretion. Abbreviations: BXR, 
biaxial rotating bioreactor enhanced osteogenic induction; VEGF, vascular 
endothelial growth factor A; ANG-1, angiopoietin-1; FGF, fibroblast growth factor-
basic. Statistics: One-way ANOVA and Tukey's multiple comparison test (mean 
±SD), N=4. NS, p>0.05; *, p<0.05; **, p < 0.01; ***, p < 0.001. 
 
 4.3.3. Vascular network formation assay 
To compare the functionality of the secretome among the three groups, 
HUVEC network formation assay was conducted using the conditioned media 
of the TEBGs as before (Figure 4-8). It can be seen that the conditioned media 
from TEBGs cultured in bioreactor for 4 weeks resulted in denser HUVEC 
population and vascular circles. Quantification on the nodule number further 
confirmed that significant more tubes were formed in Group III compared 
with the other two groups (p<0.001, p<0.05 respectively). This result verified 
the angiogenic nature of the secretome from osteogenically induced and 
dynamically cultured TEBGs, with a longer induction time correlating with a 
more angiogenic secretome.   
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Figure 4-8 Vascular network formation induced by conditioned media of TEBGs 
cultured for one, two and four weeks.  
Light microscopy images showed the HUVEC morphology and vascular networks 
formed after 24 hours of incubation. Quantification of the nodule numbers showed 
significantly more vascular networks formed in the Group III than Group I and II. 
The results suggested that longer osteogenic induction led to better angiogeneic 
paracrine effects of the TEBGs. Abbreviations: BXR 1W (2W/4W), bioreactor 
enhanced osteogenic induction for 1 week (2 weeks/4weeks). Statistics: One-way 
ANOVA and Tukey's multiple comparison test (mean ±SD), N=6 (biological 
triplicate * experimental duplicate). *, p<0.05; **, p < 0.01. 
 
4.4. Discussion 
Three dimensional human fetal MSC (hfMSC) loaded PCL-TCP scaffolds 
were induced to varied differentiation stages to test our hypothesis that 
osteogenic induction promotes cellular secretion of healing related proteins. In 
quality control assays, induced TEBGs showed higher cell density and ALP 
activity, as well as more mineral deposition. Examination of gene expression 
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and secretory proteins revealed that cultivating hfMSC cellular scaffolds in 
osteogenic media up-regulated the gene expression related to angiogenesis and 
osteogenesis, and increased VEGF secretion. When stimulating endothelial 
cell network formation, conditioned media from hfMSC-TEBG prepared in 
osteogenic media exhibited higher proangiogenic potential compared to 
TEBGs cultured in growth media. Moreover, longer duration of osteogenic 
induction resulted in more VEGF and FGF secretion, and enhanced the 
paracrine effects of hfMSC-TEBG as indicated by conditioned media-
stimulated vascular network formation assay. These findings indicate that 
osteogenic induction not only induces cellular differentiation of hfMSC-
TEBGs, but also promotes its paracrine effects in supporting angiogenesis.  
The addition of dexamethasone, ascorbic acid and β-glycerophosphate to 
growth media triggers the differentiation of MSCs and the accumulation of 
calcium phosphate minerals. The induced cellular differentiation might be 
caused by increased ALP activity among other mechanisms (Langenbach and 
Handschel 2013; Vater 2011). Cultivating hfMSC loaded PCL-TCPs in 
osteogenic media for two weeks resulted in release of ALP and deposition of 
minerals, which indicates the status of cellular differentiation. Notably, the 
dsDNA content in osteogenically induced TEBG was found nearly twice of 
that in non-induced TEBGs. This suggested that the osteogenic induction did 
not affect cellular viability or proliferation rate of hfMSCs, and denser cell 
population was formed inside induced TEBG due to the change of cell 
shapes/size and more space created by mineral deposition during osteogenic 
induction (Zhang 2009a). When stimulating the osteogenic induction in a 
bioreactor system, hfMSC were confluent from the first week, and calcium 
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deposition accumulated rapidly after Week 2. These observations validate the 
efficacy of the bioreactor and are consistent with previous observations 
(Zhang 2009b). Particularly, the dsDNA and calcium amount in TEBGs 
induced for 2 weeks in bioreactor was two times more than that of TEBGs 
induced in static condition, which further justified use of bioreactors for 
effective mass transfer and osteogenic induction.  
Along with cellular differentiation, the induction process also changes the 
secretion and paracrine effects of the cells, and thus modulates the therapeutic 
efficacies of cellular TEBGs (Gnecchi 2008; Hoch 2012; Linero and Chaparro 
2014). However, the effects of osteogenic induction on cellular secretion were 
varied depending on the cell sources, and were unclear in hfMSC cell lines. In 
previous study, TEBGs generated by differentiated hfMSC showed a great 
efficacy in supporting neo-vascularization for host bone repair (Zhang 2010a), 
which motivated us to investigate the effects of osteogenic induction on 
hfMSC-TEBG, particularly on its paracrine effects that induce angiogenesis.  
A systematic screening was done on the expression of genes that are related to 
angiogenesis and osteogenesis, and osteogenically induced hfMSC-TEBGs 
displayed overall up-regulation on genes in both pathways. The up-regulation 
of osteogenic genes including BMP-2, TGFβ, RUNX2 and SMAD2 was in 
line with previous observations and our expectation (Guillot 2008), which was 
also considered as the direct cellular responses to osteogenic induction. 
Furthermore, genes involved in angiogenesis were also observed an overall 
up-regulation, similar as osteogenic genes, which is in line with findings in 
other cell lines (Hoch 2012). The differences in cellular responses could be 
reasoned by the developmental stages of the cell sources and the duration of 
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the induction. Fetal originated cell lines used in this study may not suffer great 
reduction of activity and potency as much as adult cell lines, and it has been 
shown that VEGF expression rose during osteogenic induction (Deckers 2000; 
Schubert 2011). In addition, proinflammatory cytokines did not display an 
universal respond such as up-regulation of IL-8 and down-regulation IL-6, but 
the results are similar to previous findings in human adult cell lines (Bischoff 
2008; Haynesworth 1996). Changes in these cytokines and the subsequent 
paracrine effects on inflammation merits further exploration. 
The secretome of MSCs were reported to contain abundant soluble cues that 
can induce tissue repair, which endowed the healing capacities of MSC-
derived TEBGs (Doorn 2012; Y. Wu 2007). In this study, both induced and 
non-induced hfMSC-TEBG secreted a significant amount of VEGF and 
angiopoietin-1, which are the major proangiogenic growth factors inducing 
neo-vascularization in bone repair. After induced in osteogenic media, 
hfMSC-TEBG secreted twice more (1616 pg/mg total protein) VEGF than 
non-induced TEBGs (554 pg/mg total protein). However, this significant 
improvement was not directly reflected in VEGF gene expression, suggesting 
that the cellular secretion of VEGF were regulated by multiple pathways and 
affected by post-transcription effects. Moreover, longer duration of osteogenic 
induction (2 weeks and 4 weeks compared to 1 week) resulted in higher VEGF 
secretion, which is in line with the trends found in monolayer cultured adult 
MSCs (Mayer 2005). A four-week of osteogenic induction also resulted in the 
highest FGF-2 secretion, which is another potent trophic factor promoting 
cellular proliferation and angiogenesis. Unlike VEGF and FGF, angiopoietin-1 
displayed significant decline in secretion along with osteogenic induction. To 
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my best knowledge, no study has revealed the differentiation-dependent 
angiopoietin secretion in MSC cell lines, and the mechanism of this effect 
remains unknown. Since angiopoietin-1 mainly takes part in vessel maturation 
and stabilization, its reparative capacity might be inferior to VEGF and FGFs, 
which are more critical to initiation of angiogenesis (Fagiani and Christofori 
2013).  
Other proteins that are critical to bone repair were also tested, including BMP-
2 and IGF-1. Surprisingly, although these two genes were highly expressed at 
mRNA level and BMP-2 was even up-regulated by osteogenic induction, no 
protein was detected in conditioned media of TEBGs at all differentiation 
stages. Studies have shown that osteogenic induction promoted BMP-2 
expression in hfMSCs and other cell lines (Guillot 2008; Meinel 2005), 
however, few studies tested the secretion of these proteins and none has been 
done on hfMSCs. The contradiction in gene expression and protein secretion 
may be explained by the autocrine effects, that the differentiation of MSCs 
consumed the BMP-2 and IGF-1 generated during the process (Granero-Moltó 
2011; Kabiri 2012). The up-regulation of the receptors of these two proteins 
found in gene expression array further confirmed the autocrine effects of these 
two genes. 
As VEGFs are considered the most potent soluble cues for inducing 
angiogenesis, endothelial cell tube formation assay was conducted to validate 
the functionality of the cellular secretion of hfMSC-TEBGs. Using 
conditioned media for endothelial cell tube formation assay has been shown as 
an effective way to evaluate the functionality of the cellular secretion, 
however, few studies have been done on 3D constructs (Hoch 2012; Shen 
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2015). In order to maximize the effects of paracrine factors contained in 
conditioned media, collagen based gel instead of the common Matrigel® was 
used as the 3D matrix for the tube formation (Montanez 2002). Furthermore, 
the conditioned media were mixed with endothelial basal media to supplement 
the necessary nutrition for the endothelial cells. In this way, both media and 
gel matrix contained little trophic factors for angiogenesis unless provided by 
the conditioned media, thus the functionality of the secretome from TEBGs 
could be measured. To quantitatively measure the outcomes of vascular 
network formation, nodules formed as the joint of at least three branches were 
count and compared in a statistical manner (Khoo 2011). 
As a result, CM of TEBGs led endothelial cells to form vascular networks 
within 24 hours, while low level of complete networks was formed in control 
groups which were treated by CM of empty scaffolds. Moreover, CM from 
TEBGs induced for longer durations were more angiogenic for HUVEC 
network formation, which demonstrated that the osteogenic differentiation of 
hfMSC enhanced its paracrine effects. By contrast, studies investigating the 
effects of osteogenic induction on adult MSC’s paracrine effects showed 
conflicting results: Mayer et. al. observed more VEGF in CM of longer 
induced MSCs, while Hoch et. al. showed that the addition of dexamethasone 
(the main component of osteogenic media) reduced VEGF secretion (Hoch 
2012; Mayer 2005). The inconsistence between these studies and mine 
suggests that the developmental stages of the MSCs might affect the cellular 
response towards induction. In addition, the observations in the paracrine 
effects of hfMSC-TEBG are consistent with the observations in cellular 
secretion of VEGF, suggesting VEGF plays the dominant role in the 
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proangiogenic paracrine effects of hfMSC-TEBGs. In the next chapter, the 
efficacy of osteogenic induction on hfMSC-TEBG’s healing capacity will be 
further demonstrated in a clinical-relevant animal model. 
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Chapter 5. Effects of osteogenic induction on 
healing capacity of hfMSC-TEBG 
5.1. Experimental design 
As presented in the last chapter, the secretion of proangiogenic factors was 
promoted by osteogenic induction, and bioreactor processing further enhanced 
this effect.  These findings motivated us to further investigate the therapeutic 
efficacies of the hfMSC-TEBG being dynamically primed for 1, 2 and 4 
weeks. This is important in defining the optimal processing time for 
generating the most efficacious TEBG for critical-size bone defect repair. As 
introduced in Section 1.3.2, long bone segmental defect is a well-defined 
surgical model and suitable for evaluation of the impact of neo-vascularization. 
Therefore, a rat femoral critical-size defect was then selected and created as 
previously described (Zhang 2010a). 
Previous studies on the in vivo healing efficacy of MSC-based TEBGs 
obtained conflicting results: allogeneic bone marrow derived MSCs appeared 
the highest healing capacity after a short-term osteogenic induction (4 days’ 
static culture) and a decrease in healing capacity after longer induction 
durations (8 days and 16 days); on the contrary, human amniotic fluid derived 
MSCs showed the best healing efficacy when induced for a long duration (3 
weeks) versus shorter durations (0, 1 and 2 weeks) (Castano-Izquierdo 2007; 
Rodrigues 2012). Therefore, the effect of duration for osteogenic induction on 
TEBG’s healing efficacy remains unclear. Moreover, this effect has not been 
investigated in hfMSC cell lines ever. Accordingly, to fill this gap, hfMSC-
TEBGs were developed by seeding hfMSC on cylindrical PCL-TCP scaffolds 
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(7mm length, 5mm diameter, same size as the defect) as described in Section 
2.1.2.1, and induced in osteogenic media with biaxial rotating bioreactor 
(BXR) system for 1, 2 and 4 weeks. One TEBG was taken for FDA/PI staining 
to validate the cellular viability and status, and the rest were implanted 
immediately after induction in a rat femoral critical-size defect created as 
described (Section 2.3.1.2). 
After the transplantation, the rats were kept for up to 12 weeks, and orally 
given with cyclosporin A 30mg/kg body weight daily to suppress the immune 
reaction. Serial µCT was performed on 5 rats at 5 time points until the end of 
the study, in order to track the bone formation by radiographic imaging. At 
Week 4, three rats from each group were conducted Microfil® infusion and 
µCT imaging to track the neo-vascularization in the defect area, and one rat 
from each group was harvested for histological staining to confirm the result. 
After 12 weeks, all rats were euthanized and femurs were extracted for 
mechanical testing (n=3) and histological analysis (n=2). In addition, 
immunostaining of human specific Lamin A/C was conducted on 
cryosectioned regenerative bones at Week 2 and Week 4 (n=1), in order to 
check the engraftment of the hfMSCs. The experimental design was illustrated 
below, to simplify the terms, all the TEBGs, processed samples, animals and 
bone extract were grouped based on the bioreactor processing duration, 
namely Group I for those from or implanted with TEBGs induced for 1 week 
in bioreactor, Group II for 2-week induction and Group III for 4-week 
induction (Figure 5-1). 
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Figure 5-1 Experimental design.  
TEBGs were prepared by inducing hfMSC loaded PCL-TCP scaffolds in osteogenic 
media with BXR system for 1, 2 and 4 weeks. To simplify the terms, TEBGs, animals 
and processed samples were grouped based on the duration of induction when 
preparing the TEBGs, namely Group I for 1-week induced TEBG, Group II for 2-
week induced TEBG and Group III for 4-week induced TEBGs. One TEBG was 
stained for FDA/PI as quality control, while the rest were implanted immediately 
after preparation in each rat with femoral defect. Serial µCT tracked the radiographic 







 week respectively for different assays. Abbreviations: 1-wk BXR, 
osteogenic induction for 1 week in biaxial rotating bioreactor system; IHC, 
immunohistochemistry analysis; VK, von Kossa staining; MT, mason’s trichrome 
staining. 
 
5.2. Neo-vascularization  
As previously discussed, neo-vascularization is essential for fracture healing 
and osteogenic induction enhanced the paracrine effects of hfMSC-TEBGs in 
supporting neo-vascularization (Section 1.1.2). The vascular structure of the 
defect post TEBG implantation was visualized and analysed by radiographic 
imaging technology (Section 2.3.2.1 and Section 2.3.2.2). 3D vascular 
networks of the defected area were visible (Figure 5-2 A). Within the region of 
interest (ROI) labelled on the images, cross link microvessels inside TEBGs 
and vessels around the TEBG were visible. These vessels were considered as a 
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result of neo-vascularization that was induced by TEBGs, which should have 
direct influence on the defect healing. As can be seen, Group III animals 
formed thicker and more blood vessels in ROI compared with Group I and II 
animals, indicating a better neo-vascularization outcome. The number and 
volume of the vessels in ROI were calculated, of which Group III showed a 
significant higher levels for both results (Figure 5-2 B and C). In particular, 
TEBGs in Group III had two times more surrounding vessel branches (average 







) than Group I and II (p<0.05). This in vivo 
vascular network measurement indicates that a longer duration of bioreactor 
culture enhanced TEBG’s efficacy in angiogenesis, which is in line with our 
findings in in vitro assays (Section 4.3). 
  
 
ROI ROI ROI 
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Figure 5-2 Neo-vascularization mediated by TEBG after 4 weeks of implantation. 
(A): Contrast µCT imaging at 1 month post-surgery. Vessels were infused with 
microfil contrast agent and imaged by µCT. By adjusting the signal-to-noise 
threshold, vascular networks in vivo can be visualized and false colored in red, with 
only the vessels surrounding the TEBG being included in the region of interest. More 
vessel networks can be observed in Group III than the other two groups. (B): The 
vessel branch numbers in ROI (as labeled in A). The number of surrounding vessels 
branches were counted in a three dimensional view, and only vessels with direct 
contact with the repaired bone were included. Group III had two-fold more branches 
than the other two groups (p<0.05). (C):  The volume of the surrounding vessels. 
Volume of the vessels in the regions of interest was calculated using software. Group 
III obtained a nearly three-fold higher vessel volume than Group I (p<0.05) and 
Group II (p<0.01). Abbreviations: ROI, region of interest; Group I/II/III, animals 
implanted with TEBGs that induced in bioreactor for 1/2/4 weeks. Statistics: One-
way ANOVA and Tukey's multiple comparison test (mean ±SD, n=3). *, p<0.05; **, 
p < 0.01. 
 
In addition to radiographic imaging, the neo-vascularization was also observed 
in histological staining of the harvested femur samples. At week 4 and Week 
12, TEBG implanted femurs were harvested from one rat in each group, 
sectioned and stained with H&E (Section 2.3.2.3). In all the three groups, red 
blood cells can be seen within blood vessels found at the center of the implants 
harvested at Week 4 (Figure 5-3 A). The existence of blood vessels in the 
center of implants suggested that the femur achieved vessel ingrowth 
contiguous with host native blood cells across the TEBG. The TEBG from 
Group III displayed thicker and denser vessel ingrowth compared with the 
other two groups, alluding to better neo-vascularization outcomes. In addition, 
the TEBG from Group III had the highest cellularity as indicated by 
haematoxylin stained neuclei. On the contrary, Group I showed minimal 
vessel amount and tissue content. The result is consistent with our findings in 
µCT imaging as described above. 
In Week 12 sections, however, the distribution of vessel networks in central 
implants was different. Group I presented the highest amount of vessels, 
whereas vessels can hardly be seen in Group III sample (Figure 5-3 B). 
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However, Group III sample still presented the most abundant tissue contents, 
and mineralized ECM structure representing new bone material can be clearly 
observed. By contrast, less tissue contents and formation of bones was 
detected in Group I and Group II. Moreover, vascularization in Group III has 
been dropped as compared with the peak state at Week 4, which indicated a 
sign of active healing.  
 
Figure 5-3 Cross section of central TEBG implants stained by H&E.  
(A): H&E stained central section of the implants after 4 weeks. Microvessels within 
TEBGs (red arrows) containing red blood cells can be observed. The TEBG from 
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Group III had thicker and more blood vessels and denser cellular contents compared 
with TEBGs from the other two groups. However, no mineral contents were visible at 
Week 4 in any of the group. 40X microscopic image below showed the details of the 
tissue morphology, in which blood vessels (connective tissue) and red blood cells 
(cells lacking of nuclei) can be clearly recognized. (B): H&E stained central section 
of the implants after 12 weeks. At Week 12, less microvessels were observed in 
Group III but mineralized new bone materials were visible (labeled as “B”), 
compared with TEBGs from Group I, II and TEBGs of earlier time point. 
Abbreviations: Group I/II/III, animals implanted with TEBGs induced in bioreactor 
for 1/2/4 weeks; RBC, red blood cells; S, scaffold; B, mineralized new bone. 
 
5.3. Bone regeneration 
In addition to vascular repair, the repair of the bone was also evaluated and 
quantitatively analyzed by radiographic imaging and histological staining. The 
images of 2D longitudinal section of the repaired bones were acquired from 
µCT imaging, which allow the observation and measurement on the fracture 
gaps. The definition of fracture gap here was the smallest distance between the 
two ends of the femurs detected on longitudinal sections. As illustrated in 
Figure 5-4 A and B, the distance between the two ends of femurs was 
measured and considered as the length of fracture gap. It can be seen that after 
12 weeks, the gaps in all three groups received various levels of reduction 
compared with those at Week 4 (Figure 5-4 A and B), and the initiation of 
bone regeneration can be visualized in the Week 4 images, as the weak 
intensity of signals indicated with a red arrow (Figure 5-4 A). The length of 
the fracture gaps were recorded and compared among groups. No significant 
difference was found in images acquired 4 weeks after implantation (Figure 
5-4 C). However, after 12 weeks, the fracture gaps in Group III were 
significantly less than Group I and II (22mm versus 32mm and 39mm, 
p<0.05), and obtained a 52% of decrease compared with the gaps (Group III) 
at the point of Week 4. As shorter fracture gaps suggested better healing, the 
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results indicated that Group III animals achieved the best bone repair among 
all groups (Figure 5-4 D). 
 
Figure 5-4 Longitudinal sectioned radiographic images of the repaired bones  
(A): Images of fracture gap at Week 4. µCT scanning was processed to show the 2D 
longitudinal sectional images of the femurs, and the shortest distance between the two 
ends of the bones was measured and considered as the fracture gap. Shorter fracture 
gap represented more robust healing. The weak signal detected around the bone 
(pointed) indicates the callus formation, which formed bones at Week 12 as can be 
seen in part B. (B): Images of fracture gap at Week 12. After 12 weeks, shorter 
fracture gaps can be seen in all groups. (C): Analysis of fracture gaps (as defined and 
illustrated in A) achieved among each group at Week 4. Each dot represents the gap 
length of one animal, and no difference was observed among the three groups. (D): 
Statistical analysis of fracture gaps of each rat at Week 12. Results showed that 
Group III achieved the shortest gap length among the three groups, and significantly 
lower than that of Group II. Statistics: One-way ANOVA.  
 
To further evaluate the quality of bone repair and compare the outcomes, three 
dimensional (3D) images of the femurs were reconstructed and analysed based 
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on µCT scanning. Serial µCT on the animals allowed tracking of the bone 
repair and monitoring the continuous process (Figure 5-5). An example from 
one animal in Group III showed the evidence of new bone formation within 
the defect area over time (Figure 5-5 A), and new bone formation in all three 
groups (Figure 5-5 B). The volumes of new bones were measured 
quantitatively based on the 3D images, and the average bone volumes (n=5) 
were presented in line curves (Figure 5-5 C). As can be seen, the bone growth 
was relatively slow for all the three groups at first four weeks, and rapidly 
increased from Week 4 to the end of the study. Notably, Group III presented 
more rapid increase and obtained higher bone volumes at Week 12, compared 
with the other two groups. This data has been represented in a scatter plot 
showing new bone volumes among all groups at Week 4 (Figure 5-5 D) and 
Week 12 (Figure 5-5 E).  Group III animals had almost two-fold new bone in 







p<0.05) at Week 12, while less bone volumes (around 4 mm
3
 in average for all 
groups) and no difference was observed among the groups at Week 4. The 
results are in line with the analysis based on fracture gaps. 
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Figure 5-5 3D images and quantification of the bone volume based on µCT 
imaging.  
(A) Bone repair tracked by serial µCT images (Sample from Group III). A trend of 
bone bridging was observed within three months after transplantation of the TEBG. It 
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can be seen that the bones grew in from both ends of the host femurs and shorten the 
fracture gap. (B) Images of the bone repair after 3 month of implantation. Group III 
presented more robust bone repair and shortest fracture gap among all three groups. 
(C) Quantitative analysis of new bone volume based on micro CT imaging. Group III 
showed similar growth of the new bones to the other two groups within the first one 
month after transplantation, but rapidly increased afterwards and showed the highest 
volume after three month. (D/E) Grouped scatter graph for new bone volume after 1 
and 3 month of implantation. Each dot represents the data from one animal. The 
volume quantified based on 3D bone images confirmed that more new bone was 
formed in Group III three months after transplantation. Statistics: One –way ANOVA. 
  
In addition to radiological studies, histological staining also showed the bone 
formation and confirmed the anatomical structure of the bone (Figure 5-6 A). 
In agreement with radiological findings (Figure 5-6 A1), there is evidence of 
mineralization at the same region on Von Kossa staining(black) of the TEBG 
(Figure 5-6 A2). Mason’s trichrome staining showed the details of 
regenerative bones grown both on the side of the scaffold (Figure 5-6 A3) and 
inside the scaffold (Figure 5-6 A4). Compared to von Kossa staining, the 
connective tissues stained in blue in Mason’s trichrome staining represent new 
bone formation. Bone marrow was also found in the surrounding new bones 
and ingrown new bones. In addition, blood vessels were observed in 
surrounding tissues. (Figure 5-6 A4). 
After the contents in Mason’s trichrome stained sections were confirmed, the 
new bone formation among three groups were then compared based on one 
sample from each group (Figure 5-6 B). All three TEBGs showed evidence of 
new bone formation at the two ends of the fracture, with mineralized tissues 
growing over the area of the scaffolds and contained marrows. However, the 
TEBG in Group III showed evidence of enhanced new bone formation along 
the side of the longitudinal side of the implant, as circled by the red dashes. 
The ingrowth of the new bone from both ends of the fracture approached each 
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side in Group III, which was not seen in TEBGs from Group I and II where 
minimal new bone formation occurred at one distal end alone. 
 
Figure 5-6 Histological staining for bone regeneration at Week 12.  
(A): Illustration of radiographic image and histological staining results. (A1): 2D 
sections of µCT imaged sample. The mineral contents were captured by radiography 
and 2D section acquired from µCT imaging showed the outline of the repaired bone. 
(A2): von Kossa staining on the sections of the same sample.  Calcium phosphate 
stained in black confirmed that the content of minerals, and showed similar outline of 
the bone structure as presented by radiographic image A1. (A3/A4): Mason’s 
trichrome stained detailed of regenerative bones. Minerals were stained in blue, 
nuclei were stained in dark red/purple and cytoplasm was stained in red/pink. 
Marrows and blood vessels were observed and identified based on morphology. (B): 
Morphology of repaired bone after 12 weeks of the three groups, as illustrated by 
Mason’s trichrome staining. Areas with newly formed bones were circled with red 
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dashes. Abbreviations: Group I/II/III, samples from animals implanted with TEBGs 
induced in bioreactor for 1/2/4 weeks; S, scaffold; MT staining, Mason’s trichrome 
staining. 
 
5.4. Mechanical strength of the repaired bone 
Torsional test was applied on the repaired femurs after 12 weeks of 
implantation, in order to test the functionality of the regenerated bones as well 
as the integration of TEBG with the host tissue. Group III TEBGs 
demonstrated the highest stiffness (2N*mm/degree versus 0.45 and 
0.83N*mm/degree respectively, p<0.05) among the three groups, as calculated 
by the torsional torque per degree rotated (Figure 5-7 A). In addition, the 
maximal torque-to-failure was also measures to indicate the integration of the 
implanted TEBGs with host bones. All the three groups showed maximal 
torque strength above 15 N*mm and no significant difference was observed. 
These results indicated that the all the implanted TEBGs were well-integrated 
with the host tissue, while the Group III animals achieved the highest stiffness 
of the bone. 
 
Figure 5-7 Torsional testing on repaired bone at Week 12 post-transplantation. 
Each dot represents the result from one sample, and three femur samples were tested 
in each group. Mean value (colored curve) and SD error bars (black bar) were also 
labelled in the figure. (A): Stiffness was measured as the ratio of torsional torque to 
rotating degrees. With higher stiffness, more torsional strength was required for being 
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rotated. Group III samples showed significantly higher stiffness than the other two 
groups. (B): Maximal torque (failure torque) was acquired during the test, indicating 
the integration of the implants and bones. No significant difference was observed 
among the three groups. Statistics: One-way ANOVA. 
 
5.5. hfMSC engraftment and chimerism 
Immunostaining for human specific lamin A/C antibody on harvested repaired 
bones (TEBGs) was conducted at Week 2 and Week 4 after implantation, in 
order to observe the cellular population and hfMSC survival and persistence in 
the xenogeneic transplantation models. There was evidence of a high level of 
human cell chimerism (green nuclei) integrated among ingrowing host cells 
(blue nuclei) in all three TEBG groups at Week 2 (Figure 5-8). However, there 
were no longer any human cells detected at Week 4 after the transplantation, 
while the number of cells within the scaffolds maintained the same. Due to the 
small sample size (n=1 for each time point per group), it is not possible for a 
statistical analysis to compare the chimerism among the three groups. 
However, there is clear evidence showing that hfMSC persistence and survival 
does not extend beyond 2 to 4 weeks after implantation. 
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Figure 5-8 hfMSC engraftment and human-rat chimerism after implantation. 
hfMSCs were stained with human specific Lamin A/C antibodies (green) and cellular 
populations can be visualized by DAPI staining (blue). Stained hfMSC were visible 
in all three groups at 2 weeks after the transplantation, but no human cells could be 
observed after 4 weeks in all the three groups. 
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5.6. Discussion 
Cultivating hfMSC-TEBG over one week resulted in phenotype changes of 
hfMSC, with osteogenic differentiation and accumulation of mineral ECM 
over time. This was achieved together with maintaining a high level of cellular 
viability, and the alterations in cellular paracrine effects (Chapter 4). In this 
chapter, the in vivo therapeutic efficacies of the TEBG with various durations 
of dynamic osteogenic induction were evaluated, in order to investigate the 
overall efficacy of the osteogenic induction in a clinical-relevant model. In 
summary, 4-week osteogenic induction before transplantation enhanced the 
healing efficacy of hfMSC-TEBG compared with shorter term inductions of 1 
and 2 weeks, with significant improvement in neo-vascularization, new bone 
formation and the mechanical strength of the repaired bones. The results are 
consistent with the findings in in vitro paracrine studies (Chapter 4), and 
verified the hypothesis of this project.  
Tissue engineered bones has emerged as promising sources for treating 
excessive bone defect, and been increasingly developed in recent decades 
(Bao 2013). Osteogenic induction – conducted by cultivating monolayer cells 
or 3D cellular scaffolds in osteogenic media – has been widely used in TEBG 
generation process, in order to induce cellular differentiation and prepare more 
mature cellular populations for immediate bone repair (Mauney 2005; Watson 
2014). However, it has been reported that in vitro osteogenic induction on 
TEBGs before the transplantation did not necessarily enhance in vivo bone 
formation (Rai 2010), and several comparative studies drew controversial 
conclusions regarding the efficacies of osteogenic induction (Dumas 2009; X. 
Li 2010; Sommar 2013; Zong 2010). Moreover, the implanted cellular TEBGs 
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improves bone repair not only through the direct participation in bone 
formation, but also indirectly through paracrine effects (Watson 2014). These 
previous findings and remaining gaps motivated us to investigate the efficacy 
of osteogenic induction for TEBG’s healing capacities in a systematic way, 
and to further understand its role in increasing paracrine effects. 
MSCs are capable of supporting angiogenesis during bone repair and the 
efficacies could be further improved by overexpression of proangiogenic 
growth factors such as VEGF and FGF (Bolgen 2014; Geiger 2007; Qu 2011). 
Previous study also suggested that hfMSC-TEBG significantly improved the 
neo-vascularization through paracrine effect (Zhang 2010a). In this study, the 
effects of osteogenic induction on TEBG supported neo-vascularization were 
further investigated. As neo-vascularization completes within 4 weeks and the 
blood flow peaks between 2 to 4 weeks during rodents’ fracture repair and 
drops afterwards (Claes 2012), the vascular networks were visualized at Week 
4 in this study, by both radiographic imaging and histological staining. The 
results showed that Group III hfMSC-TEBGs (dynamically induced for 4 
weeks) resulted in the most robust neo-vascularization, while the TEBGs 
induced for shorter durations displayed delayed angiogenesis and bone healing. 
This is in line with the observations in cellular secretion analysis and in vitro 
vascular formation assay as described in the last chapter, and the difference in 
vascular networks are likely to be caused by the variance in cellular secretion 
level.  
To quantitatively compare the outcomes of bone healing, fracture gaps, bone 
volumes and the functionality of the bones were measured. Group III animals 
demonstrated shorter fracture gap, more bone volume and higher stiffness than 
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Group I and II, which were implanted with TEBGs induced for shorter periods, 
at the Week 12 after the implantation. Notably, no difference was observed at 
earlier time points in either bone volumes or fracture gaps. Zhang et. al. 
observed similar bone regeneration patterns in their study using differentiated 
hfMSC-TEBGs to treat rat critical-size bone defect, in which the efficacies of 
TEBGs in bone volume displayed only at Week 12 (Zhang 2010a). The results 
suggested that hfMSC-TEBG made minimal contributions to early 
osteogenesis but enhanced the overall bone repair process. Moreover, longer 
period of osteogenic induction further improved the healing capacity of 
hfMSC-TEBG. 
MSC are reported to be able to directly involve in host bone repair and neo-
vascularization and integrate with host tissues (Dufourcq 2008; G. Liu 2013), 
however, human specific gene immunostaining showed a loss of hfMSC 
within 4 weeks after transplantation, suggesting the healing efficacy of the 
TEBG is driven by paracrine effect instead of functional engraftment. Despite 
clearance of hfMSC, difference in bone formation and function was observed 
and 4-week osteogenic induction demonstrated the best healing results at 
Week 12, which is likely attributed to improved angiogenesis. The results are 
in line with previous findings in which hfMSC was eliminated probably due to 
acute cellular necrosis post transplantation, acute nonspecific immune 
inflammatory responses, acute anoxia, or by cellular maladaptation to a 
xenogeneic environment (Zhang 2010a). 
Neo-vascularization has been showed critical to bone repair and essential for 
bone regeneration, especially through endochondral ossification (Carano and 
Filvaroff 2003; Saran 2014). Results from histological staining showed that 
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longer duration of osteogenic induction in hfMSC-TEBG contributed better to 
bone repair through both intramembranous and endochondral ossification. In 
comparison, shorter duration of 1 and 2 weeks showed minimum 
endochondral ossification and less robust mechanical strength (stiffness) of the 
repaired bones. It has been showed that endochondral ossification is more 
effective than the endomembranous ossification, but the initiation of the 
process requires high level of neo-vascularization and sufficient blood supply 
(Claes 2012; Tortelli 2010). Our study suggests that the higher cellular 
secretion of proangiogenic factors induced by osteogenic induction improved 
post-surgical angiogenesis by osteogenic induction, which resulted in more 
robust bone formation, probably through endochondral ossification. 
Recently, the paracrine effects of the cells during cellular therapy and 
transplantation bring increasing attentions (Doorn 2012). Particularly, the 
proangiogenic paracrine effects of cell-based tissue engineering approaches 
appealed crucial impacts on bone repair applications (X. Gao 2014a; Linero 
and Chaparro 2014). However, when evaluating the therapeutic efficacies of 
newly developed TEBGs, few study focused on their paracrine effects. 
Especially, no systematic study has been done so far to evaluate the efficacy of 
osteogenic induction on TEBG’s healing capacities, focusing on paracrine 
effects. Several studies measured in vitro gene expressions and protein 
secretions that related to angiogenesis and showed varied conclusions, 
probably because of the different experimental settings in time points and cell 
sources (Hoch 2012; Schubert 2011). On the other hand, studies that evaluated 
the efficacy of osteogenic induction in clinical-relevant settings failed to 
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provide evidences for the mechanistic explanation (Castano-Izquierdo 2007; 
Dumas 2009; X. Li 2010; Meinel 2006; Sommar 2013).  
In this thesis, the role of osteogenic induction on hfMSC-based bone tissue 
engineering and therapeutic efficacy for bone repair has been systematically 
investigated. The study showed that osteogenic induction triggered cellular 
osteogenic differentiation and enhanced the proangiogenic paracrine effects of 
hfMCS-TEBG, and subsequently improved the healing efficacy for critical-
size bone defect. Since human-origin proangiogenic factors, such as VEGF, 
demonstrated cross-species activity in rodent animal models (Kanczler 2010), 
it is believed that the enhanced healing efficacies of TEBGs with longer (4-
week) induction is attributed to the promoted proangiogenic paracrine 
activities. This is the first systematic study that evaluates the effects of 
osteogenic induction on MSC-based TEBGs, focusing on proangiogenic 
paracrine effects and therapeutic efficacies, and sheds light on the optimal 
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Chapter 6. General discussion and conclusions 
6.1. Introduction 
Tissue engineering is becoming a promising source of bone grafts for clinical 
research and applications. In order to meet the need for efficacious bone grafts 
in cases such as large bone loss, TEBGs have been actively developed through 
various combinations of cell sources, biomaterial scaffolds and processing 
techniques. When implanted in vivo, TEBGs can improve fracture healing 
through direct contributions to bone formation, and also through paracrine 
effects by regulating the healing process of the host.  
Recently, a novel TEBG was developed using hfMSC which demonstrated 
great efficacies in supporting both bone regeneration and neo-vascularization, 
and evidence showed that the major efficacy of hfMSC-TEBG was from 
paracrine effects instead of direct contribution. On the other hand, although 
priming hfMSC-TEBG in osteogenic media can effectively induce the 
osteogenic differentiation of hfMSC favoured for immediate bone formation, 
the effects of the induction on hfMSC-TEBG’s cellular secretion and paracrine 
effects remained unclear. Therefore, the role of osteogenic induction in 
therapeutic efficacy of hfMSC-TEBG had been questioned.  
According to a literature review, TEBGs derived from other types of MSCs 
showed inconsistent responses to osteogenic induction on molecular level, and 
few studies were conducted in 3D settings. Moreover, the effect of osteogenic 
induction on therapeutic efficacies of TEBGs remained unclear, and no study 
has been done in context of hfMSC cell lines. These research gaps motivated 
me to answer the remaining questions through a systematic study. 
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6.2. Hypothesis and objectives 
Based on the evidence in hfMSC studies and insights from studies using other 
MSC cell lines, I hypothesized that osteogenic induction promotes human fetal 
mesenchymal stem cells’ proangiogenic paracrine effects and improves their 
efficacy for bone defect repair. Particularly, I aimed to test the hypothesis by 
achieving the following objectives: (Specific aim #1) To generate TEBGs by 
seeding hfMSC into macroporous scaffolds, and determine the better material 
for osteogenic induction by comparing PCL and PCL-TCP scaffolds; (Specific 
aim #2) To evaluate the gene expression, secretion and paracrine effects of 
hfMSC-TEBGs that affected by osteogenic induction; and (Specific aim #3) to 
evaluate the healing efficacy of hfMSC-TEBGs that were osteogenically 
induced for different duration of time in a rat critical-size femoral defect 
model. By achieving the results from a series of studies designed accordingly, 
this project aimed to reveal the role of osteogenic induction in hfMSC-TEBGs’ 
efficacies for bone regeneration. 
6.3. Summary of findings 
 6.3.1. TCP inclusion improved cellular attachment and proliferation in 
PCL-based TEBGs during in vitro priming 
hfMSC-TEBGs were successfully created by loading hfMSC on PCL or PCL-
TCP scaffolds, and osteogenically inducing the cellular scaffolds for up 32 
days. The comparative results between TEBGs generated by PCL and PCL-
TCP scaffold were well-elaborated in Chapter 3. Briefly, throughout the 
induction period, both TEBGs generated with PCL and PCL-TCP scaffolds 
maintained good viability and accumulated mineral depositions. The 
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cellularity and mineralization are similar with previous observations using 
PCL-TCP as scaffolds (Zhang 2009b), and justified that both PCL and PCL-
TCP can serve as biocompatible and osteoconductive materials for bone tissue 
engineering. 
By measuring the dsDNA in both TEBGs at different time point (osteogenic 
induction for 2, 4, 8, 16 and 32 days respectively), I observed an overall higher 
cellularity and a rapid increase after Day 8 (p<0.05) in TEBGs using PCL-
TCP as scaffold, compared with PCL based TEBGs (~40% higher cellularity 
after Day 8). This finding is consistent with studies using other basal materials 
such as PLA, gelatin and collagen (Arahira and Todo 2014; Haimi 2009; 
McCullen 2009; Y. Takahashi 2005). The improvement of cellular amount by 
TCP inclusion indicated that PCL-TCP resulted in better cellular attachment 
and proliferation. This is probably due to the higher porosity and surface area 
created by additional mineral contents in PCL-TCP scaffolds (Y. Takahashi 
2005).  
Despite of improvement in cellularity, however, the addition of TCL in PCL 
scaffolds did not show any sign of enhanced cellular differentiation, as 
indicated by normalized ALP activities and mineralization levels. This result 
is different from some studies using materials with TCP inclusion, which 
showed that the addition of TCP promoted cellular differentiation (Arahira and 
Todo 2014; Haimi 2009; Jensen 2015). However, studies also showed that the 
improvement could be subjected to TCP percentage, and 20% TCP inclusion 
(which is the parameter used in my study) showed no improvement on cellular 
differentiation in context of gelatin and PLA based materials (Jensen 2015; 
McCullen 2009; Y. Takahashi 2005). These findings are in agreement with my 
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results and suggested that 20% of TCP incorporation was not a critical ratio to 
improve cellular differentiation. 
Although the addition of 20% TCP in PCL based scaffold did not enhanced 
mineralization activity of hfMSCs, the total amount of calcium minerals were 
higher in PCL-TCP TEBGs, due to the calcium contained in the scaffold itself. 
Those extra mineral contents can enrich the calcium concentration in the 
microenvironment after transplantation, and support the in vivo bone 
formation and repair (Tan 2013; Vaquette 2013). In addition, higher cellularity 
resulted from TCP inclusion can lead to better distribution of donor cells and 
more robust bone repair (Villa 2014). Based on these findings, I determined 
PCL-TCP as more suitable material for generating hfMSC-TEBG and 
completed the specific aim #1. 
 6.3.2. Osteogenic induction triggered cellular differentiation and 
enhanced proangiogenic paracrine effects of hfMSC-TEBGs 
Next, the role of osteogenic induction on the healing efficacy of hfMSC-
TEBG was tested. Previous study suggested that induced hfMSC-TEBG 
enhances neo-vascularization in vivo (Zhang 2010a), thus the study was 
focused on the pro-angiogenic effects of hfMSC-TEBG. The study was 
performed as two parts: the effect of osteogenic induction versus non-
induction, and the effect of duration of the induction. Detailed results are 
presented and discussed in Chapter 4; while here I will only highlight the 
critical assessment and findings. 
Quality control assays confirmed that hfMSC underwent osteogenic 
differentiation during the induction process. Compared with non-induced 
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TEBGs, induced TEBGs displayed overall up-regulations of the genes that 
relate to both osteogenesis and angiogenesis, suggesting that the osteogenic 
induction not only triggered osteogenic differentiation of the cells, but also 
enhanced the expression of pro-angiogenic genes of hfMSC-TEBG. By 
contrast, other cell lines showed conflicting responses (both up-regulated and 
down-regulated) to osteogenic induction, which could be reasoned by 
differences in the developmental stages of the cells and osteogenic induction 
parameters (Deckers 2000; Schubert 2011).  
The secretome of MSCs were reported to contain abundant soluble cues that 
can induce tissue repair, which endowed the healing capacities of MSC-
derived TEBGs (Doorn 2012; Y. Wu 2007). In this study, both hfMSC-TEBG 
groups secreted large amount of VEGF and angiopoietin-1, and induced 
TEBGs for 2 weeks secreted twice more (1616 pg/mg total protein) VEGF 
than non-induced TEBGs (554 pg/mg total protein). Moreover, longer 
duration of osteogenic induction (2 weeks and 4 weeks compared to 1 week) 
resulted in double amount of VEGF secretion, which is in line with the trends 
found in monolayer cultured adult MSCs (Mayer 2005). Additionally, 4-week 
osteogenic induction also resulted in the highest FGF-2 secretion (7 pg/mg 
total protein), which is another potent trophic factor that can promote cellular 
proliferation and angiogenesis. These results suggested that osteogenic 
induction promoted hfMSC-TEBG’s proangiogenic protein secretion in a time 
dependent manner, and 4-week induction resulted in higher VEGF and FGF 
secretion than osteogenic induction of 1 and 2 weeks.  
In order to evaluate the proangiogenic potency of the TEBGs, conditioned 
media (CM) of TEBGs were used to induce endothelial cells to form vascular 
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networks and the outcomes were compared (non-induced versus induced; 4-
week induction versus 1-week and 2-week). CM from induced TEBGs (2 
weeks) led to 50% more vascular networks than CM of non-induced TEBGs, 
and longer duration tended to increase the proangiogenic effects of the TEBGs. 
The results are in agreement with the analysis on cellular secretions and 
confirmed that osteogenic induction enhances the proangiogenic effects of 
hfMSC-TEBG. In addition, complete networks can hardly be seen in control 
groups which were incubated by CM of empty scaffolds, suggesting that the 
formation of networks was mainly caused by the trophic factors contained in 
TEBG CM.  
From a series of studies, I demonstrated that the osteogenic induction can 
trigger the cellular differentiation, enhance osteogenic and angiogenic gene 
expression, and promote the proangiogenic secretion and paracrine effects of 
hfMSC-TEBG in a time dependent manner. The findings tested first part of 
my hypothesis and draw the conclusion for the Specific aim #2. 
 6.3.3. Longer duration of osteogenic induction (4-week versus 1-week 
and 2-week) enhances in vivo neo-vascularization and resulted in 
more robust bone repair in rat critical-size bone defect model 
As the last part of this project, a rat femoral defect model was utilized in order 
to test the therapeutic efficacies of TEBGs induced for different durations. The 
outcome of the defect repair was evaluated through different aspects including 
neo-vascularization, bone formation, mechanical strength and chimerism. 
Detailed results and discussion were given in Chapter 5. 
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The evaluation of neo-vascularization showed that hfMSC-TEBGs 
dynamically induced for 4 weeks resulted in the most robust neo-
vascularization, with two-fold more vessel branches and three-fold higher 
volume than TEBGs induced for shorter durations (1 and 2 weeks). This 
finding is in line with the observations in cellular secretion and vascular 
formation assay as described in the Chapter 4, and the difference in the neo-
vascularization in vivo is likely caused by the variations in TEBG’s cellular 
secretion level. 
In addition to neo-vascularization, animals implanted with 4-week induced 
TEBGs demonstrated 30% shorter fracture gap, 90% more bone volume 
and >150% higher torsional stiffness than those implanted with TEBGs 
induced for 1 and 2 weeks at Week 12 post-implantation (p<0.05 for all data). 
Notably, no difference was observed at earlier time points in either bone 
volumes or fracture gaps. This trend of bone growth is similar with 
observations in previous study (Zhang 2010a), and the results suggested that 
hfMSC-TEBG made limited contributions at early time points (before 8 weeks) 
but enhanced the overall bone repair process till the end (12 weeks). Moreover, 
longer period of osteogenic induction further improved the healing capacity of 
hfMSC-TEBGs. 
From these evaluations, I demonstrated that the efficacy of hfMSC-TEBG on 
bone formation mainly reflected at the late-stage of bone repair. However, 
hfMSC-TEBGs were efficacious for inducing neo-vascularization at early time 
points, and the efficacy was sensitive to osteogenic induction. To test whether 
this effect was driven by paracrine effects, human specific genes were stained 
on harvested implants. The results showed that hfMSC did not persist after 4 
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weeks and suggested that the neo-vascularization was supported by paracrine 
effects. Taken together, the results demonstrated that osteogenic induction for 
longer duration resulted in higher neo-vascularization and more robust bone 
repair in vivo. The findings in this Specific aim #3 together with previous 
findings in Specific aim #1 and #2 jointly verified my hypothesis proposed for 
this thesis. 
6.4. Implications of this research 
The main objectives in studying bone tissue engineering are to develop the 
optimal TEBGs for clinical uses and to understand the mechanism of TEBG 
mediated bone defect healing. My findings provided insights for both 
directions and moved a step forward to fill the gaps remained in the field. 
Recently, the paracrine effects of the cells after transplantation increasingly 
draw attentions (Doorn 2012) and proangiogenic paracrine effects of TEBGs 
demonstrated critical impacts on bone repairs (X. Gao 2014a; Linero and 
Chaparro 2014). However, when evaluating the therapeutic efficacies of novel 
TEBGs, few study focused on their paracrine effects. My study investigated 
the role of osteogenic induction on hfMSC-TEBG’s healing efficacy, focusing 
on TEBG’s paracrine effects. This is the first systematic study that showed the 
effects of osteogenic induction on TEBG’s proangiogenic effects in a clinical-
relevant setting, and the results demonstrated the value of osteogenic induction 
in generating TEBGs for bone repair. 
Several in vitro studies measured gene expressions and protein secretions that 
related to angiogenesis and showed varied conclusions, probably because of 
the different cell sources and experimental parameters used (Hoch 2012; 
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Schubert 2011).  In my study, evaluations were done in a series of studies 
from gene expression until functionality assays, and the results acquired from 
different assays supported each other and drew solid conclusions. Furthermore, 
the in vivo therapeutic effects were confirmed in a pre-clinical model. The 
combination of in vitro analysis and in vivo evaluations makes the findings 
more convincing than in vitro or in vivo studies alone.  
Using conditioned media (CM) induced endothelial cell tube formation has 
been shown as an effective way to evaluate the proangiogenic paracrine 
effects of the cells, however, few studies have been done on 3D constructs 
probably due to the technical difficulties (Hoch 2012; Shen 2015). In order to 
maximize the effects of paracrine factors contained in conditioned media and 
acquire the most accurate results, I optimized the experimental design by using 
a collagen based gel instead of the common Matrigel® as the 3D matrix for 
the tube formation (Montanez 2002). Furthermore, the CM were mixed with 
endothelial basal media to supplement the necessary nutrition for the 
endothelial cells. As a result, endothelial cells maintained good viability in the 
tube formation assays, and the vasculature level was mainly dependent on the 
trophic factors contained in TEBG-CM. 
In my study, the in vivo bone repair was evaluated through variety of tests, 
which gained more information than using histology analysis or radiographic 
imaging analysis alone (Semyari 2015; Zong 2010). Moreover, studies that 
evaluated the efficacy of osteogenic induction in clinical-relevant settings 
failed to provide evidences for the mechanistic explanation (Castano-Izquierdo 
2007; Dumas 2009; X. Li 2010; Meinel 2006; Sommar 2013). By contrast, my 
study evaluated the neo-vascularization level in the rat femoral defect model, 
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and the underneath mechanism was supported by the in vitro analysis on the 
cellular secretion. In such way, the entire study investigated the role of 
osteogenic induction for hfMSC-TEBG’s bone healing efficacy in a 
systematic approach.  
6.5. Limitations 
Aside from the critical findings and implications gained from this research, 
many challenges and inevitable limitations were encountered during the study. 
As tissue engineering involves a various combination of elements and multiple 
disciplines, several technical challenges and limitation of sources emerged 
when I tried to answer scientific questions from stem cell biology, 
biomaterials, bioprocessing, transplantation medicine and pre-clinical study at 
the same time. While time was the biggest limit for answering some of the 
questions that emerged along the way, some other factors limiting further 
research are detailed as follows. 
Different from studies using monolayer cells, each TEBG requires more than 
0.2 million cells, 100 mm
3 
biomaterial scaffolds and 100mm
3 
Tisseel fibrin 
reagents to generate. Such cost for materials and processing time limited the 
use of multiple cell lines to reduce the sample variations. Therefore, all the 
experiments in this thesis used only one line of hfMSCs. It is reported that the 
gestation, condition of the donor and harvesting parameters may affect the cell 
properties (Campagnoli 2001; Colleoni 2009). Nevertheless, the cell line used 
in the study was well characterized, and multiple experimental replicates were 
applied to acquire solid data. In addition, the results from different assays were 
in line with each other and drew integrated conclusions. 
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In my studies comparing PCL and PCL-TCP scaffolds, I did not use apply 
gradient on TCP percentage, because 20% TCP incorporated PCL scaffold 
was the only option from the company. However, studies showed that the 
effect of TCP inclusion on cellular differentiation was subject to TCP 
concentrations (Jensen 2015; McCullen 2009; Y. Takahashi 2005). Therefore, 
in order to acquire the most compatible scaffold for hfMSC differentiation, 
scaffolds with different percentages of TCP inclusion should be tested, and 
other basal materials should also be considered such as PLA, gelatin and 
collagen. However, this will bring in a separate question and deviate from my 
research objectives. 
In the study of paracrine effects, the complex spectrum of hfMSC secretion 
made it impossible to examine all the healing related molecules in the cellular 
secretome. For example, it has been reported that molecules such as 
inflammatory cytokines IL-6, IL-8 can also influence the healing cascade and 
efficacies (Ai-Aql 2008; Bischoff 2008), and these molecules were found 
affected by osteogenic induction in gene screening assays in my study. 
Therefore, it can be assumed that the osteogenic induction may also arouse 
changes in other cellular responses in addition to pro-angiogenic effects, 
which are critical for TEBG’s in vivo healing efficacy. However, in order to 
narrow down the scope, I chose to focus on the proangiogenic paracrine 
effects, which I believe is the key factors to determine hfMSC-TEBG’s 
healing efficacies based on literature reviews.  
In order to test the efficacy of hfMSC-TEBG, a rat femoral defect model was 
utilized. The use of animal model to test sources from human origin will 
inevitably bring in the challenges in xenotransplantation. Of note, although I 
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administrated immunosuppressive medication, the hfMSC only survived for 2-
4 weeks in vivo. This was similar to the studies using hfMSC and other human 
MSCs (Niemeyer 2010b; Niemeyer 2010c; Zhang 2010a). The mechanism for 
cell loss and the cell fate in human patient settings remained unknown and 
unpredictable. 
6.6. Recommendations for future research 
In this project, the effects of osteogenic induction on in vitro performances 
and in vivo efficacies of hfMSC-TEBG were investigated. The results showed 
that osteogenic induction can induce cellular differentiation, upregulate the 
healing related gene expressions, enhance proangiogenic paracrine effects and 
improve healing capacities of hfMSC-TEBGs. These findings may shed lights 
on the future studies, along the two major directions in bone tissue engineering 
field: healing mechanisms and TEBG optimization. 
 6.6.1. Mechanisms of TEBG’s healing capacity 
The scope of this study was narrowed down to the proangiogenic paracrine 
effects provided by osteogenically induced hfMSC-TEBGs, due to the various 
limitations as discussed before. Although it is suggested that the neo-
vascularization is the major factor during defect repair, the target could be 
more specific to individual proteins and other aspects in TEBG supported 
bone healing should also be considered and tested. 
 6.6.1.1. Effect of VEGF secretion on hfMSC healing capacity 
As introduced in Chapter 4, hfMSC secreted a large amount of VEGF and the 
secretion is sensitive to osteogenic inductions. In the following studies, VEGF 
was found to increase along with osteogenic inductions, and longer osteogenic 
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induction resulted in higher potency of hfMSC-TEBG to support in vivo and in 
vitro vascular formation (Chapter 4 and Chapter 5). Since VEGF is considered 
as the most potent trophic factor to induced angiogenesis, it is necessary to 
verify the efficacies of VEGF secretion for hfMSC-TEBG supported bone 
repairs. 
Studies have showed the improved neo-vascularization and bone repair 
capacities of TEBGs transfected with VEGF (Geiger 2012; R. Li 2009), and 
addition of VEGF proteins in MSC-TEBGs resulted in better bone healing 
outcomes (Kanczler 2010). Since VEGF was found highly expressed in 
induced hfMSC-TEBGs, a VEGF knock-down study is highly recommended 
to confirm that the improvement in proangiogenic effects is caused by the up-
regulation of VEGF secretions. 
 6.6.1.2. Engraftment and in vivo secretion of hfMSC 
Aside from paracrine effects, hfMSC-TEBG may also involve in early 
osteogenesis by direct participation in bone formation. On the other hand, the 
intensity of paracrine effects can be affected by the implanted cell fate as well 
(Gnecchi 2008). Therefore, it is crucial to improve the engraftment and to 
track the in vivo secretion of the potent proteins such as VEGF after 
transplantation. Studies in Chapter 4 verified the in vitro proangiogenic 
capacity of hfMSC-TEBGs, but the cellular secretion was not confirmed after 
TEBG transplantation. In order to verify the secretion of functional proteins 
after transplantation and track the amount, a real-time study using 
bioluminescent imaging techniques is recommended (Granero-Moltó 2009). 
Moreover, attempts to improve cellular engraftment are also recommended, 
 - 147 - 
 
including using immunodeficient animals as models, or applying delayed cell 
seeding approaches  (Berner 2015). 
 6.6.1.3. Effects of inflammatory cytokines 
As mentioned earlier, this project could not cover the whole spectrum of 
hfMSC secretomes, thus other paracrine effects that are potentially efficacious 
on fracture healing provided by hfMSC-TEBG were possibly missed in this 
study. For instant, several inflammatory cytokines such as IL-6 and IL-8 were 
also influenced as a result of osteogenic induction. As inflammation initiated 
the fracture healing cascade but might trigger immune rejection on implanted 
cells, the paracrine effects of inflammatory cytokines in hfMSC-TEBG for its 
efficacies in bone healing remained to be tested (J. Wu 2015). 
 6.6.2. Optimization of TEBG’s paracrine effects 
This project showed that the proangiogenic effects of TEBGs are important for 
in vivo bone healing efficacies. In addition to osteogenic induction, several 
other approaches can also enhance the TEBG’s potency for inducing neo-
vascularization and repairing bone defects. The efficacies of these approaches 
merit to be tested in pre-clinical or clinical settings. 
 6.6.2.1. Cell sources  
The TEBGs used in this thesis was generated by using hfMSCs alone. 
Although it has been showed that hfMSC secreted potent trophic factors such 
as VEGF and FGFs, addition of other cells may further enhance the pro-
angiogenic effects of the TEBGs. In particular, several attempts have been 
made in generating vascularized bone graft for defect healing through co-
culture systems, combining endothelial lineages with osteogenic cells (Fuchs 
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2009; Y. Liu 2012a; Y. Liu 2012b; Seebach 2010b; Usami 2009). A recent 
study also showed that co-cultured hfMSC and umbilical cord blood derived 
endothelial progenitor cells (UCB-EPC) loaded on PCL-TCP scaffolds 
induced more neo-vascularization and better ectopic bone formation than 
using hfMSC alone (Y. Liu 2012a). However, obstacles still remained in the 
co-culture parameters and deserved to be tackled. 
 6.6.2.2. Scaffolds for TEBG 
Aside from the selection of cellular mediator for vascularization, scaffolds can 
also be designed to allow vascular in-growth and incorporation of vascular 
cues such proangiogenic growth factors (Mastrogiacomo 2006). For instance, 
the usage of silk fibroin and PCL as porous scaffolds exhibited a good support 
to endothelial cell growth and consequent vascularization (Unger 2004; Yu 
2009); while poly(lactic-co-glycolic acid) (PLGA) and poly(lactide-co-
glycolide) (PLG) scaffolds showed the ability of incorporate VEGFs and 
released them locally so that angiogenesis was improved (Kaigler 2006; 
Murphy 2004). 
Additionally, the structural properties, such as geometry and porosity can also 
affect the angiogenic ability of the scaffolds. Narayan and Venkatraman 
showed that the porosity of scaffolds have a profound influence on the growth 
of endothelial cells, with enhanced cell growth with smaller pore sizes and 
lower interpose distances (Narayan and Venkatraman 2008). As 
vascularization has been shown as a critical factor in TEBG supported bone 
healing, the design of scaffolds should pay more attentions on supporting the 
vessel ingrowth and homing of vasculatures. 
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 6.6.2.3. Processing techniques  
As the main hypothesis of this project, the role of osteogenic induction on 
hfMSC-TEBG’s paracrine effects has been well demonstrated. Nevertheless, 
future studies are still required to further understand the efficacy of conducting 
osteogenic induction and other applicable processing techniques. 
Although it has been showed that long-term (4-week) osteogenic induction 
resulted in higher healing capacities of hfMSC-TEBG (Chapter 5), the cellular 
responses to osteogenic induction were not fully understood yet. For instance, 
how osteogenic induction affects the cell fate was unknown. Studies have 
showed that dexamethasone may reduce the cellular viability in vitro but no 
agreement was made to its effect on in vivo survival (H. Wang 2012). This 
could be tested together with the in vivo secretion and hfMSC engraftment as 
discussed in the last section. 
In addition, even the animals implanted with 4-week induced TEBGs, the best 
healing outcomes among all groups, did not achieve such exciting results. The 
stiffness and integration was still too weak for any load-bearing strength, and 
plenty of fibroblast and collagenous ECM were found in the central area of 
TEBGs. These indicate that the hfMSC-TEBG requires further optimization, 
probably through co-culture, gene transduction or addition of extra trophic 
factors as additional bioprocessing steps. 
6.7. Conclusions 
Osteogenic induction has been widely applied in bone tissue engineering to 
provide mature bone tissue for bone repair. However, compelling evidence 
showed that the paracrine effects are critical to the therapeutic efficacies of 
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TEBGs, and the influence of culture period on hfMSC-TEBG’s paracrine 
effects and healing efficacy remains unclear. This thesis aimed to fill the 
remaining gaps through a series of studies. First, hfMSCs were isolated, 
characterized, and generated into hfMSC-TEBGs combined with PCL or PCL-
TCP scaffolds. The cellular responses to osteogenic induction were compared 
between the TEBGs formed by PCL scaffolds and PCL-TCP scaffolds, and 
PCL-TCP demonstrated as more suitable material for creating hfMSC-TEBGs 
(Specific aim #1, Chapter 3). Next, the gene expression, protein secretion and 
paracrine effects of hfMSC-TEBGs were examined, and the effects of 
osteogenic induction on hfMSC-TEBG’s proangiogenic paracrine effects were 
tested. Induced TEBGs (2-week differentiation media) showed higher gene 
expression and secretion levels of angiogenic proteins than non-induced 
TEBGs (2-week growth media), and this effect was stronger along with longer 
duration of the induction (Specific aim #2, Chapter 4). Finally, hfMSC-
TEBGs induced with different durations (1, 2 and 4 weeks) were implanted in 
a rat critical sized femoral defect model and their healing efficacy was 
evaluated. Animals implanted with 4-week induced TEBGs achieved the most 
robust bone formation, highest neo-vascularization and strongest stiffness 
among all groups (Specific aim # 3, Chapter 5). Taken together, this project 
showed that long duration of osteogenic induction enhances hfMSCs’ 
proangiogenic secretion and paracrine effects, and improves the healing 
capacities of hfMSC-TEBGs. This study indicates the value of conducting 
osteogenic culture on MSC loaded scaffolds for healing bone defects, and 
sheds light on the optimal strategy to prepare clinically relevant tissue 
engineering bone grafts. 
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